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Abstract 
Alzheimer’s disease (AD) is the most common cause of dementia, and the deposition of 
amyloid β (Aβ) peptide in the AD brains is a hallmark of the disease. Other amyloidogenic 
proteins like Transthyretin (TTR) and human Cystatin C (hCC) can modulate the 
aggregation of Aβ. These two proteins are proposed to play a role in the pathophysiology 
of AD as they are found co-deposited in amyloid deposits in the brains of AD patients, 
most notably at the cell surface. Animal models and cell line assays showed protective 
roles for TTR and hCC against Aβ-induced toxicity, and Aβ fibril formation is inhibited 
through interaction with TTR and hCC.  
This study investigated the mechanism of in vitro interaction of TTR with Aβ. The ability 
of WT TTR to inhibit Aβ fibrillisation in the presence of Aβ binding surfaces was higher 
than in the presence of non-binding surfaces. Then, the interaction between different TTR 
mutants with different multimeric stabilities and different alloforms of Aβ showed that 
TTRs with less stable tetramers and unfolded monomers are the best inhibitors of Aβ 
fibrillisation. Analysing the thioflavin T curves of Aβ aggregation in the presence of 
TTRs and the interaction of TTRs with different forms of Aβ showed that the interaction 
between the two proteins occurs mainly through binding to early nucleating species of 
Aβ rather than to the monomer.  
The dose-dependent inhibition of Aβ fibrillisation and the promotion of amorphous 
aggregates by hCC were validated. However, the previous suggestion of simple monomer 
to monomer interaction between Aβ and hCC was not confirmed. Instead, a proposed 
hCC binding to oligomeric species of Aβ was supported by the observed hCC interaction 
with different aggregated species of Aβ. The dimeric form of hCC was found to be a less 
effective inhibitor compared to WT monomer, indicating that the active site could be the 
hydrophobic loops involved in dimerisation and protease inhibition. This interpretation 
was supported, as mutation of hydrophobic residues in the active site significantly 
reduced the intensity of hCC to inhibit Aβ fibrillisation.   
We showed that these two proteins are mainly inhibit Aβ fibrillisation through interaction 
with the early aggregated structures of Aβ (some form of oligomers). As it is known that 
oligomers are responsible for Aβ toxicity in vivo, the potential of these two proteins to be 
used as natural modulators is supported by this study. 
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Chapter 1: Introduction 
Background 
There are a growing number of human diseases, known as amyloid diseases, which are 
identified by the deposition of protein aggregates in the body (Westermark et al., 1990, 
Dobson, 2002, Horwich, 2002, Westermark et al., 2002). Alzheimer’s disease (AD) 
(Selkoe and Schenk, 2003a), Parkinson’s disease (Lang and Lozano, 1998), prion 
diseases (Prusiner, 1998, Collinge, 2001) and Huntington’s disease (Perutz, 1999) are 
among these diseases. Most of these diseases are late-onset diseases and as the world’s 
population gets older these diseases are becoming more prevalent. Alzheimer’s is the 
most common cause of dementia, an estimated 46.8 million people worldwide were living 
with dementia in 2015, with 9.9 million new cases per year (Alzheimers.co.uk). For that 
reason, understanding the cause and developing new drugs for amyloid diseases is 
important.  
Amyloid diseases are identified by the deposition of amyloid fibril in affected tissues. 
Amyloid fibrils are formed through conformational change and aggregation of normally 
soluble proteins to insoluble, highly ordered and typically highly stable protein deposits 
(Fandrich, 2012a).Whereas in the past, each disease was usually associated with one 
amyloid-forming protein, current data suggest the involvement of multiple amyloid-
forming proteins in the pathophysiology of the amyloid disease. In vitro, the aggregation 
behaviour of different proteins has been characterised extensively but the effect of 
individual proteins on each other’s aggregation is not well known. In order to develop 
novel ways for targeting amyloid formation for therapeutic purposes, we need a better 
understanding of natural protection mechanisms occurring in the body. An increasing 
number of studies suggest amyloid aggregation is perturbed by other amyloid proteins 
under physiological conditions (Li and Buxbaum, 2011). As we search for a cure, the 
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purpose of this project is to study the natural regulation of amyloid β aggregation by two 
other amyloidogenic proteins, transthyretin and cystatin C.  
1. 1. Classification of Amyloid  
An increasing number of proteins have been found to form amyloid deposits in the human 
body. At least 31 proteins have been recognized to form extracellular amyloid plaques, 
and some others are found to form intracellular amyloids where they form fibril-like 
intracellular deposits (Table 1.1) (Sipe et al., 2014). The majority of deposited amyloids 
are extracellular and may be found in an organ or throughout all the body (Sipe and 
Cohen, 2000, Dobson, 2004). The amount of deposited amyloid is hugely variable from 
nearly undetectable to kilograms found in the case of systemic amyloidosis (Dobson, 
2004). Most amyloid protein mutants are associated with induced fibril formation because 
of native state destabilisation, therefore increasing the steady state concentration of the 
partially unfolded species. Amyloidogenic diseases can be categorized into different 
groups according to deposition site and affected organs. Three main groups of 
amyloidogenic diseases can be classified: non-neurodegenerative systemic amyloidosis 
where amyloid deposition occurs in multiple organs, non-neurodegenerative localised 
amyloidosis where the amyloid deposition is localised in only one organ, and 
neurodegenerative amyloidogenic diseases where the deposition is confined only to the 
brain (Chiti and Dobson, 2006a). 
Amyloidogenic 
protein 
Precursor protein Disease Systemic 
or 
localized 
Target organs 
AL Immunoglobulin 
light chain 
Systemic amyloid light 
chain amyloidosis 
Nodular amyloidosis 
S, L All organs except CNS 
AH Immunoglobulin 
heavy chain 
Immunoglobulin heavy 
chain associated 
amyloidosis (Eulitz et 
al., 1990) 
S, L All organs except CNS 
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AA (Apo) Serum 
amyloid A 
AA amyloidosis S All organs except CNS 
ATTR Transthyretin, wild 
type 
Senile systemic 
amyloidosis 
S 
 
Heart mainly in male, 
Ligaments, 
Tenosynovium 
Transthyretin, 
variants 
Familial amyloid 
polyneuropathy, 
Familial amyloid 
cardiomyopathy 
S PNS, ANS, heart, eye, 
leptomen 
Aβ2M β2-Microglobulin, 
wild type 
 
Haemodialysis-related 
amyloidosis 
L 
 
Musclo-skeletal system 
β2-Microglobulin, 
variant 
Familial systemic 
amyloidosis (Stoppini 
and Bellotti, 2015) 
S ANS 
AApoAI Apolipoprotein A I, 
variants 
Hereditary systemic 
amyloidosis 
S Heart, liver, kidney, 
PNS, testis, larynx (C-
terminal variants), skin 
(C-terminal variants) 
AApoAII Apolipoprotein A 
II, variants 
 S Kidney 
AApoAIV Apolipoprotein A 
IV, wild type 
 S Kidney medulla and 
systemic 
AGel Gelsolin, variants Hereditary systemic 
amyloidosis 
S PNA, cornea 
ALys Lysozyme, variants Hereditary systemic 
amyloidosis 
S Kidney 
ALECT2 Leukocyte 
chemotactic factor-
2 
Leukocyte chemotactic 
factor amyloidosis 
(Benson et al., 2008) 
S Kidney, primarily 
AFib Fibrinogen α, 
variants 
Hereditary renal 
amyloidosis 
S Kidney, primarily 
ACys Cystatin C, variants Hereditary cystatin c 
amyloid angiopathy 
S PNA, skin 
ABri ABriPP, variants Familial British/Dutch 
amyloidosis 
S CNS 
Adan ADanPP, variants Familial Danish 
dementia (Holton et 
al., 2002) 
L CNS 
Aβ Aβ protein 
precursor, wild type  
Aβ protein 
precursor, variant 
Alzheimer’s Disease L CNS 
APrP Prion protein, wild-
type 
Prion protein 
variants 
Creutzfeldt-Jakob 
disease 
Gerstmann-Strassler-
Schneiker syndrome 
Fatal familial insomnia 
Bovine spongiform 
encephalopathy 
L CJD, fatal insomnia 
ACal (Pro)calcitonin Medullary carcinoma 
of the thyroid 
L C-cell thyroid tumors 
AIAPP Islet Amyloid 
Polypeptide 
Type 2 Diabetes L Islet of Langerhans, 
Insulinomas 
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AANF Atrial Natruritic 
factor 
Atrial amyloid L Cardiac atria 
APro Aprolactin Ageing pituitary gland 
amyloidosis 
L Pituitary 
polycarcinomas, aging 
pituitary 
AIns Insulin Injection-localized 
amyloidosis 
L Iatrogenic, local 
injection 
ASPC Lung Surfactant 
Protein 
Pulmonary alveolar 
proteinosis 
(Gustafsson et al., 
1999) 
L Lung 
AGal7 Galectin 7 Skin amyloidosis  L Skin 
ACor Corneodensomin Cornified epithelia, 
hair follicles 
amyloidosis 
L Cornified epithelia, Hair 
follicles 
AMed Lactadherin Aortic medial amyloid L Senile aortic, Media 
AKer Kerato-epithelin Lattice corneal 
dystrophy 
L Cornea, hereditary 
ALac Lactoferrin Corneal amyloidosis L Cornea 
AOAAP Odontogenic 
Ameloblast-
Associated Protein 
 L Odontogenic tumors 
ASem1 Semenogelin 1  L Vesicula seminalis 
Enf Enfurvitide  L Iatrogenic 
 
Table 1.1. The amyloidogenic proteins and amyloid-related diseases, mainly adapted from 
(Sanders et al., 2009, Sipe et al., 2014). 
1. 2. Alzheimer’s disease  
Alzheimer’s disease (AD) is the most common cause of dementia (Prince et al., 2015). 
The probability of being diagnosed with AD over the age of 65 is 6% (Burns and Iliffe, 
2009), and this figure increases to 50% over the age of 85 (Irvine et al., 2008).  Although 
AD diagnosis is based on specific criteria, currently the only accurate technique of 
diagnosis is post-mortem autopsy. Advancements in the magnetic resonance imaging 
(MRI) and/or single photon emission computed tomography (SPECT) imaging 
techniques will improve diagnosis and allow pre-symptomatic identification of AD 
(Coimbra et al., 2006).  
The presence of extracellular amyloid plaques and intracellular neurofibrillary tangles 
(NFT) in the brain is one of the characteristic features of AD (Annaert and De Strooper, 
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2002). Amyloid plaques contain fibrils mostly formed from the Aβ peptide, while the 
neurofibrillary tangles are formed from hyper-phosphorylated tau protein. Besides the 
deposition of plaques and tangles, there is a gradual decline in cognitive ability (Caughey 
and Lansbury, 2003). The pyramidal neurons of the third and fourth layers of the cerebral 
cortex are most susceptible to loss in AD, and enlarging of the ventricles, widening of the 
sulci and thinning of the cortical gyri results in a complete loss of grey matter (Deng et 
al., 2001). The molecular basis for the connection between Aβ peptide levels and 
neurotoxicity is not well understood (Annaert and De Strooper, 2002). It is believed that 
Aβ is involved in various toxic activities such as apoptosis, generation of radicals, 
complement activation, calcium homeostasis disruption and the pore formation in the cell 
membrane (Small et al., 2001, Benilova et al., 2012). The prominent hypothesis is that 
the oligomeric forms of Aβ are the toxic species responsible for degeneration. 
There are two types of AD: late-onset (sporadic), which accounts for the majority (90%) 
of the cases, and early-onset (familial), which is usually caused by a mutation that either 
causes overproduction of Aβ1-42 or increases its tendency to form fibrils (Caughey and 
Lansbury, 2003). The presenilin-1 gene encodes for one of the enzymes responsible for 
the Aβ peptide cleavage from its precursor, mutations in this gene leads to an increase in 
both brain and extracellular concentrations of Aβ (Scheuner et al., 1996). Polymorphisms 
are also noticed in the presenilin-2 (PS2) gene encoding an enzyme which is responsible 
for the further downstream processing of Aβ. Mutations in the gene for the amyloid 
precursor protein (APP) itself lead to overproduction of both Aβ1-40 and Aβ1-42 or changes 
in the Aβ peptides production spectrum (Ancolio et al., 1999, Kumar-Singh et al., 2000). 
These polymorphisms can also be linked to cerebral amyloid angiopathy (CAA) and late-
onset AD (Yamada et al., 1997, Yamada, 2000). Down’s syndrome patients above the 
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fourth decade normally develop AD; this is most possibly because of the chromosome 21 
trisomy which houses the APP gene (Caughey and Lansbury, 2003).  
Amyloid-β (Aβ) is a short peptide generated from the amyloid precursor protein (APP) 
cleavage. The Aβ fragments are different in length, ranging from 38 to 43 amino acids 
(Benilova et al., 2012), however, Aβ1-40 and Aβ1-42 are the most common fragments 
(Jarrett et al., 1993). Aβ1-40 is present at higher levels compared to Aβ1-42 (ratio 10:1) 
(Kuperstein et al., 2010), where the latter is the most toxic form of the peptide (Storey 
and Cappai, 1999). Although studies show that oligomerisation of these different Aβ 
alloforms occurs by different assembly pathways, there is enough evidence to prove 
formation of similar intermediates by both peptides, although at different concentrations 
of the peptide (Bitan et al., 2003). The peptides are very hydrophobic, particularly the C-
terminal and central cluster (residues 17-21) (Serpell, 2000).   
The amyloid cascade hypothesis (Hardy, 1997, 1999, Sisodia et al., 2001, Annaert and 
De Strooper, 2002) proposes that the amyloid β peptide, and in particular its aggregates 
are the cause of all of the Alzheimer’s disease pathophysiology, including the 
characteristic hyperphosphorylation of tau proteins and the consequent formation of 
intracellular tangles. 
1. 3. The structure of amyloid 
Despite the differences in the amino acid sequence of the native forms of amyloid 
precursor proteins, the deposited amyloid fibrils exhibit similar basic structural features 
(Serpell et al., 1995, Sunde et al., 1997, Serpell et al., 2000), and similar toxicity 
mechanisms (Makin and Serpell, 2005). For example, amyloid beta peptide (40-42 
residues) which is the Alzheimer’s disease (AD) amyloid (Selkoe and Schenk, 2003b), 
and a >3000 residue huntingtin which is the Huntington’s disease amyloid, form similar 
  
7 
 
fibrils. Furthermore, structurally different proteins varying from the all-β tetrameric 
transthyretin in senile systemic amyloidosis to small -helical prion protein in Creuzfeld-
Jacob disease (Zahn et al., 2000), also form similar fibrils.  
Actually, it appears that nearly all proteins can assemble to amyloid fibrils in vitro, 
suggesting that amyloid is a model structure that proteins will adopt when subjected to 
certain conditions (Guijarro et al., 1998, Chiti et al., 1999, Dobson, 1999, Fandrich et al., 
2001). However, even in the absence of accessory components, protein self-assembly into 
amyloid can still occur in vitro (Dobson, 2004), implying a more subtle role, probably 
analogous to molecular chaperones in the folding of the protein (Thomas et al., 1995, 
Revesz et al., 2003). 
Early electron microscopic investigations showed that amyloid fibrils are unbranching 
and straight, with a diameter of 70-120 Å (Shirahama and Cohen, 1967), and formed from 
several protofibrils arranged in parallel. Amyloid fibrils have a specific cross-β structure 
formed by an organised core of β-strands that run perpendicular to the fibril axis. It is 
believed that the fibril is stabilised via hydrogen bonding from main chain interactions 
(Makin et al., 2005), explaining not only the amyloid fibrils’ common structure but also 
the process by which any protein can make fibrils when it is exposed to the correct 
conditions (Fandrich et al., 2001).  
Because amyloid fibrils are heterogeneous, large and insoluble, it is difficult to gather 
structural information applying conventional techniques like X-ray crystallography and 
NMR (Serpell, 2000). However, biophysical techniques such as X-ray diffraction and 
solid-state NMR (ssNMR) can be adopted to great effect, in combination with other 
techniques like electron microscopy, limited proteolysis and hydrogen-deuterium (H/D) 
exchange to evolve structural information leading to improvements in structural models.  
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1. 4. Atomic-level structural determination 
1. 4. 1. X-Ray Fibre Diffraction 
X-ray fibre diffraction provided the key structural details on the amyloid fibrils (Blake 
and Serpell, 1996). Fibre diffraction creates diagnostic reflections in two positions: strong 
meridional reflections of 4.7Å correspond to repeated inter-strand hydrogen bond spacing 
between the β-sheets along the fibril axis whilst weaker equatorial reflections 10 Å 
created from electron density due to intersheet interactions vertical to the fibril axis, 
which is characteristic of a cross-β structure (Figure 1.1) (Geddes et al., 1968, Blake and 
Serpell, 1996). Further structural information can be obtained through using well-aligned 
fibril preparations, information like helical pitch/helical repeating unit, precise overall 
appearances, dimensions and even the existence of a hydrated fibril core (Blake and 
Serpell, 1996, McDonald et al., 2012).  However, fibril diffraction can only disclose these 
molecular features in exceptionally appropriate situations (Stubbs, 1999, Chandrasekaran 
and Stubbs, 2006). 
Based on the fact that all amyloid fibrils demonstrate the same diffraction pattern, the 
“cross-β structure” model was proposed (Figure 1.2). According to this model, the β-
sheets run parallel to the fibril axis and their component β-strands are perpendicular to 
the axis of the fibril (Blake and Serpell, 1996, Sunde et al., 1997, Makin and Serpell, 
2005). The cross β structure was originally noticed in silk fibrils (Geddes et al., 1968). 
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Figure 1.1. X-ray fibril diffraction from aligned islet amyloid polypeptide (IAPP) fibrils, 
showing the positions of the 4.7 Å meridional and approximately 10 Å equatorial reflections 
in a cross-β pattern. Taken from (Makin and Serpell, 2005). 
 
1.4.2. Microscopy Techniques 
 Transmission electron microscopy (TEM) and atomic force microscopy (AFM) are 
useful techniques not only for identification of amyloid fibrils, but are also used to explore 
oligomer formation and fibrillisation by discontinuous and continuous methods (Figure 
1.2 A) (Goldsbury et al., 1999). Improvements in real-time AFM techniques could 
provide some exciting insights into the fibrillisation mechanism.  Mass per unit length 
(MPL) measurements can be performed applying specific scanning transmission electron 
microscopy (STEM) which is employed to calculate the spaces between repeating units 
in amyloid fibril (Wall et al., 2008).  Thus, these calculations have been conducted on a 
number of amyloid fibril-forming proteins and play a major part in the structural 
modelling of amyloid fibrils (Petkova et al., 2002a). 
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Figure 1.2.  Amyloid Fibril Structure. (A) Electron micrograph of negatively stained Aβ1-42 
amyloid fibrils. (B) Model of the cross-β fibril structure consisting of β-strands running 
perpendicular to the fibril axis, with inter-strand hydrogen bonds in the direction of the fibril 
axis. Adapted by Prof. Peter Artymiuk from (Sunde et al., 1997). 
 
1.4.3. Cryo-electron microscopy  
The three-dimensional structure of amyloid fibrils can be revealed by cryo-electron 
microscopy, by averaging several sections of EM images of amyloid fibril. Cryo-EM 
investigations have shown that fibrils are made of filamentous subunit structures named 
protofilaments. Twisting of protofilaments around one another along the axis of the fibril 
gives a helical appearance (Goldsbury et al., 2000, Serpell, 2000, Jimenez et al., 2002). 
Cryo-EM examinations verified the cross-β model, as striations can be observed running 
across the fibril with a 4.7 Å repeat in fibrils produced from Aβ (Aβ11-25) (Serpell and 
Smith, 2000a). This observation also confirms that the β-strands are in direct register and 
run perpendicular to the fibril axis. Microscopy is particularly beneficial for 
characterizing common species within a mixture as the different structural families can 
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be investigated individually. This technique has been used to study fibrils formed by the 
SH3 domain of phosphatidylinositol-39-kinase (Jimenez et al., 1999), Aβ1-40 (Serpell and 
Smith, 2000b), insulin (Figure 1.3 A) (Jimenez et al., 2002), and β2 microglobulin (White 
et al., 2009). More recently, a high resolution structure has been proposed for Aβ1-42 
fibrils (Figure 1.3 B). 
 
 
Figure 1.3. Cryo-EM reconstructions of amyloid fibrils. (A) Insulin protofilaments within a 
mature amyloid fibril, where the four protofilaments are coloured separately, Taken from 
(Jimenez et al., 2002). B) Top; cross-sectional view of the Cro-EM reconstruction (rendered at 
5Ao. down; best fits for the sequence of Aβ1-42 superimposed on electron density, taken from 
(Schmidt et al., 2015). 
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1.4.4. Hydrogen-deuterium exchange (HX) 
HX is an effective technique that can be used to resolve the secondary structure and 
solvent accessibility of single protein chains within the fibrils.  The proton exchange rate 
between the amide and the solvent deuterated water can be measured by this technique. 
Faster rates of proton exchange happen between the exterior amide protons and solvent 
deuterons compared to amides involved in hydrogen bonds or that are hidden within the 
protein structure.  The latter amides are thus “protected” from exchange (Bai et al., 1993, 
Scholtz and Robertson, 1995, Englander et al., 1996, Raschke and Marqusee, 1998).  The 
magnitude of amide proton resistance to exchange can be evaluated and indicated as a 
protection factor which correlates with the regions protected by the structure of the fibril. 
This can be considerably helpful in identifying which residues are involved in the 
formation of the hydrogen bond; i.e. secondary structure. 
Successful conjugation of HX with NMR spectroscopy has been performed. As deuterons 
are invisible to 1H NMR (i.e. proton NMR) experiment, the decrease in the intensity of 
amide proton peaks can be detected. Quantitative estimation of the exchange rate can be 
achieved by monitoring weakened resonances. Labelling of protein with 15N can provide 
residue-specific information from an assigned 2D transverse relaxation optimised 
spectroscopy - heteronuclear single quantum coherence - NMR (TROSY HSQC) 
spectrum (Pervushin et al., 1997), which displays a single peak for each amide proton in 
the protein. 
Basically, HX is accomplished on the intact fibril, then the fibril is dissociated and 
unfolded to monomers by adding dimethyl sulfoxide (DMSO) to trap the hydrogen 
exchange state of the amides. This approach formed the basis of investigating amyloid 
fibrils from the HET-s prion protein  (Ritter et al., 2005), β2-microglobulin (Hoshino et 
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al., 2002, Yamaguchi et al., 2004), a 10 residue fragment of Aβ (Ippel et al., 2002), an 
SH3 domain (Carulla et al., 2005) and cystatin B (Morgan et al., 2008). HX has also been 
applied to study the dynamic nature of the amyloid fibril, as dissociation and re-
association rates of the molecules with the fibril are detected (Carulla et al., 2005, 
Sanchez et al., 2011).   
HX can also be combined with mass spectrometry (MS). Changes in the mass of protein 
can be detected as deuteration occurs. HX-MS has been employed on Aβ peptide to 
identify the protected regions within both the precursor states and the amyloid core 
(Kheterpal et al., 2000, Nettleton et al., 2000, Kheterpal et al., 2003). 
  
1. 4. 5. Limited proteolysis 
Similar to HX, limited proteolysis can be used to identify the accessible regions of the 
amyloid fibril (Hubbard, 1998). The amyloid fibrils are subjected to proteolytic enzymes; 
then proteolytic products are investigated with MS to find the regions which are protected 
and therefore construct a model of the fibril structure. Regions that are exposed on the 
outside of the amyloid fibril are in contact with proteases and accordingly can be quickly 
hydrolysed, however, regions within the fibril’s secondary structure are not accessible to 
proteolysis and allow the protected fibril core to be determined. 
Limited proteolysis has been employed to analyse the structural features of the Aβ1-40 
fibril. The data collected indicate that the first ten residues from the N-terminal region are 
not involved in the amyloid fibril core (Kheterpal et al., 2001). SH3 domain analysis 
showed that intermediates in the fibrillisation pathway are less folded than the native form 
of the protein (Polverino de Laureto et al., 2003a). 
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Limited proteolysis has been used to obtain structural information for fibrils in several 
systems including Aβ1-40 peptide (Kheterpal et al., 2001), α-synuclein (Miake et al., 
2002), HET-s (Balguerie et al., 2003, de Laureto et al., 2003), Ure2p (Baxa et al., 2003), 
PI3-SH3 (Polverino de Laureto et al., 2003b) bovine α-lactalbumin (de Laureto et al., 
2005), β2-microglobulin (Myers et al., 2006), lysozyme (Frare et al., 2006) and cystatin 
B (Davis et al., 2015). 
1. 4. 6. Solid-state nuclear magnetic resonance spectroscopy 
Solid-state NMR (ssNMR) spectroscopy is now accepted as a powerful technique to 
provide insight into the atomic level of amyloid fibril structure. The insolubility of 
amyloid fibrils makes it difficult to reveal its structure by solution state NMR (Naito and 
Kawamura, 2007).  
Solid-state NMR (ssNMR) provides high-resolution information which is not obtainable 
applying other techniques. A range of different ssNMR techniques has been utilised 
which are basically very similar to those used in the solution. Labelling strategies have 
been developed to label residues selectively with 15N and 13C and minimize the number 
of peaks obtained in each spectrum. This labelling allows measurements of distance 
constraints between specific residues, which provide details on secondary, tertiary and 
quaternary structures as well as dynamic data. From these measurements, a structural 
model can be developed. 
ssNMR has been used to resolve the structure of the prion-forming domain of the HET-s 
protein describing a left-handed β-solenoid model, which was the first theorized model 
of what is thought to be an infectious fibrillar state (Wasmer et al., 2008). Other structures 
of fibrils include transthyretin (Correia et al., 2006) and β2-microglobulin (Iwata et al., 
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2006) and of course the different structures proposed for Aβ1-40 (Figure 1.4) (Petkova et 
al., 2002b). 
 
 
 
Figure 1.4. Structural model of the Aβ1-40 fibril as resolved by SSNMR. Residues 1 – 8 are 
thought to be fully disordered and are omitted. Adapted from (Petkova et al., 2002b). 
 
1. 5.  Amyloid probing  
 Amyloid identification is performed through displaying characteristic properties at the 
time of binding to some specific dyes, most notably Congo red and thioflavin T (ThT). 
1. 5. 1. Congo red 
Congo red staining is one of the most valuable diagnostic methods in clinical practice for 
the detection and screening of amyloid. Upon staining with Congo red, fibrils display the 
characteristic pink-orange colour by light microscopy and exhibit a characteristic green 
birefringence when observed under a cross-polarized light microscope (Elghetany et al., 
1989, Sipe and Cohen, 2000, Makin and Serpell, 2005). Depending on its polarization, 
the light splits into two rays when it passes through a specific type of material. This is 
birefringence, which will only happen when the structure is anisotropic. When the 
  
16 
 
amyloid fibril is bound to Congo red, the observed birefringence is evidence of the 
presence of a sub-microscopic ordered structure (Glenner et al., 1972). It is proposed that 
these changes originate from the molecular alignment of the dye upon binding to the 
exposed specific epitope on the fibril. It is believed that binding is specific and 
associative, either via the extended β-sheet or intercalation (Wolfe et al., 2010).  
1. 5. 2. Thioflavin T (ThT) 
Specific binding between the benzothiazole dye ThT and amyloid fibrils leads to a 
dramatic increase in fluorescence intensity of ThT spectra. The ThT excitation maximum 
is 385 nm and emission is 445nm, when it is unbound.  Upon interaction with amyloid 
fibrils, it exhibits a different excitation maximum of 450 nm and enhanced emission of 
482 nm. The resulting shift from ThT binding to amyloid fibrils can be measured over 
time to monitor amyloid fibrillisation in solution (LeVine, 1993, Sipe and Cohen, 2000, 
Khurana et al., 2005, Makin and Serpell, 2005).  
1. 6. Definitions of amyloid structures 
1. 6. 1. Amyloid fibril 
Amyloid fibrils are unbranched, long protein fibrils with diameters of 2-20 nm and a 
length of several micrometres (Kodali and Wetzel, 2007, Fandrich, 2012a). Amyloid 
fibrils are usually formed of 2-6 protofilaments and can be flat or twisted around each 
other to form obvious fibril constrictions at fixed intervals, called crossovers.  The helicity 
of fibrils is often left-handed, with few exceptions (Fandrich, 2012b). Despite the fact 
that amyloid fibril toxicity is not yet confirmed, however, they should be investigated 
because they are tough with extensive hydrogen bonding, therefore may deposit and 
remain inside the cells for a prolonged period of time and are suggested to act as toxic 
oligomer and protofibril reservoirs (Harper et al., 1997, Walsh et al., 1997, Benilova et 
al., 2012). The amyloid fibril ability to act as a reservoir species is recommended because 
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of its dynamic nature which exhibits extensive, but slow molecular recycling by which 
the protein constituents of a fibril dissociate and re-associate over (Carulla et al., 2005, 
Sanchez et al., 2011). Therefore, studying amyloid fibril structure as one of the 
therapeutic targets is important by which stabilisation or ablation of fibrils can reduce 
harmful levels of toxic species. 
1. 6. 2. Protofilament 
Protofilaments are single strands which together form mature amyloid fibrils. 
1. 6. 3. Amyloid intermediates  
Amyloid intermediates can be categorized into different groups including protofibrils, 
annular aggregates, oligomers (Fandrich, 2012a), and Aβ-derived diffusible ligands 
(ADDLs) (Figure 1.5). It is thought that a large number of different species and 
subspecies are present which makes classification of diverse intermediates complicated. 
The study of these intermediates is very difficult because of their transient heterogeneous 
nature. The investigation of soluble oligomeric species is highly important as they are 
proposed to be the toxic species (Lansbury, 1999).  
1. 6. 3. 1. Protofibrils 
Protofibrils can be differentiated from oligomers by their elongated, filamentous 
structures. They are believed to represent late-stage intermediate species in the formation 
of amyloid fibrils. They are characteristically thinner (< 10 nm), shorter (< 400 nm in 
length) and more curved compared to mature fibrils. Protofibrils are not highly ordered 
and do not exhibit amyloid fibrils periodic symmetry. They usually have a lower affinity 
for ThT and CR dyes compared to mature fibrils but still encompass high levels of β-
sheet structure as shown by CD, FTIR, and x-ray fibre diffraction (Fandrich, 2012a). 
Stabilisation of Aβ by applying a specific protofibril antibody (B10AP) allowed the 
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observation of high levels of typical β-sheet structure, which were shown by ssNMR to 
surround two β-strands expanding from residues 16-22 and 30-36 (Scheidt et al., 2011), 
this is a smaller number of residues than in mature fibrils but is consistent with the idea 
of protofibrils representing a precursor to the fibrils.   
1. 6. 3. 2. Annular aggregates  
Annular aggregates maintain a donut-like appearance confining a central channel, which 
is assumed to be filled with water (Lashuel et al., 2002). Some amyloidogenic proteins, 
like Aβ and α-synuclein variants, have been shown to make ring-like aggregates (Lashuel 
et al., 2002, Caughey and Lansbury, 2003). Exploring the detailed molecular structures 
of these samples is difficult because of the high levels of heterogeneity, yet because of 
their similarity to pore forming toxins it has been suggested that these species are able to 
penetrate the cell membrane and disrupt its integrity and consequently lead to cell death 
(Caughey and Lansbury, 2003, Butterfield and Lashuel, 2010, Fandrich, 2012a).  
1. 6. 3. 3. Oligomers 
The term ‘oligomer’ is derived from the Greek oligos meaning ‘a few’, thus it is suggested 
that this terminology is preferable for the description of small assemblies with few units, 
like dimer and trimers, and employing the term ‘non-fibrillar aggregates’ (Morgado and 
Fandrich, 2011) for bigger multimeric species. However, in the amyloid field, oligomer 
is an umbrella term used to describe any structure larger than monomer which has a non-
fibrillar morphology. Low and high molecular weight oligomers are also used in the 
literature to describe non-fibrillar structures. Soluble oligomeric intermediates form both 
on and off-pathway to amyloid fibril formation. For example, from the Aβ peptide, these 
can include dimers, small multimers (3-10mers) all the way up to several mega-Dalton 
large macromolecular structures (Haass and Selkoe, 2007).  
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It is accepted that amyloid fibrils possess a characteristic cross-β structure; however a 
similar common structural conformation has not yet been found for oligomers (Fandrich, 
2012a). While different oligomeric species share both β-sheet and random coil 
conformations, characteristic secondary structures can be remarkably different (Habicht 
et al., 2007, Campioni et al., 2010, Sandberg et al., 2010). Nonetheless oligomer 
preparations from different polypeptides found to be recognized by the same oligomer-
specific antibodies such as A11 (Kayed et al., 2003) and these oligomers exhibit similar 
effects in the metabolic assays of cells (Bucciantini et al., 2002), indicating the presence 
of common structural properties. Oligomers are highly heterogonous, with variability in 
size and structure happening within the same sample, or from different preparations 
(Glabe, 2008).  Because of their transient, dynamic properties, oligomeric species usually 
aggregate further and grow to more mature forms (Fandrich, 2012a).  
1. 6. 3. 4. Aβ-derived diffusible ligands (ADDLs).  
ADDLs are highly ordered soluble oligomers of Aβ1-42 peptide. They are formed from 
multiple units of trimers, tetramers, or 12mers. ADDLs are highly neurotoxic 
(Lambert et al., 1998). 
1. 6. 4. Amorphous aggregate 
Accumulation of protein molecules without a defined structural characteristics detectable 
by electron microscopy, while it is possible that structure could exist at the molecular 
level. 
1. 6. 5. Amyloid fibril seed 
Seeds are small amyloid fibril fragments usually developed through sonication of mature 
fibrils. Kinetically stable protein molecules might be induced to aggregate upon addition 
of seeds, the aggregation usually occur through growth of the seed itself (Kodali and 
Wetzel, 2007). 
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Figure 1. 5. Amyloid Fibrils, Protofibrils and Oligomeric Structures 
EM and AFM images of structures formed by amyloid-forming proteins.  (A) Globular Aβ 
oligomers (B) Annular Aβ oligomer (C) Small curly α-synuclein protofibrils and thicker mature 
fibrils (D) Mature Aβ amyloid fibril.  Figure adapted from (Bartolini et al., 2011) (A, D),  
(Lashuel et al., 2002) (B) and (Koo et al., 1999) (C). 
 
1. 7. Transformation to the amyloid-forming competent 
state 
It has been shown that even non-amyloidogenic proteins can form fibrils under 
destabilising conditions (Fandrich et al., 2001), this has given rise to the hypothesis that 
amyloid fibril formation is a potential shared by all proteins and that this is not only 
restricted to disease-associated amyloid proteins (Guijarro et al., 1998). However, 
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amyloid peptides and proteins which aggregate promptly, primarily acquire unstructured 
conformations in their normal biological state (Chiti et al., 2003), and consequently 
become more liable to form partially unfolded intermediates which is a key triggering 
event in amyloidogenesis (Kelly, 1998, Calamai et al., 2005, Chiti and Dobson, 2006a). 
Amyloid protein, if not natively unstructured, becomes partially unfolded before amyloid 
formation. Similar to fibril formation, partial unfolding is also found in amorphous 
aggregation. It is believed that amorphous aggregation is driven by interactions between 
exposed hydrophobic interiors of the protein (Ohnishi and Takano, 2004) but in amyloids, 
further stabilization happens as a result of more specific interactions between 
complementary sections of the polypeptide chains. The protein in the fully folded state is 
therefore not directly transformed into an amyloid fibril. The lack of interactions between 
side chains or its destabilization, for instance because of changes in the conditions or 
mutations can cause a rise in unfolded or partially folded protein, and accordingly 
increases subjection of hydrophobic amino acids and the normally hidden main chain to 
the solvent (Dobson, 2003). The crucial driving force for the formation of amyloid is the 
need of partially unfolded protein to bury the exposed hydrophobic residues and find an 
alternative energetically favourable conformation that is kinetically accessible in  specific 
conditions (Chiti and Dobson, 2006b). The idea of partially unfolded conformations 
having a major effect in amyloidogenesis comes from the fact that less stable mutant 
versions of amyloidogenic proteins are more aggregation prone compared with their wild-
type counterparts (Hurle et al., 1994, Abrahamson, 1996, Booth et al., 1997, Wei et al., 
1998, Kad et al., 2001). Furthermore, native state stabilization by ligand binding 
decreases fibril formation (Peterson et al., 1998, Chiti et al., 2001, Hammarstrom et al., 
2003). 
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1. 8. Mechanism of fibril formation 
Amyloidogenic proteins are different in terms of both amino acid sequence and 
conformation. However, they all form similar amyloid structures through similar 
mechanisms (Glabe, 2006). Amyloidogenesis followed by thioflavin T assays and other 
kinetic methods exhibit three major steps with typical sigmoidal kinetics. The first step is 
the lag phase, where little fibril is produced, followed by an exponential growth phase, 
and finally ends up with an equilibrium plateau phase. The protein species populated in 
the lag phase are not well characterized. The existence of a lag phase on its own indicates 
the multistep nature of the process. However, when combined with the observation that 
the lag phase can significantly reduce or be completely removed by the addition of 
‘seeds’, a nucleated growth mechanism can be suggested, where the rate limiting step 
relies on the presence of a rare possibly stochastically created nucleus (Figure 1.6) 
(Hortschansky et al., 2005). The infrequency of the nucleus can be explained by its 
production not being thermodynamically favourable where the resultant intermolecular 
interactions cannot exceed the association entropy. The simplest description of the 
exponential phase is that monomer addition is becoming more favourable 
thermodynamically by intensifying intermolecular interactions and outweighing the 
entropic barrier  (Jarrett and Lansbury Jr., 1993). Other researchers correlated the 
exponential phase with fibril fragmentation and introduction of new growing fibril ends 
(Kodali and Wetzel, 2007). Others still suggest adhering of the oligomers to form 
protofibrils, which are short beaded fibrils, followed by mature fibrils forming either by 
a conformational change or protofibril association. 
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Figure 1.6. Typical Fibrilisation Kinetics. Amyloid fibril  (aggregate) formation typically 
follows a kinetic profile of a nucleation-dependent process which exhibits a lag phase followed 
by an exponential growth period and subsequent thermodynamic equilibrium (solid line).  At 
a high concentration or very favourable environmental conditions, nucleation is so rapid no lag 
phase is observed (dashed line).  The addition of a nucleus or seed eliminates the nucleation 
step and therefore also ablates the lag phase.  Diagram from (Jarrett and Lansbury Jr., 1993). 
  
1. 9. Kinetic models 
There are four conspicuous models of amyloid formation (Figure 1.7), the latest one, 
nucleated conformational conversion, integrate the elements of the other three (Kelly, 
2000, Serio et al., 2000).  
The first model is known as templated assembly, in which an amyloidogenic (A-state) 
pre-assemble to form a nucleus, then bind to a soluble non-amyloidogenic (S-state) 
peptide, causing a rate-limiting structural conversion in the latter followed by peptide 
addition to the end of growing amyloid fibril (Griffith, 1967). This model implies a direct 
change in the lag phase with a change in soluble protein concentration, but the fibril 
elongation rate will stay unaltered. The addition of seed should reduce the lag time.  
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The second model is monomer-directed conversion and predicts that a monomeric 
peptide will adopt an amyloid-competent conformation (A-state). This species will induce 
transformation of further monomeric peptides which initiates aggregation and 
fibrilisation. This model suggests that the addition of seed will not alter the fibrillisation 
rate or shorten the lag time, as the rate-limiting step occurs with the transformation of the 
soluble protein (Prusiner, 1982).   
The third model is nucleated polymerisation. This paradigm assumes that nucleus 
formation happens through association of soluble amyloid-competent species, then 
addition of the assembly-competent monomers to the nucleus leads to fibril formation. 
An equilibrium between both amyloid-competent and amyloid-incompetent protein 
species occur, with the equilibrium greatly favouring the incompetent species. Thus, the 
process is rate-limited by the amount of amyloid-competent species associated to create 
a nucleus. In this model, high levels of soluble protein will increase the rate of fibril 
assembly and shorten the lag time (Jarrett and Lansbury, 1993). In vitro assembly of 
amyloid fibrils usually have a lag phase before a rapid growth phase. In many 
circumstances preformed aggregate addition reduces the lag phase which is known as 
‘seeding’ (Dobson, 2003). In addition to amyloid fibril formation, the nucleation model 
is also common among a number of well-defined processes, such as protein 
crystallisation, actin polymerisation and microtubule association (Jarrett and Lansbury, 
1993).  
The fourth model is nucleated conformational conversion which suggests that 
formation of nuclei is enhanced by conformational rearrangements of structurally 
dynamic oligomers. These oligomers have not a defined quaternary structure, but it is 
thought that they might have a micelle-like structure. The formed nuclei interact with 
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other structurally flexible oligomers, then generate a group of subunits which can either 
add onto the end of the fibril or associate with similar structures. This model explains the 
often observed low level concentration dependence and suggests that higher molecular 
weight complexes formed by oligomers at higher protein concentrations are assembly-
incompetent.  This model can also explain why higher concentrations of seed produce 
sometimes minimal rate enhancements, because the oligomer concentration is limiting, 
not fibril ends (Serio et al., 2000).  
The discovery of secondary processes which involve the generation of new nuclei 
suggests that the nucleation process is greatly determined by the aggregates produced 
during the assembly reaction (Buell et al., 2014). These secondary processes involves 
fragmentation and secondary nucleation. When a critical concentration is achieved, the 
fibrillar structures act as a catalytic surface for the formation of new nuclei, and causes a 
rapid generation of toxic oligomeric species and amyloid fibrils in a secondary nucleation 
event (Cohen et al., 2013). Amyloid fibril fragmentation increases the number of 
available elongation sites for soluble protein attachment, bring on further production of 
fibrils (Xue et al., 2009). Fibril fragmentation can cause a negative concentration 
dependence, as fragmentation is enhanced by a low concentration, therefore the seed 
concentration increases (Bernacki and Murphy, 2009, Xue et al., 2009). As the amyloid 
assembly mechanism is intrinsically complex and heterogeneous, it is hard to find a 
concrete or general model to describe aggregation. Most models rely on nucleation, and 
seeding is a characteristic feature of most amyloids. However, as argued by (Bernacki 
and Murphy, 2009), these models can only clearly be differentiated with a complete set 
of data, not only on the disappearance of monomer, but also on quantity and size 
distribution of intermediate aggregates and the amount of fibrillar structure. 
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Figure 1.7. Models of Fibril Formation. Proposed models for amyloidogenic peptide 
conversion into amyloid fibrils. Jagged circles represent soluble (S-state) protein, smooth 
circles represent amyloid-competent (A-state) protein which takes a similar structure to that 
adopted in amyloid fibrils and open circles represent potential conformational heterogeneity in 
A) templated assembly, B) monomer-directed conversion, C) nucleated polymerisation and D) 
nucleated conformational conversion. Figure taken from (Kelly, 2000). 
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1.10. Alzheimer’s disease and related proteins 
1. 10. 1. Transthyretin (TTR) 
Transthyretin (formerly known as pre-albumin) is a homotetrameric protein made up of 
127 amino acid subunits. The TTR structure is mainly β-sheet, most of the residues except 
ten N-terminal and five C-terminal residues are involved in the β-strands, with a small 
helix and small loops connecting them (Figure 1.8A) (Blake et al., 1971). The monomer 
is composed of two four-stranded β-sheets, an outer sheet and an inner sheet. While the 
dimer forms by extensive hydrogen bonding between two monomers, the tetramer 
assembles largely through hydrophobic interactions (Hamilton and Benson, 2001). 
TTR is produced in the liver and choroid plexus and its function is to transport thyroid 
hormone and retinol via the retinol binding protein (RBP) (Hamilton and Benson, 2001). 
Thyroxin and RBP bind the TTR tetramer non-competitively (Raghu and Sivakumar, 
2004): thyroxin binds the tetramer pocket (Richardson, 2007b) while RBP binds residues 
in the loop between the strands E and F (Monaco, 2000) (Figure 1.8B). The concentration 
of TTR in plasma is around 3.16 μM with a range of 3-6 μM,  however, although it 
constitutes 25% of cerebrospinal fluid (CSF) total proteins, the TTR concentration is 18 
times less in the CSF 0.26 μM with a range of 0.1-0.4 μM (Weisner and Roethig, 1983, 
Herbert et al., 1986). TTR plays an important role in the body: in serum, TTR normally 
binds and transports 30% of RBP and 15-20% of thyroxin (Richardson, 2007a), but it 
transports 80% of thyroxin in the central nervous system (Hamilton and Benson, 2001), 
and thus serves as a major thyroxin transporter there. Thyroxin is important for the 
development of the nervous system, and influences mood and cognition (Bauer et al., 
2008). TTR gene silencing in mice leads to a behavioural deficit and neuropathological 
changes in the brain (Buxbaum and Reixach, 2009). Silencing of the RBP gene in mice 
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leads to cortical and hippocampal neuronal loss, some degree of gliosis and a major 
reduction in neuroblast proliferation (Buxbaum et al., 2014).  
Figure 1.8. X-ray structure of Transthyretin. TTR is a homotetrameric protein. The contacts 
between the dimers form two hydrophobic pockets where thyroxin binds. A) The monomer 
structure of TTR with the sheets colour coded and labled, the monomer is composed of two 
four stranded β-sheets (DAGH and CBEF). B) The residues involved in thyroxin binding are 
coloured in orange and residues involved in retinol binding protein coloured in red. The 
structures made using Pymol (DeLano, UK). 
 
1. 10. 1. 1. TTR amyloidosis 
TTR is one of the approximately 30 known amyloidogenic proteins. Wild-type TTR is 
normally stable at neutral pH, but acidic conditions facilitate tetramer dissociation to 
monomer and consequent formation of fibrils. Several mutants that form fibrils at 
physiological pH have also been discovered (Lashuel et al., 1998). There are currently 
124 TTR naturally occurring mutants listed in the amyloid protein mutations database 
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(http://www.amyloidosismutations.com/mut-attr.php, last accessed on March 26, 2016). 
Crystallographic data shows that most of the amyloidogenic TTR variants retain their 
normal tetrameric structures (Hornberg et al., 2000); and function. Thus, it is the 
increased tendency of the mutant to dissociate and misfold, not their incapacity to fold 
and function; that results in disease through a gain-of-toxic function mechanism 
(Hammarstrom et al., 2001, Sousa et al., 2001, Reixach et al., 2004). Wild-type TTR is 
the precursor of Senile Systemic Amyloidosis (SSA) (Westermark et al., 1990) whereas 
mutants are responsible for Familial Amyloid Polyneuropathy (FAP), (Saraiva et al., 
1984) and Familial Amyloidotic Cardiomyopathy (FAC) (Jiang et al., 2001). These 
diseases are characterized by the deposition of aggregated WT TTR or variants in 
extracellular tissues. The deposition occurs throughout the body (SSA) or in specific 
organs, like peripheral nervous system (FAP) or heart (FAC). SSA affects, 25% of the 
population above 80 years of age and this involves amyloid deposition in the heart causing 
congestive heart failure. With FAC, cardiac involvement is noticeable, whereas in FAP 
deposition of amyloid in the peripheral nervous system is more prominent (Miller et al., 
2004). 
1. 10. 1. 2. TTR and Aβ 
The first suggestion of a relevant relationship between TTR and Aβ was revealed by 
(Schwarzman et al., 1994), who showed that TTR, as a major constituent of the CSF, can 
sequester Aβ. This finding was followed by several animal model studies further 
supporting this interaction. Co-expression of TTR and Aβ lowered the number of Aβ 
deposits in muscle and controlled abnormal motility in Caenorbiditis elegans (Link, 
1995). It has also been shown that  levels of TTR expression increased 8 fold in Tg2576 
transgenic mice over-expressing the Swedish mutation of APP (APPsw) (Stein and 
Johnson, 2002), and unilateral anti-TTR antibody infusion in the brains of Tg2576 
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transgenic mice triggered Aβ related pathology compared to the non-injected hemisphere 
(Stein et al., 2004). A later study showed that a hemizygous deletion of the TTR gene in 
ceAPPswe/PS1_E9 transgenic mice led to the elevation of soluble Aβ levels and 
acceleration of its deposition in the brain (Choi et al., 2007). Buxbaum et al. (2008) 
observed cognitive and behavioural improvement in progeny from human TTR 
expressing mice crossed with APPsw mice. Collectively these findings mark TTR’s 
ability to sequester Aβ and protect cells from Aβ’s cytotoxic effects. 
Cell line experiments also show TTR’s protective ability against Aβ cytotoxicity. 
Physiological levels of TTR protected neuroblastoma cells form Aβ induced apoptotic 
changes (Giunta et al., 2005). It has been shown that TTR abolishes apoptosis and cell 
death caused by Aβ toxicity in human neuroblastoma cells (Costa et al., 2008) and murine 
cortical neuronal cultures (Yang et al., 2013b). Substoichiometric concentrations of TTR 
significantly restored cell viability and prevented Aβ’s apoptotic effects in murine cortical 
neurons (Liu et al., 2009) and human SH-SY5Y neuroblastoma cells, probably by 
reducing Aβ’s tendency to acquire cytotoxic properties (Li et al., 2011). 
Although there is evidence for a direct interaction between WT-TTR and Aβ, 
contradictory results were achieved regarding which species of TTR and Aβ were 
interacting when different methodologies were used. In general, methodologies 
depending on immobilizing one of the proteins like surface plasmon resonance (SPR) and 
ELISA show that TTR tetramers bind all forms of Aβ (Costa et al., 2008) with preferential 
binding of TTR tetramers to Aβ aggregates than to Aβ monomers (Du and Murphy, 2010) 
and fibrils (Yang et al., 2013a). Using the same methodology, Murphy and colleagues 
showed that TTR monomers bind more strongly to Aβ monomers than TTR tetramers 
(Du and Murphy, 2010). In contrast, and more accurately, liquid phase NMR experiments 
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showed that only TTR tetramers bind to Aβ monomers despite the greater inhibitory 
effect of TTR monomers on Aβ fibrillisation. This suggests that TTR monomers play a 
different role by binding to a larger Aβ species and preventing its further aggregation (Li 
et al., 2013a).  
It has been suggested that the co-incubation of wild type and variant TTRs with Aβ lead 
to a triggering of tetramer dissociation which exposes the hydrophobic inner sheet of the 
TTR monomer and consequently inhibits Aβ aggregation (Yang et al., 2013a). In support 
of this, it was found that kinetically unstable tetramers are better inhibitors of Aβ 
aggregation than highly kinetically stable tetramers (Li et al., 2013a). Solution NMR 
assays suggest that the TTR tetramer pocket which is also the thyroxin binding site is 
involved in Aβ binding. Indeed, Aβ binding is less effective when this site is occupied by 
small molecules (Li et al., 2013a). This result is consistent with the binding site identified 
through peptide array and site-directed mutagenesis assays (Du et al., 2012, Cho et al., 
2014) (Figure 1.9). Thioflavin T assays have shown that the TTR monomer is a greater 
inhibitor of Aβ fibrillogenesis in vitro. However, HSQC NMR assays failed to show TTR 
monomer binding to Aβ monomers. It can be concluded that TTR monomers prevent Aβ 
aggregation through binding to larger oligomers and suppress any further aggregation of 
Aβ to make fibrils (Li et al., 2013a).  
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Figure 1.9. The crystal structure of tetrameric TTR with the Aβ binding sites. The residues 
coloured in red are showed chemical shifts upon Aβ1-40 binding investigated by NMR (Li et al., 
2013a), the residues found to bind to Aβ detected by peptide array are coloured in blue (Du et 
al., 2012), and the residues showed binding in both studies are coloured in purple. The crystal 
structure by (Klabunde et al., 2000). The structure made by using Pymol (DeLano, UK). 
 
The TTR equilibrium greatly favours tetramer in vivo and TTR tetramer is in equilibrium 
with only a small population of monomer in the body (Buxbaum et al., 2012). The 
concentration of TTR tetramer is 0.25-0.5µM in human CSF and 3-5µM in human serum, 
much higher than the monomer. Based on a WT TTR Kassociation of 1.1X 10
24M-3, the  TTR 
monomer concentration (Hurshman Babbes et al., 2008), is predicted to be ~25 nM in 
CSF and ~46nM in serum, consistent with the detected TTR monomer concentration in 
human serum (5-10nM) (Sekijima et al., 2001). The Aβ monomer concentration in the 
human brain is in the high picomolar to low nanomolar range (Cirrito et al., 2003, 
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Buxbaum et al., 2008, Moore et al., 2012). Thus, the in vivo concentration of TTR 
monomer may be present in excess compared to Aβ, however, the absolute concentration 
of TTR tetramer is much higher. Based on the above facts, it seems that binding of 
tetrameric TTR to Aβ monomers and possibly Aβ oligomers is the main mechanism of 
inhibition of Aβ fibrillogenesis in vivo. 
1. 10. 2. Human Cystatin C  
Cystatin C is also known as γ-trace (Hochwald et al., 1967) and was initially identified 
in the CSF before being observed in all body fluids and tissues (Bobek and Levine, 1992, 
Turk et al., 2008). Cystatin C is an inhibitor of papain-like cysteine protease inhibitors 
which include some of the cathepsins (cathepsin B and D) in humans, which are required 
for protein degradation during protein turnover (Turk et al., 2000). Different neurological 
diseases which have been related to uncontrolled proteolysis happen when the balance 
between active proteases and their inhibitors is disturbed (Nakamura et al., 1991). As well 
as its main protease inhibition activity, cystatin C has a diverse range of biological 
functions, including, regulation of the inflammatory response (Warfel et al., 1987, Bobek 
and Levine, 1992), cell growth and proliferation (Sun, 1989, Tavera et al., 1992), and 
astrocytic differentiation during mouse brain development (Kumada et al., 2004). 
Cystatin C expression is also enhanced in patients with epilepsy (Tizon et al., 2010c). 
Cystatin C is a brain-specific protein as the bulk of cystatin present in CSF is produced 
by the choroid plexus (Tu et al., 1992) and, unlike other protein constituents, its normal 
CSF concentration is five times higher  than in serum, indicating a possible important role 
in the brain (Grubb, 1992). 
1. 10. 2. 1. Cystatin C amyloidosis 
Cystatin C was recognised as an amyloidogenic protein causing a dominantly inherited 
disorder known as hereditary cystatin C amyloid angiopathy (HCCAA) (Cohen et al., 
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1983). This disease is systemic since immuno-histochemical assays have detected 
amyloid deposits of cystatin C in diverse tissues including the brain, spleen, salivary 
glands, and the skin (Abrahamson and Grubb, 1994). As cystatin C is found in all body 
fluids, so its systemic deposition is expected. However, the highest plaque burden is found 
in brain arteries and arterioles, causing vessel wall thickening and causing brain 
haemorrhage (Palsdottir et al., 2006). This disease is normally found in 20 to 40 year old 
Icelandic individuals.   
The cystatin C variant (L68Q) causes the hereditary cystatin C amyloid angiopathy 
(HCCAA) disease (Ghiso et al., 1986a). Although the mutation does not directly 
participate in amyloid-formation interactions, it destabilises the monomer and makes it 
more susceptible to dimerisation. L68Q hCC is similarly effective in inhibiting cathepsin 
B with similar equilibrium constants for dissociation (Kd) as WT hCC, suggesting that 
the mutant is able to fold into the right conformation;  the dissimilarities are in their 
propensity to dimerise and form aggregates (Abrahamson and Grubb, 1994). Both hCC 
dimers and monomers are found in the blood plasma of patients with the disease when 
only monomeric species are detected in healthy individuals (Palsdottir et al., 2006). The 
existence of inactive dimers in CSF caused a decrease in the total cysteine protease 
inhibition capacity, this could cause cerebral haemorrhages in HCCAA (Olafsson et al., 
1990). Despite the L68Q mutation, the variant detected in HCCAA amyloid deposits also 
has an N-terminal truncation of 10 amino acids when compared to normal hCC (Grubb 
and Lofberg, 1985, Ghiso et al., 1986b). It is suggested that leucocyte elastase is 
responsible for this truncation (Abrahamson et al., 1991). 
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1. 10. 2. 2. Cystatin C and Aβ 
The link between hCC and AD was initially proposed because of their co-localisation in 
amyloid plaques. Human immunohistochemical investigations demonstrated that hCC is 
mainly detected in amyloid deposits encircling blood vessels and less frequently in 
parenchymal deposits (Deng et al., 2001, Sastre et al., 2004b). Co-localisation of hCC 
and β-APP have been detected inside both mouse neuroblastoma N2a cells and human 
embryonic kidney HEK293 cells. Cell culture assays show intracellular localisation of 
hCC and β-APP in both mouse neuroblastoma N2a cells and human embryonic kidney 
HEK293 cells. Co-localisation of hCC with Aβ has also been detected in the brains of 
transgenic mice over-expressing human APP (Tizon et al., 2010a). Cystatin C co-
localization with Aβ is not only limited to AD, it is found in the core of amyloid senile 
plaques in brains of patients with Down’s syndrome, HCHWA-D (hereditary cerebral 
haemorrhage with amyloidosis – Dutch type), intracranial haemorrhage, cerebral 
infarction, and of elderly individuals without any neurological disorder (Maruyama et al., 
1990, Vinters et al., 1990b, Itoh et al., 1993, Haan et al., 1994, Levy et al., 2001). Studies 
were performed to reveal whether hCC co-exists with Aβ as amyloid fibrils or soluble 
hCC trapped or adsorbed in Aβ fibril bundles. An ELISA based study found hCC included 
in crude Aβ fibrils in a ratio of 1:100 in amyloid plaques isolated from cerebral blood 
vessels (Nagai et al., 1998). Cystatin C was found to be soluble in fibrillar Aβ samples 
isolated in leptomeningeal vessels in another case of sporadic CAA (cerebral amyloid 
angiopathy) (Maruyama et al., 1992). One interpretation is that hCC deposition is driven 
by Aβ deposition (Itoh et al., 1993), and leads to an increased local concentration of hCC 
and this leads to cerebral haemorrhage (Kaur and Levy, 2012). Despite that, the main 
deposited amyloidogenic protein in HCCAA is hCC. However, Aβ co-deposition has not 
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been confirmed using different anti-Aβ antibodies (Vinters et al., 1990a, Haan and Roos, 
1992). 
hCC levels are found to be increased in susceptible parts of the human brain (Deng et al., 
2001) and in animal models, indicating a physiological response to the disease pathology, 
by which hCC expression is increased (Steinhoff et al., 2001). Transgenic mice studies 
demonstrated that overexpressing hCC to twice the normal levels inhibits Aβ deposition 
in transgenic mice expressing the Swedish mutant APP (Kaeser et al., 2007b, Mi et al., 
2007a). 
1. 10. 2. 3. Genetic studies 
Genetic studies reveal an association between AD and hCC at the genetic level. The 
Cystatin C gene, CST3, is located on chromosome 20 (Abrahamson et al., 1989, Saitoh 
et al., 1989), studies show a link between CST3 polymorphism and an increased risk of 
AD (Crawford et al., 2000, Bertram et al., 2007). A reduction in hCC levels has been 
observed as a result of a mutation in which threonine substitutes for alanine at position -
2. This leads to a reduced signal peptide cleavage and impaired secretion (Tizon et al., 
2010a) such polymorphism increases the risk of AD for homozygous individuals 
(Selenica et al., 2007a). Late onset AD is also related to other polymorphisms including 
the CST3 +73 G/A mutation (Crawford et al., 2000) or the CST3 –157 G/C polymorphism 
(Finckh et al., 2000). However, some studies have failed to prove the link between CST3 
polymorphism and AD in a German cohort (Dodel et al., 2002), a Dutch sample with 
early onset AD (Roks et al., 2001), Japanese AD patients (Maruyama et al., 2001), a 
Finnish population (Helisalmi et al., 2009) and in early onset AD families (Parfitt et al., 
1993). Other researchers have found a connection between AD and the CST3 
polymorphism AD in Caucasian populations, but not in Asian populations (Hua et al., 
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2012), including Chinese (Wang et al., 2008). Many of these findings are difficult to 
reproduce, probably due to the diversity of different risk factors associated with AD 
which lead to considerable difficulties in selecting controls (Bertram and Tanzi, 2008). 
However, these genetic studies with accumulated evidences on physiological roles of 
hCC in animal and cell line models of AD and evidences on biochemical interactions of 
hCC with Aβ in test tube models strengthen the suggested protective role for hCC in AD.  
1. 10. 2. 4. Mechanisms of neuroprotection 
Cystatin C can protect neuronal cells through different mechanisms meaning there could 
be direct and indirect roles of hCC in Alzheimer’s disease. The indirect mechanisms 
include cysteine protease inhibition, inducing autophagy and enhancing neurogenesis, 
while a direct mechanism exists through interaction with Aβ and inhibition of its 
aggregation. 
1. Inhibition of cysteine proteases: The balance between cathepsins and hCC as an 
inhibitor is important for neuronal health. The inhibitory effect of cystatin C against 
cathepsin B was investigated by knocking out the cystatin C gene in mice. This resulted 
in an increased cathepsin B activity (Sun et al., 2008). In a separate study, it was shown 
that cathepsin B and D activity decreased, and neuropathological symptoms were rescued 
by over-expressing cystatin C in cystatin B knocked out mice (Kaur et al., 2010). 
2. Induction of autophagy: Using different methodologies, it was revealed that hCC 
enhances autophagy in cells under basal conditions, and induces autophagic activation in 
cells subjected to oxidative stress and nutritional deprivation (Tizon et al., 2010c). 
Autophagy is lysosomal degradation of cytoplasmic components. It is essential for normal 
cell growth and survival. It is important for destruction and removal of undesirable 
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contents such as misfolded protein, aberrant protein aggregates, dysfunctional organelles 
and invading pathogens (Lamark and Johansen, 2012). 
3. Protection by neurogenesis: Cystatin C can also adjust proliferation of cells (Sun, 1989, 
Tavera et al., 1992). Levels of both cystatin C mRNA and protein are elevated in the 
dentate gyrus and hippocampus in rats experiencing status epilepticus-induced 
epileptogenesis and acute hippocampal injury (Aronica et al., 2001, Lukasiuk et al., 
2002). The increase in hCC expression and prominent neurogenesis was observed to 
occur at the same time (Parent et al., 1997, Nairismagi et al., 2004). Additionally, in hCC 
knockout mice, the basal level of neurogenesis in the dentate gyrus was reduced and 
newborn granule cell proliferation and migration in the dentate gyrus were impaired 
(Pirttila and Pitkanen, 2006), supporting an hCC role in neurogenesis. Thus, induction of 
neurogenesis might be another mechanism of neuroprotection enhanced by hCC. 
4. Protection by inhibition of Aβ oligomerization and amyloid ﬁbril formation: -  
ELISA was used as one of the first techniques to investigate the hCC interaction with Aβ 
(Sastre et al., 2004a). This revealed high-affinity binding between two proteins at 
physiological pH and temperature, with a dissociation constant (Kd) in the nanomolar 
range. Only 5nM of a monoclonal antibody 6E10 was needed to block hCC binding to 
Aβ. This antibody specifically binds to residues 1-17 (the N-terminal region of the 
peptide), proposing that hCC also bind in this region. A concentration dependence of the 
binding of hCC to Aβ was first investigated by this study. 
Further investigation by Sastre et al. (2004a) using electron microscopy showed 
inhibition of Aβ fibril formation by hCC in vivo in a concentration-dependent manner. 
Direct and sub-stoichiometric binding between hCC and Aβ was suggested which led to 
reduced Aβ fibril formation. Selenica et al. (2007b) suggest that the in vitro formation of 
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protofibrils and oligomers of Aβ, including toxic ADDLs can be prevented by hCC. This 
finding could have important implications because Aβ oligomers are potentially causative 
in AD. The hCC binding to Aβ was detected using size-exclusion chromatography (SEC) 
and immunoprecipitation, with a one to one equimolar complex observed by the authors. 
The concerned species was not resolved by the chromatography used which makes the 
results somewhat ambiguous. Despite this, the authors suggested that hCC and Aβ react 
rapidly to form high-affinity one to one molar complexes, involving the N-terminal region 
of Aβ in the binding (Selenica et al., 2007a). When the mixture was incubated for longer, 
the initial complexes had less tendency than the monomeric Aβ to produce higher species 
such as ADDLs, protofibrils or even fibrils. Rather larger, amorphous aggregates are 
assembled without the structural characteristics of the preceding species and precipitate 
from solution.  
1. 10. 3. Neuroserpin 
Neuroserpin is a member of the serine protease inhibitor (serpin) superfamily 
(Osterwalder et al., 1996) and its main function is the inhibition of tissue plasminogen 
activator (tPA) (Miranda and Lomas, 2006). Low levels of tPA are produced within the 
CNS and are believed to contribute to the development of synaptic plasticity and learning 
and memory (Yepes and Lawrence, 2004). Neuroserpin was initially found in neurons of 
the central and peripheral nervous system, and then in other organs like kidney, testis, 
pancreas and heart (Hastings et al., 1997).  
1. 10. 3. 1. Neuroserpin amyloidosis 
Four different neuroserpin variants (Ser49Pro, Ser52Arg, His338Arg and Gly392Glu) 
have been found in humans (Davis et al., 1999, Davis et al., 2002). Neuroserpin mutants 
polymerise spontaneously and form inclusion bodies in neurons causing an inclusion 
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body dementia which is called “familial encephalopathy with neuroserpin inclusion 
bodies” (FENIB). 
1. 10. 3. 2. Neuroserpin and Aβ 
Recently, neuroserpin has been reported as another protein associated with extracellular 
Aβ plaques in the brains of AD patients. Neuroserpin has been found at the periphery and 
within the Aβ plaques (Kinghorn et al., 2006a). Neuroserpin specifically interacts with 
Aβ to form a 1:1 binary complex, in which Aβ fills the β-Sheet A of neuroserpin.  The 
dissociation constant for the neuroserpin- Aβ complex is 10± 5nM (Chiou et al., 2009). 
Pre-incubation of neuroserpin with Aβ irreversibly inactivated its inhibitory action 
against serine protease (tPA). Formation of homopolymers at elevated temperatures 
through loop sheet polymerisation is a distinctive character of the serine superfamily 
(Figure 1.10). The N-terminal and middle part fragments but not the C-terminal of Aβ 
also inhibit neuroserpin loop sheet polymerisation, suggesting that the N-terminal and 
middle parts of Aβ are involved in the interaction. Neuroserpin reduces Aβ cytotoxicity 
in both cell culture and in an in vivo drosophila model, supporting a neuroprotective role 
for neuroserpin in AD. A fibrillisation assay where fibril formation is detected using 
Thioflavin T fluorescence showed an apparent acceleration of Aβ aggregation by 
neuroserpin, however electron microscopic inspection showed that different species of 
aggregate were formed (short amorphous aggregates) and so it is suggested these are off-
pathway non-toxic aggregates (Figure 1.11) (Kinghorn et al., 2006b).  
Other studies have found an indirect role for neuroserpin regarding the accumulation of 
Aβ in the brain. It has been found that its substrate tPA plays a role in Aβ clearance 
through activation of inactive plasminogen to plasmin which consequently degrades both 
Aβ monomers and fibrils (Selkoe, 2001, Melchor et al., 2003, Medina et al., 2005). The 
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activity of plasmin (Ledesma et al., 2000) and tPA are both remarkably diminished, while 
neuroserpin levels significantly increased in the brain of AD compared to age-matched 
control brains (Fabbro and Seeds, 2009). High levels of neuroserpin can inhibit tPA 
activity through the tPA-neuroserpin complex formation in the AD brain tissue (Fabbro 
and Seeds, 2009), and consequently, inhibit Aβ clearance. Furthermore, AD mice model 
studies showed that knocking out the neuroserpin gene results in decreased levels of brain 
Aβ (Fabbro et al., 2011) which also confirm a negative role of neuroserpin in Alzheimer’s 
disease. 
 
Figure 1.10. Model of a domain-swapped serpin polymer. Both sheet 5A and the reactive 
centre loop (RCL) insert into the A-sheet of another serpin monomer (Yamasaki et al., 2008). 
 
 
Figure 1. 11. TEM of neuroserpin / Aβ1-42 mixtures. Monomeric Aβ1–42 was incubated at 1 
mg/ml for 1 h at pH 7.4 and 37 °C in the absence (b and d) or presence of 12 µM neuroserpin 
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(c and e). Samples were diluted 1:1 with buffer and placed directly onto the electron microscopy 
grid (b and c) or centrifuged at 10,000 x g for 10 min, and the pellet placed on the grid (d and 
e). The morphology of the resulting protein species was examined by transmission electron 
microscopy. Aβ1–42 incubated in the absence of neuroserpin formed amyloid fibrils (b and d), 
whereas co-incubation Aβ1–42 and neuroserpin abolished fibril formation and promoted the 
formation of smaller species (c and e). Scale bar, 100 nm (Kinghorn et al., 2006b). 
 
1. 10. 4. Albumin  
Serum albumin reduction with age is one of the known AD risk factors. Human serum 
albumin (HSA) has been found bound to 89-95% of Aβ in blood plasma (Biere et al., 
1996, Kuo et al., 2000b) with a Kd of 5-10 µM and with a 1:1 stoichiometry (Kuo et al., 
2000a). HSA concentration in blood serum is 640 µM (Carter and Ho, 1994) which is the 
highest among all serum proteins. However, its concentration is much lower in CSF at 
only 3 µM, which is comparable to levels of TTR and cystatin C (Stevens et al., 1979). It 
is suggested that the decreased HSA level in the CSF results in a diminished availability 
for Aβ binding, and this could explain the presence of extracellular Aβ plaques only in 
the brain, instead of peripheral tissues (Stanyon and Viles, 2012a). 
It is still a subject of controversy as to whether HSA binds Aβ monomer or oligomers. 
Some researchers have demonstrated that HSA binds monomers of Aβ (Kuo et al., 2000a, 
Rozga et al., 2007). Stanyon and Viles (2012a) suggested that HSA interacts with Aβ 
monomers and small oligomers of less than five monomers. Another study employing 
biotin labelling and immobilized Aβ polymers showed that HSA inhibits soluble Aβ 
monomer in addition to immobilized Aβ seeds, indicating inhibition of Aβ aggregation 
(Bohrmann et al., 1999). However, results obtained through a series of STD NMR 
experiments on Aβ and HSA binding showed that HSA binds to Aβ oligomers but not 
monomers and fibrils (Milojevic et al., 2007, Milojevic et al., 2009, Milojevic et al., 
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2014). It is well known that HSA binds to many hydrophobic molecules, especially 
pharmaceuticals and endogenous fatty acids (Carter and Ho, 1994). The hydrophobic 
pockets of HSA have been described through the investigation of the crystal structure of 
HSA bound to fatty acids (Curry et al., 1998), hemin (Zunszain et al., 2003) and bilirubin 
(Vander Jagt and Garcia, 1987), which might be the pocket where the hydrophobic C-
terminal part of Aβ binds. It has also been proposed that hydrophobic molecules such as 
cholesterol (Peng et al., 2008) and pharmaceuticals compete with Aβ to bind to HSA 
(Bohrmann et al., 1999). Recent studies have found that HSA binds to Aβ oligomers 
through multiple binding sites, distributed evenly across the three albumin domains 
(Milojevic and Melacini, 2011). 
Since HSA is not observed within amyloid plaques in brains of AD patients, it is believed 
that it does not interact or become incorporated into the plaques. However, Thioflavin T 
experiments showed that a micromolar human CSF concentration of HSA significantly 
elongates the lag phase and the bulk of produced fibril by both Aβ1-40 and Aβ1-42 variants 
in vitro (Stanyon and Viles, 2012b). Given the fact that a large proportion of serum Aβ is 
bound to HSA, it is hypothesized that the replacement of plasma albumin could lower Aβ 
levels in the CSF and brain because Aβ peptides are able to cross the blood brain barrier 
(Mackic et al., 1998). Promising results have been obtained in phase II (Boada et al., 
2009) and phase ΙΙΙ clinical trials through plasma albumin exchange schedule 
(http://grifols.com/en/web/uk/view-news/-/new/grifols-achieves-ten-years-of-research-
into-alzheimers, last accessed on 17/February /16).  
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1. 10. 5. Prion (PrPC) 
Prion is a ubiquitously expressed cell surface glycoprotein with its highest concentration 
in the brain. The cellular prion protein has recently been recognized as a cell surface 
receptor for Aβ oligomers (Zhou and Liu, 2013). Lauren et al. (2009) found that prion is 
able to intervene in Aβ oligomer toxicity. They showed that Aβ oligomers bound to prion 
with high affinity and specificity. They also found that nanomolar concentrations of Aβ 
oligomers are capable of halting LTP in cultured hippocampal slices, however, this affect 
is not observed in slices without PrPC receptors or when receptors are occupied with an 
antibody. This suggests that LTP is specifically suppressed by Aβ oligomers binding to 
PrPC. Lauren et al. (2009), then attempted to test whether, in vivo, PrPC is crucial to the 
ability of Aβ to arrest cognitive function. They crossed transgenic mice encoding β-APP 
gene with mice encoding the PrPC gene or not. They, found that mice containing Aβ 
plaques but lacking PrPC demonstrated no detectable impairment of spatial learning and 
memory, while the AD transgene mice with PrPC developed considerable deficits in 
spatial learning and memory, suggesting that PrPC is specifically needed for the toxicity 
of naturally occurring Aβ in the brain. Deletion analysis, antibody binding (Lauren et al., 
2009) and surface plasmon resonance (Chen et al., 2010) experiments identified two 
specific binding sites of Aβ oligomers on PrPC. One is at the N-terminal and the other is 
close to middle part of the protein and both are rich in positively charged basic residues. 
Deletion of either part significantly reduced the binding affinity for Aβ oligomers, 
suggesting that both parts act together to render high-affinity binding to oligomers (Chen 
et al., 2010, Biasini et al., 2012). 
The PrPC role in mediating Aβ oligomer toxicity was questioned by other researchers’ 
findings. Roberto Malinos’ group demonstrated that PrPC is not needed for Aβ-induced 
synaptic toxicity. The Aβ mediated synaptic plasticity was noticed in both wild-type and 
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prnp-1- mouse slices (Kessels et al., 2010). Forloni and his team found that PrP 
expressing and PrPC knock-out mice were equally susceptible to cognitive impairment 
when they injected with Aβ oligomers into the lateral ventricle, proposing that PrPC is 
not necessary for Aβ oligomer-mediated cognitive impairment (Balducci et al., 2010), yet 
they have verified nanomolar affinity binding between Aβ oligomers with PrPC. Other 
researchers found conflicting results on the role of PrPC in Aβ mediated toxicity. 
Overexpression or ablation of PRNP in AD model transgenic mice was shown not to 
prevent impairment of synaptic plasticity of neurones in the hippocampus (Calella et al., 
2010), nor improve abnormal neurone activity or improve cognitive dysfunction (Cisse 
et al., 2011).  These results indicate that Aβ toxicity is not dependent on PrPC. The wide 
variation in results may be due to the use of different preparations and concentrations of 
Aβ, and the use of different mouse models and cell lines (Freir et al., 2011).  Perhaps the 
Aβ oligomers used are capable of causing PrPC -independent damage but are not found 
in vivo, and hence were not isolated in the AD brain extracts used by (Freir et al., 2011). 
Alternatively, perhaps Aβ requires PrPC for only some of the pathological effects 
observed in AD patients, for example, prevention of LTP. 
Despite the controversial results found by different researchers on the role of PrPC as a 
mediator of Aβ oligomer toxicity, there are no conflicts on two end points: high-affinity 
binding between PrPC and Aβ oligomers and Aβ oligomer-mediated synaptic toxicity. 
The challenge remaining to researchers is to make the two ends meet. 
1. 11. Sugars and Polysaccharides  
1. 11. 1. Simple sugars 
Sugar molecules interact with peptides and proteins using their hydrophobic surface to 
form contacts with hydrophobic pockets of proteins, as well as hydrogen-bonds. It has 
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been proposed that this characteristic is crucial to binding amyloidogenic proteins (Fung 
et al., 2005). Less mobile sugar molecules are likely to form more stable and stronger H-
bonds with amyloid proteins and consequently stabilise the soluble forms of protein and 
prevent fibrillogenesis. 
In contrast, some carbohydrates enhance fibrillogenesis by induction of nucleation (Kim 
et al., 2001) or mature fibril formation (Yang et al., 1999). Indeed, it has been shown that 
glucose enhances nucleation and seeding of the amyloid Aβ peptide fibrillogenesis, while 
galactose and maltose enhance amyloid fibril formation (Fung et al., 2005). In contrast, 
other disaccharides have been shown to prevent protein unfolding and inhibit amyloid 
fibril formation. These disaccharides include sucrose, maltitol, turanose, cellobiose and 
trehalose (Tanaka et al., 2005). The most effective of these disaccharides is trehalose, it 
is a simple disaccharide composed of two glucose molecules binding together through 
α,α-1,1 linkage (Liu et al., 2005). It has been shown that trehalose is effective against 
protein denaturation by heat shock and might be able to prevent denatured protein from 
aggregation (Singer and Lindquist, 1998). Insulin aggregation can be delayed or inhibited 
by Trehalose (Arora et al., 2004). Oral administration of trehalose reduced brain atrophy 
by decreasing polyglutamine aggregates and increasing the lifespan of a transgenic mouse 
model of Huntington's disease (Tanaka et al., 2004). Trehalose efficiently reduced Aβ 
aggregation and toxicity in human neuroblastoma cell lines (Liu et al., 2005).  
Other simple saccharides such as sucrose increase Aβ protein stability and consequently 
its fibrillogenesis (Fung et al., 2005). This shows that carbohydrates with similar 
molecular weights have different effects on amyloid fibril formation according to their 
pattern of potential H-bonding. 
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1. 11. 2. Glucose metabolism 
The most energy-demanding organ in the body is the brain and glucose is the main energy 
source used by the brain to generate the ATP it requires to function (Hoyer, 1998). 
Anumber of in vivo studies have therefore focused on the relationship between glucose 
metabolism and AD. The endothelial cells lining cerebral blood vessels are responsible 
for transporting glucose across the blood-brain barrier (BBB), yet constitutes less than 
1% of brain cells. They are high in GLUT1, a specific protein transporter that aids glucose 
to pass the BBB and enters the brain (Harik et al., 1990). 
A substantial decrease of glucose metabolism in affected areas of the brain is one of the 
evident features of Alzheimer’s disease. Applying positron emission tomography (PET) 
with 2-[F-18]-fluoro-2-deoxy-D-glucose as a label shows a gradual decrease in brain 
glucose metabolism and flow in association with the dementia severity. Interestingly, 
regional brain glucose hypometabolism was shown not only in patients but also in 
younger family members with familial AD in a preclinical phase before the onset of 
disease (Perani, 1999), indicating a causal involvement in the disease process. 
Subsequently, the depletions in the endothelial GLUT1 transporter were shown in the 
brains of AD patients, suggesting that reduced utilization of glucose was a result of the 
deficiency in glucose transport across the BBB (Harik et al., 1990, Mooradian et al., 
1997). However, the effect of the endothelial GLUT1 transporter reductions on brain 
performance and disease progress remained unresolved for over twenty years. Winkler et 
al (2015) started to answer this question employing GLUT1 gene deficit mice (Slc2a1+/– 
mice). They showed that Slc2a1 haploinsufficiency in the brain gives rise to a decline in 
vascular length, blood flow and glucose uptake with age, and to an increase in BBB 
permeability. With ageing, Slc2a1-deficent mice also display evidence of cortex and 
hippocampus neurodegeneration. These findings revealed an unpredicted impact of 
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deficiency in endothelial GLUT1 on the brain and its vessels that leads to brain 
dysfunction and neurodegeneration. 
Therefore (Winkler et al., 2015), investigated the effect of the brain GLUT1 deficiency 
on AD pathology by crossing Slc2a1-haploinsufficient mice with mice overexpressing 
the amyloid precursor protein containing the Swedish mutation (APPSw mice). They 
found that the endothelial GLUT1 reduction noticed in AD could potentially work 
synergistically with AD pathology to intensify its detrimental effects on the brain and 
stimulate the development of dementia. 
One explanation of the reduced brain glucose metabolism is that the hypometabolism is 
the outcome of diminished neuronal activity and accordingly, a depletion in energy 
expenditure. However, an alternative explanation would be that the reduction in GLUT1 
could decrease glucose uptake and restrain the brain’s energy supply, which, could impair 
neuronal activity and, eventually, bring on neurodegeneration (de la Monte and Tong, 
2014). 
GLUT1 has been investigated as a potential target for the development of new therapeutic 
interventions aimed at restoring GLUT1 levels for the relief of brain dysfunction and 
damage in AD. To begin to address this possibility, Winkler et al. (2015) conducted 
adenoviral gene transfer in APPSw mice deficient in Slc2a1. They discovered that 
GLUT1 restoration in the hippocampus notably decreased local Aβ levels. This may open 
new therapeutic approaches for this devastating neurodegenerative disease. 
 
 1. 11. 3. Polysaccharides 
Extensive investigation into amyloid diseased tissues has confirmed the presence of a 
large amount of polysaccharide along with amyloid proteins in the deposits. The 
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deposited polysaccharides are mainly glycosaminoglycans (GAGs). Heparan sulphate 
(HS) is among the most commonly deposited GAGs, being observed in a number of 
amyloid diseases including Alzheimer’s disease, type II diabetes, light chain amyloidosis, 
and prion-related diseases (Snow et al., 1990, Young et al., 1992). 
Recent studies propose that GAGs can enhance misfolding through favouring the 
formation of β-sheet rich intermediates by polypeptides, and accordingly increases the 
number of nucleation seeds. Furthermore, GAGs can act as a template for amyloid 
assembly. GAGs can also interfere with amyloid formation in its late stages by promoting 
lateral association of small fibrils affording insolubility and avoiding proteolysis 
(McLaurin et al., 1999, Ancsin, 2003).  
In vitro studies further disclosed the link between GAGs and amyloid formation. Heparan 
sulphate has been shown to trigger fibril formation by the Aβ peptide in vitro (Castillo et 
al., 1997, Castillo et al., 1999, McLaurin et al., 1999). The interaction of GAGs with both 
Aβ peptides (Aβ1-40 and Aβ1-42) were investigated to reveal their effect on peptide 
conformation and fibril formation. In the presence of heparin, the transition of the Aβ 
peptide from random-coil to amyloidogenic β-sheet is accelerated, with Aβ1-42 quickly 
adopting a β-sheet conformation. This stimulation is followed by amyloid fibril 
formation, indicating that Aβ1-42 nucleation is enhanced. These results obviously suggest 
that GAGs affect amyloid fibril formation at the very early stages. The crucial part of 
GAGs, which enhance Aβ fibril formation is the sulphates, its complete removal causing 
a full disappearance of the enhancing effect (Castillo et al., 1999, Valle-Delgado et al., 
2010). 
It has been suggested that surface HS mediates the internalization and toxicity effects of 
Aβ (Sandwall et al., 2010). These authors showed that HS-deficient cells were unable to 
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internalise Aβ and were substantially resistant to Aβ toxicity. Over-expression of 
heparanase in cells also debilitated Aβ1-40 toxicity. Furthermore, heparin addition to cells 
blocked Aβ1-40 internalisation and inhibited Aβ toxicity.  
Low-molecular-weight heparins (LMWHs) can prevent the formation of β-plated 
structure and inhibit fibril formation (Bergamaschini et al., 2009, Ariga et al., 2010). 
Scholefield et al. (2003) showed that heparin can also inhibit the activity of β-secretase 
activity in neurons, i.e., the β-site APP-cleaving enzyme 1 (BACE-1), whose activity is 
essential for the production of the amyloidogenic Aβ peptide (Walsh et al., 1997). The 
ability of heparin to interfere with both Aβ production and fibril formation, suggesting a 
possible role of heparin in a therapeutic approach (Bergamaschini et al., 2009, Ariga et 
al., 2010). 
1. 12. Lipids  
Post-mortem brain tissue investigations showed biochemical alterations of lipid 
composition as a first clue to a link between Alzheimer’s and lipid metabolism. 
Subsequently, a closer link was built when the e4 allele of the Apo lipoprotein E (APOE) 
gene was confirmed as a genetic risk factor for AD (Corder et al., 1993, Bertram and 
Tanzi, 2008). APOE encodes a ~34-kDa protein that acts as an important cholesterol 
metabolism regulator in the brain. It mediates the lipoprotein particle uptake in the brain 
through the very low-density family lipoprotein receptor and low-density lipoprotein 
(LDL) receptor-related protein (LRP) (Bu, 2009, Kim et al., 2009). Data on the binding, 
clearance and modulation of Aβ aggregation by the e4 allele of APOE, support its role in 
the pathology of Alzheimer’s disease. Moreover, the role of cholesterol in the 
pathophysiology of Alzheimer’s is also supported by several epidemiological studies (Bu, 
2009, Kim et al., 2009).  
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Its now well-known that most of the lipids that modulate Alzheimer’s pathology do so 
through different mechanisms which can be summarized as follows: firstly, they control 
the movement and activity of membrane-bound enzymes like APP, BACE1 and the 
presenilins. Secondly, Aβ exerts its effect on cell membranes by direct and indirect 
mechanisms which is responsible for the manifestation of Alzheimer’s pathology. 
Thirdly, lipids can affect Aβ’s propensity to aggregate and modulate its pathogenic 
potential.  
1. 12. 1. Role of cholesterol metabolism and transport in 
amyloidogenesis. 
The most cholesterol-containing organ in the body is the brain, which contains as much 
as 25% of the whole cholesterol present in the body. Cholesterol is a fundamental factor 
of cell membranes and plays a critical role in neuronal function and plasticity (Pfrieger, 
2003). Nearly all of the brain cholesterol is acquired from de novo biosynthesis, rather 
than plasma, since the blood–brain barrier blocks any significant traffic between brain 
and plasma lipoproteins (Dietschy and Turley, 2001, Vance et al., 2005). Exceptions 
include the cholesterol oxidisation products, 27-hydroxycholesterol and 24 
Shydroxycholesterol (Papassotiropoulos et al., 2000) which can cross the blood–brain 
barrier. The daily exchange rate of cholesterol between the brain and periphery is less 
than 1%. Accordingly, it has to be supposed that the brain cholesterol homeostasis is 
mainly, but not entirely independent of the cholesterol level in the blood (Dietschy and 
Turley, 2001). 
Longitudinal, population-based studies reveal that cholesterol levels correlate with 
developing AD in later lifetime and hypercholesterolemia is an early risk factor for the 
development of amyloid pathology (Kivipelto et al., 2001). Animal model studies using 
rabbits fed a cholesterol-enriched diet exhibited a progressively mild-to-moderate-to-
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severe intracellular accumulation of immunolabeled Aβ (Sparks et al., 2005). 
Furthermore, cerebral amyloid concentrations become elevated in APP transgenic mice 
fed on a cholesterol-enriched diet (Refolo et al., 2001, Shie et al., 2002).  
Studies in which de novo synthesis of cholesterol is repressed by pharmacological drugs 
further justifies the vital role of cholesterol in APP processing. Cholesterol synthesis 
inhibitors were capable of diminishing extracellular and intracellular concentrations of 
Aβ1-42 and Aβ1-40 peptides in mixed cortical neurons and primary cultures of hippocampal 
neurons. In vivo, cerebrospinal and brain homogenate levels of Aβ1-42 and Aβ1-40 peptides 
were reduced in guinea pigs treated with high doses of simvastatin, an inhibitor of de 
novo cholesterol synthesis (Fassbender et al., 2001). Similar results were obtained when 
cholesterol was depleted from the membrane by physical extraction with cyclodextrin 
(Fassbender et al., 2001). 
Cells convert excess free cholesterol to cholesteryl esters using the enzyme acyl CoA: 
cholesterol acyltransferase 1 (ACAT1) (Chang et al., 2010). Aβ release in cultured cells 
is enhanced by increasing levels of cholesteryl esters, while inhibition of ACAT1 by 
drugs caused a reduction in both cholesteryl ester and Aβ levels (Puglielli and Kovacs, 
2001, Hutter-Paier et al., 2004). In a mouse model of AD, both Aβ pathology and 
cognitive impairment were reduced by genetic ablation of ACAT1 (Bryleva et al., 2010). 
However, ablation of ACAT also raises the concentration of oxysterol, 24(S)-
hydroxycholesterol which complicates interpretation and proposes a possible role of this 
cholesterol metabolite in decreasing amyloidogenesis (Bhattacharyya and Kovacs, 2010, 
Bryleva et al., 2010). One presumed mechanism compatible with these results is that the 
excessive free brain cholesterol evolving from ACAT1 ablation can be changed to 24(S)-
hydroxycholesterol and then travel across the blood–brain barrier to reach the periphery, 
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thus causing lowered brain cholesterol levels. Conclusively, these findings suggest that 
the equilibrium between free cholesterol and cholesterol esters is an essential parameter 
controlling amyloidogenesis. However, the molecular mechanism underlying this 
relationship is unclear (Bhattacharyya and Kovacs, 2010).  
 
1. 12. 2.  Role of sphingolipids in Aβ production.  
Besides cholesterol, sphingolipids including ceramide, sphingomyelin and 
glycosphingolipids (GSLs) play some critical roles in cell function associated with 
normal as well as diseased states (Hannun and Obeid, 2008, Posse de Chaves and Sipione, 
2010). Ceramide is a major component in sphingolipid metabolism and it is used as a 
backbone for developing GSLs and sphingomyelin via the addition of sugars or 
phosphocholine at the hydroxyl group, respectively. GSLs and Sphingomyelin are 
plentiful in the brain, and gangliosides, which are GSLs containing sialic acids, are the 
main constituents of neuronal membranes.  
Initial reports reveal that ceramide concentrations are increased at the earliest clinically 
recognizable stage of AD, conceivably mediating neuronal death by oxidative stress 
induction. However, independently of its contribution in oxidative cell death (He et al., 
2010), ceramide also modulates BACE1-mediated processing of APP. The mechanism 
appears to be associated with the enhancement of BACE1 stability in cells, probably by 
the generation of ceramide-enriched platforms (Puglielli et al., 2003) 
Sphingolipids also directly participate in the metabolism of APP. Inhibition of the enzyme 
(sphingomyelinase) that favours the sphingomyelin conversion to ceramide, and the 
resulting sphingomyelin accumulation, decreases Aβ secretion which leads to γ-secretase 
inhibition. Sphingomyelinase activity enhancement is also observed in cells harbouring 
FAD mutations in PS1, further suggesting an important role for sphingolipids in AD 
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(Grimm et al., 2005). However, complete suppression of sphingolipid biosynthesis causes 
an increase in Aβ1-42 production, while the level of Aβ1-42 remains unaffected. Consequent 
sphingosine addition restores the normal ratio of Aβ1-40 to Aβ1-42, suggesting that 
sphingolipids can act as a modulator of γ-secretase (Sawamura et al., 2004).  
Finally, the Aβ V3 loop domain has been identified as a sphingolipid-binding sequence 
(Fantini et al., 2002), and suggests an Aβ affinity to raft-like sphingolipid and cholesterol-
rich regions of cellular membranes, with important implications for Aβ aggregation, 
internalization and intracellular sorting, all of which can affect its pathogenic capability 
(Zhang et al., 2009).  
Altogether, these studies demonstrate that sphingolipids modulate γ-secretase and 
BACE1 activities as well as Aβ microdomain localization, even though additional 
research is required to decide the mechanistic details and to verify these lipid-dependent 
models in vivo (Di Paolo and Kim, 2011). 
 
1. 12. 3. Other lipid changes in AD brains 
During AD pathogenesis, along with the mentioned modiﬁcations, some other lipid 
changes occur. Brain autopsy samples from AD patients showed a selective and 
significant reduction in ethanolamine plasmalogens (PLs) concentrations relative to 
phosphatidyl ethanolamine. These changes happen neither in Parkinson’s nor in 
Huntington’s disease (Ginsberg et al., 1995, Wells et al., 1995, Guan et al., 1999). 
 At a very early stage in AD, a substantial decrease up to 40 mol% in PL content in white 
matter and 10 mol% in grey matter was observed already. Once dementia is at a severe 
stage, up to 30 mol% in grey matter was also noted. However, the importance of PL 
reduction in AD is not well understood. It can be associated with synapse loss and 
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neurodegeneration since the decrease in PL might cause instability of the membrane 
(Ginsberg et al., 1998). This reduction might be explained by the elevated oxidative 
damage in the AD brain caused by Aβ accumulation (Albers and Beal, 2000, Bassett and 
Montine, 2003), where Aβ itself has been identified as an oxidant species (Davis, 1996, 
Markesbery and Carney, 1999). Indeed, a significant decrease has been noticed in 
ethanolamine PL content of cultured embryonic rat brain oligodendrocytes treated with 
Aβ (Cheng et al., 2003). In addition, reactive oxygen species (ROS) can affect PLs 
through their vinyl-ether bond that makes them susceptible to oxidation. Oxidative stress 
in AD creates ROS and accordingly ROS-mediated degradation may deplete PL (Han, 
2005). 
1. 13. Membrane surfaces 
Investigations into membrane-stimulated fibrillogenesis have been motivated by various 
important medical and physiological questions, such as the cytotoxic effect of amyloid 
aggregates exerted at the cell membranes rather than in the bulk (Williams et al., 2011). 
Recent findings have revealed the role of surfaces in favouring or disfavouringdisfavoring 
the aggregation process and in increasing the rate of formation of nuclei (Sani et al., 2011, 
Burke et al., 2013). The conformational state of the protein and its aggregates may be 
determined by different physicochemical properties of surfaces (Rocha et al., 2012). 
Fresh Aβ interactions with lipid vesicles of different compositions have revealed that the 
membrane hydrophobicity and surface charge can modulate Aβ binding to the surface of 
the membranes. Various studies have shown that anionic phospholipids which form most 
of the membrane constituent are responsible for the enhancement of fibril formation. It 
was noted that Aβ1-40 is preferably bound to negatively-charged lipids of complex 
membranes and negatively-charged phosphatidylglycerol membranes compared to 
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neutrally charged membranes (Williams and Serpell, 2011). The degree of Aβ1-40 
fibrillisation increases upon association with anionic lipids (PA, PS, PI, PIP, PIP2, and 
CL), in contrast with to the neutral (cholesterol, cerebrosides, and diacylglycerol) and 
zwitterionic lipids (PC, PE, and SM), and phosphate group lacking anionic lipids (Knight 
and Miranker, 2004).  
The phospholipids head-group charges have been proposed to contribute to the Aβ 
association to the membrane through electrostatic interactions. The affinity of Aβ1-40 to 
1-palmitoyl- 2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) (POPG) is stronger than for 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (Kremer and Murphy, 2003), 
confirming the idea that the head-groups moderate binding. Furthermore, a 50–100% 
greater mass adsorption was detected between Aβ1-40 and POPG compared with Aβ1-40 
mass adsorption to POPC membranes. It seems that, whilst POPC binding does not lead 
to aggregation of the Aβ peptide, POPG liposomes considerably boost aggregation 
(Williams and Serpell, 2011). 
Several studies support that in vitro formation of amyloid fibrils is not only induced by 
anionic phospholipid containing membranes, but is also enhanced by bilayers composed 
of phospholipid (PC and PE) mixed with cholesterol or gangliosides, and the commonly 
named ‘raft’ containing cholesterol and sphingomyelin. Therefore, it does not appear 
possible to accredit the ability to enhance protein fibrillisation to specific lipid classes. 
Yet, it is believed that the chemical properties of the bilayer constituents have a capacity 
to determine the extent and mode of these proteins binding to the membranes, in favouring 
the aggregation-prone conformation of the protein. However, the molecular details of 
interactions between protein and lipids which lead to the transformation of protein into 
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aggregated structures may differ remarkably, according to the structural characteristics of 
the investigated peptides or proteins. 
It was shown that adsorption of Aβ1-42 oligomers to hydrophilic surfaces was not followed 
by further aggregation, while adsorption on hydrophobic surfaces was enhanced 
conformational changes and aggregation (Saraiva et al., 2010). AFM imaging and single 
molecule fluorescence tracking were also applied to investigate the mechanism of Aβ1-42 
fibril formation following oligomer formation and adsorption on substrates covered with 
polymers of different hydrophobicity. Results confirmed that only weakly adsorbed 
peptides with enough mobility enhance peptides to interact and start fibrillisation at 
several orders of magnitude lower concentration of Aβ peptide than in bulk (Shen et al., 
2012). In summary, consistent with other works on lipid membranes, it was demonstrated 
that surface favoured fibrillisation, was crucially dependent on the physical properties of 
the polymer covered surfaces. 
One day fibrillised Aβ1-40 adsorption displayed small variations in the kinetics of 
membrane binding compared to fresh Aβ. The fibrillar Aβ affinity to neutrally charged 
membranes is higher than its affinity for negatively-charged membranes. Hydrophobic 
forces were argued to be more influential regarding fibrillar Aβ adsorption on 
membranes, although the electrostatic forces were noticed to be more important regarding 
fresh Aβ binding to membranes (Lin et al., 2007). Generally, protein recruitment can be 
favored via interaction of surface charges with the amino acid residues of opposite charge, 
accordingly increasing protein concentration at the interface (Giacomelli and Norde, 
2005). 
Amyloid fibril formation is a multistep process which can be modulated by a number of 
different factors, specifically by lipid-protein interactions. Fibril formation in a membrane 
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environment can be enhanced through some principal factors including first: enhancing 
structural transformation in proteins to form partially folded conformation. Second: local 
concentration of protein increases up on binding to the membranes. Third: orientation of 
the bound protein into aggregation favouring direction. Fourth: influencing the membrane 
bound protein nucleation propensity. 
Aβ-membrane interactions and permeation 
The amyloid oligomers amphipathic nature has been proposed to contribute to the 
membranes insertion and penetration capacity, adsorbing to the membrane surfaces, or 
possibly act as cell-penetrating peptides (Lansbury and Lashuel, 2006). Three different 
models have been suggested for Aβ membrane induced toxicity. The first model is 
carpeting of the peptide on one side of the membrane surface, which cause small 
molecules to leakage through creating an asymmetric pressure between the two sides 
(Hebda and Miranker, 2009). The carpet model was suggested to explain the inexistence 
of the lag phase and exponential rather than sigmoidal leakage kinetics in hIAPP and 
mouse IAPP-induced LUV permeation (Engel et al., 2008). 
The second proposed model for amyloid-mediated toxicity is stable pores and ion 
channels formation. Ca2+ channels formation in lipid bilayers was suggested in AD 
cytotoxicity as the Aβ1-40 adsorption into planar phosphatidylserine bilayers created 
channels that produced linear current–voltage relationships in symmetrical solutions 
(Arispe et al., 1993). Direct observation of channels by AFM showed an 8–12 nm 
doughnut-shaped structure with a 1–2 nm internal pore diameter that extends 1 nm above 
the surface of the bilayer (Lin et al., 2001). 
The third model suggested is based on the detergent-like effect of amyloidogenic peptides 
on lipid membranes. The peptide electrostatically interacts with phospholipid head group 
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or membrane surface receptors, which accompanied by peptide alignment to the 
hydrophilic surface of the phospholipid head groups. The hydrophobic residues of the 
peptide orients towards the hydrophobic core of the membrane, and consequently the 
membrane disintegrate by bilayer curvature disruption (Shai, 1999). The detergent effect 
arises from the surfactant- like properties of the amphiphilic peptide, which causes a 
decrease in membrane surface tension. This reduction led to the removal of lipid and 
membrane thining when it happens on one side or formation of holes in the membrane 
bilayer when both sides are affected (Hebda and Miranker, 2009).  
The amyloid forming peptides associated cytotoxicity might not entirely linked to only 
one mechanism but more possibly to a collection of mechanisms. Each mechanism may 
be involved at a specific stage amyloid formation. The carpeting and detergent models 
may only happen while the peptide is in its monomeric or small oligomeric phase and 
causes nonspecific membrane permeation; the formation of ion channels or amyloid-
induced pores might happen through specific receptors of amyloid- induced permeation 
(Williams and Serpell, 2011). 
1.14. Aims of this study 
The initial aim of this study was to investigate the interactions between both Transthyretin 
(TTR) and human Cystatin C (hCC) with Aβ peptide. The studies on the interaction of 
TTR and Aβ showed contradictory results on the binding and inhibition intensity of TTR 
against Aβ using different methodologies. Studies in which one of the proteins 
immobilized showed strong binding of TTR to nearly all forms of Aβ, however the 
solution based studies showed a weak binding between the two proteins. In chapter 3, 
conditions were optimized for fibrillisation of Aβ in the presence of two different (binding 
and non-binding) surfaces. The intensity of WT TTR for inhibition of Aβ1-42 fibrillisation 
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were investigated and compared in the presence of these two different surfaces. In chapter 
4, in order to study the details of TTR interaction with Aβ, four different TTR mutants 
with different stabilities of their tetramers and monomers were developed and their 
inhibitory effect compared to WT TTR. The interaction of WT and mutant TTRs with 
different structures of Aβ were also investigated. Aβ1-40 is less aggregation prone, 
however, it is more abundant in vivo. The ability of WT TTR and some mutants to inhibit 
Aβ1-40 fibrillisation is also considered. 
Previous study found monomer to monomer interaction between hCC and Aβ, however 
previous works in our group showed that this is not the case. Instead they suggested that 
hCC binds to oligomeric Aβ and inhibition of fibrillisation occurs as binding disfavours 
the fibrillisation pathway. In chapter 5, we confirm the dose dependence inhibition of Aβ 
fibrillisation by hCC and investigate the monomer-monomer interaction between the two 
proteins in different buffer conditions to the previous study. The hCC binding to 
aggregated Aβ structures were further supported by hCC binding to Aβ fibrils and 
monitoring the disappearance of both Aβ and hCC monomers in the mixture using 1D 
NMR experiments. In order to find the binding interface to Aβ on hCC some hydrophobic 
residues throughout the hCC structure were mutated to alanine and their inhibitory effect 
on Aβ compared to WT hCC. An E. coli contaminant protein was co-purified along with 
hCC purification and it was interfering with the hCCs inhibitory effect on Aβ 
fibrillisation. In chapter 6, the E. coli contaminant protein was sequenced by mass 
spectrometry and identified as glutamate/aspartate binding protein. Then, its inhibitory 
effect on Aβ aggregation were investigated using thioflavin T assays and electron 
microscopy. 
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Chapter two: Materials and Methods 
 
This chapter covers the details of common experimental procedures used throughout the 
research work presented. Further details of materials and methods of specific experiments 
are found in relevant chapter. 
2.1. Buffers and Reagents 
All chemicals and reagents were purchased from, Sigma-Aldrich, Fisher Scientific or 
Melford, unless stated otherwise. Deionised water (18.2Ω) which was used throughout 
all experiments was from Elga Purelab 611 Classic UVF.  Buffers were prepared 
according to the protocol described in (Sambrook et al., 1989) and filtered through a 0.2 
μm filter. Final concentration of 1 or 2 mM sodium azide (NaN3) was added as standard 
to all buffers, except those used for bacterial growth and unless otherwise stated. 
2.2. Growth Media and Solutions 
2.2.1. Luria-Bertani Media 
Taken from (Sambrook et al., 1989). For each litre of deionised water, the following was 
added: 
bacto-tryptone (Oxoid ltd, UK)  10 g 
yeast extract (Oxoid)    5 g 
NaCl (Melford)    10 g 
The pH of media was adjusted to 7.0 and made up to 1L prior sterilisation by autoclaving, 
then antibiotics added after the media had cooled.  If LB-agar was required, 28 g Nutrient 
agar (Oxoid Ltd, UK) was made up to 1L and autoclaved. 
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2.2.2. Minimal media 
Per litre of deionized water: 
Na2HPO4   6 g 
KH2PO4   3 g 
NaCl    0.5 g 
The volume made up to 1L after adjusting pH to 7.4 and sterilized by autoclaving. 
The following were added to the media directly before use (per litre): 
trace elements    650 μl       (autoclaved) 
glucose      3g         (filter sterilized) 
10 mg/ml thiamine      0.1 ml          (filter sterilized) 
0.5 mg/ml (NH4)2SO4       2 ml           (filter sterilized) 
1 M MgSO4         1 ml  (autoclaved) 
1 M CaCl2         0.1 ml  (autoclaved and added last) 
The flask was swirled immediately to disperse precipitate; if precipitate did not disperse 
then the preparation was discarded. 
Trace elements  
Per 100 ml deionised water:  
CaCl2.2H2O   550 mg 
CuSO4.5H2O   40 mg 
CoCl2.6H2O   45 mg  
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H3BO4    40 mg 
KI    26 mg  
MnSO4.H2O   140 mg 
Na2MoO4.2H2O  26 mg  
ZnSO4.H2O   220 mg  
The above components were added to 70 ml of deionised water and the pH adjusted to 
8.0 before adding: 
EDTA    500 mg 
The pH was again adjusted to 8.0 before adding: 
FeSO4.7H2O   375 mg 
The solution was made up to 100 ml with deionised water before autoclaving. 
 
 
2.2.3. 2X TY media  
Per litre of deionised water the following was added: 
Bacto-tryptone (Oxoid ltd, UK)  16 g 
Yeast extract (Oxoid, UK)   10 g 
NaCl      5 g 
The pH was adjusted to 7.2 and the volume made up to 1 litre. Media was transferred into 
conical flasks and sterilised by autoclaving. Antibiotics were added after the media had 
cooled. 
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2.2.4. Antibiotic Stock Solutions 
Ampicillin (Melford, UK): stock solution (1000x) was produced by dissolving ampicillin 
sodium salt in water at a concentration of 100 mg/ml and then filter-sterilised with a 0.2 
μm syringe filters. Aliquots were stored at -20°C until needed, when they were gently 
thawed and added to growth media to a final concentration of 100 μg /ml. 
2.2.5. Isopropyl-β-D-galactosidase (IPTG) 
IPTG (Melford): stock solution (1 M) was prepared by dissolving 120 mg/ml in water, 
and 0.2μm filter-sterilised.  Fresh solution (or aliquots stored at -20°C and thawed on ice) 
was added to growth media to a final concentration of 1, 1.5 or 2 mM to induce protein 
overexpression.  
2.3. DNA Manipulation 
2.3.1. Bacterial strains and expression system 
Transthyretin and variants; wild type TTR previously cloned into the pMMHa 
expression system, was provided by Gareth Morgan (Scripps Research Institute, 
California, USA). Expression was carried out in Escherichia coli BL21/DE3 strain. Site-
directed mutagenesis was carried out on the wild type plasmid to produce the variants. 
Thre pMMHa plasmid contains ampicillin resistance (β-lactamase) gene. 
Human cystatin c and variants; wild type hCC previously cloned into the pIN-III-ompA 
periplasmic expression system was provided by Dr. Adham Elshawaidhe. Expression was 
carried out in E. coli BL21/DE3 strain for which an efficient purification had been 
established (Elshawaihde, 2012). The rare codons found in genes for human proteins had 
been removed previously to allow expression in this strain. Site-directed mutagenesis was 
carried out on the wild type plasmid to produce the variants. 
  
65 
 
2.3.2. Competent cells 
Escherichia coli cells of the XL10 blue (Novagen) strain were used for plasmid minipreps 
and BL21/DE3 strain were used for protein purifications. Competent cells were made 
using the following protocol. 
The desired strain of E. coli cells from glycerol stock were plated onto LB agar and grown 
overnight at 37°C. Five ml of LB media inoculated by a single colony, which was grown 
overnight at 37°C, 200 rpm. 10 ml of LB was inoculated with 200 μl of starter culture, 
and grown at 37°C, 200 rpm until its OD600 reached 0.6. The cells were spun down  by 
centrifugation, the supernatant was discarded, the cells resuspended in 3.3 ml RF1 buffer 
(30 mM KCH3CO2, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl4, 15% glycerol, pH 5.8) 
and incubated on ice for 30 minutes. The cells were pelleted again, the supernatant was 
discarded and the cells were resuspended in 1 ml RF2 buffer (10 mM MOPS, 10 mM 
RbCl, 75 mM CaCl2, 15% glycerol, pH 6.5). After incubating on ice for a further 30 
minutes, the cells were divided into 100 or 200 μl aliquots and either transformed 
immediately or stored at -80°C until needed. 
2.3.3. Preparation of plasmid DNA 
Plasmid DNA was extracted and purified from overnight grown cell cultures using 
QIAprep Spin Miniprep kits (Qiagen), according to the manufacturer’s instructions. 
Plasmid was eluted with MilliQ water or Tris-Cl, pH 8.5 and stored at -20°C. 
2.3.4. Transformation 
200 μl competent cells thawed on ice and transferred to 15 ml falcon tube then 1.5 μl of 
plasmid DNA was added and incubated for 30 minutes on ice. Cells were heat-shocked 
for 90 s at 42°C in a water bath and incubated on ice for a further 2 minutes. 800 μl of LB 
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media was added and the cells were incubated at 37°C, 200 rpm for 90 minutes. 2, 20 and 
200 μl of cells were plated onto selective LB agar (generally containing 100 μg/ml 
ampicillin) and grown overnight at 37°C. 
2.3.5. Quantification of DNA Concentration 
UV-Vis Spectrophotometer; The concentrations of plasmids and oligonucleotide primer 
solutions were estimated using the optical density at 260 nm, where an absorbance 
reading of 1 is equivalent to a nucleotide concentration of 33 μg/ml.  Protein 
contamination of plasmid preparations were calculated using A260 nm/A280 nm ratio. DNA 
samples considered free of contamination, if this value was greater than 2. Absorbance 
readings were taken with a Varian Cary 50-Bio UV-Vis spectrophotometer. 
Nanodrop Spectrophotometer; the spectrophotometer cleaned, initialized and blanked 
by loading 1-2μl of deionized water. DNA concentration measured by loading 1μl of the 
sample on lower optic surface and lowering the lever arm to trap the sample between both 
optical surfaces and concentration measured as ng/μl. Absorbance readings were taken 
with a Thermo Nanodrop spectrophotometer. 
2.3.6. Site- Directed Mutagenesis 
Site-directed mutagenesis (SDM) for TTR and hCC genes were performed using 
QuikChange® II mutagenesis kit (Stratagene). The following protocol used for producing 
all the mutants and the manual can be referred to for more details. 
PCR reaction mixture prepared as follow: 
5 µl 10x reaction buffer (100 mM KCl, 100 mM (NH4)2SO4, 200 mM Tris-HCl pH 8.8, 
20 mM MgSO4, 1 % Triton® X-100, 1 mg/ml nuclease-free BSA).  
30 ng plasmid template. 
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 1 µl dNTP mixture. 
1µl Pfu Turbo DNA polymerase was added to the reaction. 
125 ng of each forward and reverse primer containing the desired mutation 
then final volume made up to a 50 µl with sterilised deionised water. 
  PCR was then performed in a Techne Progene thermocycler, using 18 cycles of: 
 30 seconds at 95°C (melting) 
 1 minute at 55°C (annealing) 
  9 minutes at 68°C (extension). 
Reaction mixtures were subsequently digested with Dpn1 restriction endonuclease for 1 
hour to selectively digest methylated template DNA. Plasmid DNA was transformed into 
competent XL1-Blue E.coli cells and plated onto selective LB-agar, containing the 
relevant antibiotic.  Colonies which grew on the selective agar were grown overnight and 
the plasmid extracted as described previously. The primers were designed using the 
Stratagene QuikChange® Primer Design Program.   
2.3.7. DNA Sequenceing 
Wild type TTR Plasmid and its mutants produced by site-directed mutagenesis were 
sequenced to confirm the correct identity by the Core Genomic Facility, University of 
Sheffield. Wild type hCC Plasmid and its mutants produced by site-directed mutagenesis 
were sequenced to confirm the correct identity by GATC (Biotech, Germany). Sequences 
were aligned and analysed using Finch TV Version 1.4.0 (Geospiza, Inc) and the basic 
local alignment search tool (BLAST) available on the NCBI website 
(http://blast.ncbi.nlm.nih.gov/bl2.seq/wblast2.cgi). 
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2.4. Protein Expression and Purification  
2.4.1. Expression and Purification of Transthyretin 
2.4.1.1. Overexpression 
Single colonies of freshly transformed E. coli BL21/DE3 were used to inoculate 50 ml 
starter culture of LB media, and incubated overnight at 37°C, 250 rpm. 6 ml of the starter 
culture was used to inoculate 0.6 litre of LB media containing 100 μg/ml ampicillin, and 
incubated at 37°C with 250 rpm shaking until OD600 reached 0.6.  Cultures were then 
induced with IPTG to a final concentration of 2 mM and incubated for a further 19 hours. 
2.4.2.2. Cell Harvesting 
Harvesting of induced cells were performed by centrifugation at 10 000 rpm, 4°C for 10 
minutes.  The growth media was discarded, and the cell pellets resuspended in 25 mM 
Tris buffer, 2 mM EDTA, 0.1% (v/v) Triton X-100, pH 7.5. Cell resuspensions were 
directly frozen at -80C. 
2.4.2.3. Cell Lysis 
Cell resuspension were lysed by two cycles of freeze-thaw by freezing at -80°C and 
thawing at 60°C in a water bath, and then sonicated on ice for 4 x 30 seconds, operating 
at maximum intensity and allowing one minute rest between sonication cycles.  The 
suspension was centrifuged at 15 000 rpm, 4°C for 15 minutes.  The pellet was discarded 
and the supernatant used for purification. 
2.4.2.4. Purification 
The volume of supernatant was measured by a measuring cylinder and 50% of ammonium 
sulphate were added, then centrifuged at 18000 rpm for 20 minutes to precipitate 
contaminant proteins. The pellet discarded and TTR precipitated by addition of 90% 
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ammonium sulphate. The pellet resuspended in a minimal volume of 5 mM Tris buffer, 
pH 8.0, and desalted by overnight dialysis against 5L of 5 mM Tris buffer, pH 8.0 at 4°C. 
The desalted protein solution heated at 60°C for 30 min in order to precipitate out 
contaminating proteins.   
The mixture centrifuged at 15000 rpm for 15 minutes and the supernatant was loaded 
onto a 100 ml Q-Sepharose (Pharmacia) ion-exchange column at 2 ml/min, equilibrated 
with 5 mM Tris buffer, pH 8.0.  The column was washed with the same Tris buffer until 
the OD280 of the eluent stabilised.  Bound protein was eluted with 400 ml total volume 
0.20-0.35 M NaCl gradient employing 25mM Tris buffer, pH 8.0. Eluent was collected 
in 8 ml fractions and fractions containing TTR were pooled and Precipitated with 
ammonium sulfate (90%) and store as a pellet at 4°C. 
2.4.2. Expression and Purification of Human Cystatin C 
2.4.2.1. Over-expression 
5 ml of LB broth inoculated with a single colony of E. coli BL21 (DE3). Culture was 
grown overnight at 37°C and used to inoculate 100 ml of LB broth for overnight at 37°C. 
10 ml of starter culture was used to inoculate 600 ml of M9 minimal media. The total 
growth was 4.8 litres. Cultures were grown at 37°C with shaking at 220 r.p.m. Cell growth 
was followed by measuring the OD600, and expression cultures were induced with IPTG  
to a final concentration of 0.75 mM when OD600 reached 0.4 – 0.6 and growth continued 
for 6 hours after induction.  
2.4.2.2. Periplasmic Extraction 
Induced cells were harvested by centrifugation at 10,000 rpm at 4°C for 10 minutes and 
the pellets re-suspended in 20% sucrose, 0.2 M Tris pH 8.0. The suspension was 
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centrifuged at 20,000 rpm at 20 °C for 15 minutes. Cold EDTA solution (2 mM), pH 8.0 
was used to re-suspend pellets. Phenylmethylsulphonyl fluoride (PMSF) was added 
immediately to give a final concentration of 1 mM. The re-suspended sample was 
centrifuged at 20,000 at 4 °C for 15 minutes. The supernatant was recovered and protease 
inhibitors (EDTA-free, 1 tablet per 50ml), 0.1 mg/ml DNase and 20 mM MgCl2 were 
added. The sample was dialysed into cold 10 mM sodium phosphate buffer pH 7.0 to 
remove small molecules.  
2.4.2.3. Cation Exchange Chromatography 
100 ml SP-Sepharose (Pharmacia) cation exchange column had been equilibrated with 
cold 10 mM sodium phosphate buffer pH 7.0, and cold periplasmic extract was loaded at 
a rate of 2 ml/min. The column was washed with 10 mM sodium phosphate pH 7.0 until 
A280 of the eluent stabilized. Elution of hCC has been performed using 10 mM sodium 
phosphate buffer pH 7.0, 0.2 M NaCl, and 5 ml fractions collected. Any remaining bound 
protein was eluted with sodium phosphate buffer pH 7.0, 1 M NaCl.  Fractions were 
analysed by SDS-PAGE and those containing hCC were pooled and stored at -20°C. 
2.4.2.4. Size-Exclusion Chromatography 
The fractions containing hCC were pooled and concentrated to less than 10 ml using an 
Amicon ultra-filtration stirred-cell device in conjunction with a Millipore regenerated 
cellulose membrane with a molecular weight cut-off of 10,000 Da and filtered using a 0.2 
μm filter. Superdex G75 (GE Healthcare, UK) gel filtration column (400 ml) equilibrated 
with 10 mM sodium phosphate buffer (pH 6.0) before loading of the sample. The column 
had been run at a rate of 3 ml/min and 6 ml fractions collected applying 0.1 M NaCl. 
Phosphate buffer pH 6. The fractions were analysed using SDS-PAGE and any containing 
hCC were pooled. The average yield of cystatin C was 1-2 mg per litre of cell growth. 
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2.5. Protein procedures 
2.5.1. Electrophoresis 
SDS-PAGE (polyacrylamide gel electrophoresis on proteins denatured using sodium 
dodecyl sulphate) was accomplished using a BioRad Mini Protean II apparatus, according 
to the method of Laemmli (1970), and described in Sambrook et al. (1989). A stacking 
gel (4% acrylamide, tris-HCl pH 6.8) was cast above a resolving gel (16% acrylamide, 
tris-HCl pH 8.8), with a ratio of acrylamide to bis-acrylamide of 37.5:1. The running 
buffer was tris-glycine pH 8.6. All buffers contained 0.1% SDS. The samples were loaded 
in 50 mM tris-HCl, pH 6.8, containing 20% glycerol, 0.2% bromophenol blue. Proteins 
were incubated at 90°C for 5 minutes to reduce any disulphide bonds. 
A standard of low molecular weight proteins (Sigma) was run alongside the samples. 
Neuroserpin runs an apparent molecular weight of 46 kDa. The gels were run at a constant 
voltage of 180 V for around 55 minutes, until the loading dye approached the edge of the 
gel. After removing the gel from its glass plates, it was stained for 1-2 hours with 
Coomassie Blue (in 10% acetic acid, 45% water, 45% methanol), then destained with the 
same solvent until the bands were visible. The gels were scanned with an Epson Imagejet 
scanner. 
2.5.2. SDS-PAGE buffers and markers 
SDS-PAGE buffers: 
4 x  stacking gel buffer        0.5 M Tris/HCl, 0.4 % (w/v) SDS, pH 6.8 
4 x resolving gel buffer        1.5 M Tris/HCl, 0.4 % (w/v) SDS, pH 6.8 
Running buffer          25 mM Tris/HCl, 0.19 M glycine, 0.1 % (w/v) SDS, pH 8.3 
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Loading buffer          50 mM Tris/HCl, 100 mM DTT, 2 % (w/v) SDS, 0.1 % 
(w/v) Bromophenol blue, 10 % (v/v) glycerol 
Stain                         0.4 % (w/v) Coomassie blue R, 8 % (v/v) acetic acid, 46 % (v/v) 
methanol 
Destain                     10 % (v/v) acetic acid, 30 % (v/v) methanol 
16 % resolving gel    Lower buffer                                    2.5 mL 
                                40 % (w/v) acrylamide/Bis (29:1)    4 mL 
                                dH20                                                 3.5 mL 
                                10 % (w/v) APS                               100 μL 
                                TEMED                                           10 μL 
4 % stacking gel       Upper buffer                                    2.5 mL 
                                40 % (w/v) acrylamide/Bis (29:1)    1.125 mL 
                                dH20                                                 6.4 mL 
                                10 % (w/v) APS                               110 μL 
                                TEMED                                           11 μL 
TEMED and Acrylamide solutions were purchased from Bio-Rad. 
Molecular Weight Marker 
Bio-Rad pre-stained broad range molecular weight markers were used with the typical 
mass values stated below: 
 Myosin   200 000 Da 
 Β-galactosidase  116 250 Da 
 Bovine serum albumin   86 000 Da 
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 Ovalbumin     51 000 Da 
 Carbonic anhydrase               37 000 Da 
 Soybean trypsin inhibitor   29 000 Da 
 Lysozyme     19 700 Da 
 Aprotinin       7 000 Da 
 
2.5.3. Protein concentration and buffer exchange 
Large volumes of protein solutions were concentrated and using an Amicon ultrafiltration 
stirred cell conjugated with an appropriate Millipore 10kDa MWCO filter. Vivaspin 
centrifugal concentrators (Viva science) with 5-10kDa MWCO were used to concentrate 
smaller volumes (≥10 ml) of protein solutions. Buffer exchange was accomplished either 
using Vivaspin concentrators, or by dialysis against the desired buffer using Spectra/Por 
dialysis tubing or dialysis cassettes with a 10kDa MWCO (Spectrum labs, USA). 
2.5.4. Determination of protein concentration 
The protein concentrations were determined by measuring UV absorption spectra at 280 
nm on a Cary spectrophotometer, and analysed using Cary Win-UV software. The 
concentrations were determined by using the Beer-Lambert Law: 
A = c x l x ε 
Absorbance = concentration x pathlength x molar extinction coefficient 
The transthyretin tetramer has a molar extinction coefficient of 77600 M-1.cm-1, hCC has 
a molar extinction coefficient of 11050 M-1.cm-1, and W106A hCC variant has a molar 
extinction coefficient of 5550 M-1.cm-1. These values were calculated from the proteins’ 
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sequences using the “ProtParam” tool at http://web.expasy.org/cgi-
bin/protparam/protparam. 
2.6. Analytical Size Exclusion Chromatography 
The purity of the protein samples was analysed by size exclusion high-pressure liquid 
chromatography (SEC-HPLC). 20-180 μl samples were analysed using a Superdex 200 
column (GE Healthcare, UK) with a Perkin Elmer Series 200 HPLC system equipped 
with a UV-visible absorbance detector (Perkin Elmer, UK). The OD of the eluent was 
monitored at OD280.  Specific HPLC experiments are discussed further in the appropriate 
chapters. 
2.7. Spectroscopic Techniques 
2.7.1. Fluorescence Spectroscopy 
Thioflavin T fluorescence measurements were taken on a Fluostar Omega plate-reader 
(BMG Labtech, UK). The spectra were recorded at time-points with an excitation 
wavelength of 442 nm and an emission wavelength of 482 nm. Further details on specific 
fluorescence experiments are provided in the relevant chapters.  
2.7.2. Nuclear Magnetic Resonance (NMR) 
NMR spectra were recorded on Bruker DRX spectrometers operating at 500, 600 or 800 
MHz controlled using XWinNMR (Bruker) and NMR data was processed using Felix 
(Accelrys). Experiments are discussed in further detail in the appropriate chapter.  
2.7.3. Transmission Electron Microscopy (TEM) 
Carbon-coated copper grids (Agar Scientific) were glow-discharged with 2x 20 second 
pulses using a Cressington 208 glow-discharge unit. Samples were adsorbed on a freshly 
glow-discharged grid for 1 minute and then blotted. Each grid was washed shortly in two 
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drops of water and two drops of 0.75% uranyl formate and blotted between each wash; 
the grid was held in the final drop of 0.75% uranyl formate for 30 seconds and dried with 
gentle vacuum suction after blotting. A Philips CM-100 electron microscope, operating 
at 100 kV and equipped with a 1024 x 1024 pixel Gatan CCD camera, was used to record 
micrographs.  
  
2.8. Aβ peptide Manipulation 
2.8.1. Preparation of Monomeric Aβ 
1 mg aliquots of Hexafluoroisopropanol (HFIP) (HFIP- is a polar, volatile, organic 
solvent used to dissolve pre-aggregated peptides) -treated recombinant Aβ peptide were 
purchased from rPeptide (Georgia, USA) and stored at -20°C. To prevent condensation 
upon opening, each closed vial was allowed to equilibrate at room temperature for 10 
minutes before dissolution. A 1 mg/ml solution was produced by adding 1 ml of cold 
HFIP to the lyophilised peptide and complete dissolution was ensured by sonication for 
10 minutes in a DECON Ultrasonics sonicator bath (Sussex, UK). 0.1 mg aliquots were 
produced by transferring 0.1ml of the clear solution into sterile micro-centrifuge tubes. A 
nitrogen stream was used to remove excess HFIP and any remaining traces were then 
removed by lyophilisation. The lyophilised aliquots of peptide were stored as thin clear 
films at -20°C. 
 
2.8.2. Aβ Fibril Formation  
Each 0.1 mg aliquot of HFIP-treated Aβ was allowed to equilibrate to room temperature 
before the addition of 20 μl DMSO (peptide concentration 10 mM). The sample was then 
sonicated for 10 minutes before being further aliquoted depending on the number of 
experiments being performed. Phosphate buffered saline (PBS) (50 mM 
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Na2HPO4/NaH2PO4, 150mM NaCl, 2mM NaN3, pH 7.4) containing 10μM thioflavin T 
was added to DMSO-dissolved Aβ aliquots, then 100 μl samples were added to 96 half-
well plates (Corning) which were either polystyrene (3694) or PEG treated (non-binding-
3686). These were incubated in a Biotech Omega fluorescence plate reader (BMG 
Labtech, UK) at 37°C with either double orbital shaking at 100 r.p.m for only 10 seconds 
before each reading (minimal shaking) or continuous double orbital shaking at 300 r.p.m. 
(continuous shaking) . Each condition was replicated 5 times and each experiment 
repeated at least 3 times. The mean of these replicates was plotted and standard errors of 
the mean were shown. The excitation wavelength was 440 nm and fluorescence emission 
was measured at 485 nm every 5 minutes.  
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Chapter Three: Transthyretin and Aβ interaction in the 
presence of different surfaces 
 
3.1 Introduction 
 
Accumulation of Aβ peptide aggregates into extracellular amyloid plaques in the brain is 
the hallmark of Alzheimer’s disease. A number of other amyloidogenic proteins have 
been found co-deposited in these plaques. Recent findings suggest the involvement of 
these proteins in the plaques and in the pathophysiology of Alzheimer’s disease. 
Transthyretin is one of the amyloidogenic proteins that have been found within amyloid 
plaques along with Aβ.  
Transthyretin and Aβ 
Transthyretin (TTR) is a homotetrameric protein of 127 amino acid subunits. In the 
serum, the 55KDa homotetramer is in equilibrium with a small proportion of monomer 
(Buxbaum et al., 2012). Transthyretin is one of several proteins which have been found 
inside Alzheimer’s plaques along with Aβ. It is a major constituent of the CSF and can 
sequester Aβ (Schwarzman et al., 1994). This finding was followed by several studies 
using either animal models or cell culture assays which further supported this interaction 
and showed TTR’s protective ability against Aβ cytotoxicity. In vitro studies then showed 
a direct inhibitory effect of wild-type and mutant TTRs on Aβ aggregation. Although 
there is clear evidence for the interaction between WT-TTR and Aβ, in vitro studies give 
contradictory results regarding the binding affinity between the two proteins. In general, 
methodologies depending on immobilising one of the proteins like surface plasmon 
resonance (SPR) and ELISA measured a KD of 28nM (Costa et al., 2008). However, 
liquid phase experiments (ITC) showed the KD to be 24 µM in solution (Li et al., 2013a), 
a difference of 3 orders of magnitude.  
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Binding of Aβ to surfaces has been suggested by a number of studies. The formation of 
sheet-like deposits of Aβ on graphite and micelle-like structures on mica have been 
observed by AFM (Kowalewski and Holtzman, 1999). Neutron reflectometry applied to 
show the formation of dense Aβ films on cationic or hydrophobic surfaces (Rocha et al., 
2005). Garai et al. (2008) and Morinaga et al. (2010) found that polypropylene was an 
effective catalyst for the aggregation of Aβ1-40. Shen et al. (2012) found that Aβ1-42 binds 
tightly on the polystyrene (PS) surface and loosely on the polyethylglycate (PEG) surface, 
however it fibrillises faster on the loosely bound surfaces better than tightly bound ones.  
The thickness of the film detected by Rocha was 2 nm which is nearly twice the 
hydrodynamic radius or gyration radius of Aβ monomer in solution (Massi et al., 2001, 
Raffa and Rauk, 2007, Nag et al., 2011). Thus, it is likely that these films might be Aβ 
monolayers. Given the fact that Aβ has a tendency to bind to different surfaces, even in 
solution phase experiments, Aβ will still interact with surfaces and the peptide’s 
interactions with other proteins can therefore be affected. The observation of both the 
deposition of films of Aβ on hydrophobic surfaces as well as its nucleation in these films 
supports the idea that Aβ can tightly bind to polystyrene and nucleate in this environment. 
Work carried out by my colleague Alex Taylor during the writing of this thesis has 
suggested that the fibril yield reflects the available Aβ monomer concentration in solution 
(Taylor, MSc thesis, 2016 and manuscript in preparation). He observed the relationship 
between the initial Aβ monomer concentration and final fluorescence intensity for 
thioflavin T timecourse data at different Aβ1-42 concentrations (Figure 3.1.). Each set of 
data was independently fitted to the equation:  
𝑌 ≈ 𝑉 ([𝑀]0 – 𝑘𝑔–/ 𝑘𝑔+ ) – 𝜌𝑚𝑎𝑥𝐴, 
where 𝑌 is the yield, 𝑉 is the volume of reaction mixture, [𝑀]0 is monomer concentration, 
kg+ is the elongation rate constant, and kg- is the disaggregation rate constant, 𝜌𝑚𝑎𝑥 is the 
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maximum packing capacity and 𝐴 is the surface area. Using the 𝑥-intercept of these 
graphs, a reaction volume of 100 μl, and the calculated surface area of the plates, the 
concentration of Aβ disappeared on surface binding and therefore the mean packing 
density were detected. The observed difference in the 𝑥-intercept between non-binding 
(treated with PEG) and untreated polystyrene (PS) plates was significant (compare 
Figures 3.1A and B), suggesting that tight binding was actually occurring on untreated 
(PS) plates. The likely packing densities and corresponding intermolecular spacings for 
idealised square-lattice monolayers of Aβ1-42 were calculated. Given that the effective 
diameter of a random coil (RC) Aβ monomer in solution may be ~2 nm, these idealised 
spacings are consistent with the formation of tightly packed monolayers of structured or 
partially structured Aβ1-42 on exposed polystyrene surfaces.  
 
Figure 3.1.The effect of plate type on the fluorescence intensity change, measured in the 
early plateau phase. A) shows the relationship between initial Aβ1-42 concentration and 
fluorescence intensity change (‘yield’) in nonbinding plates (PEG), while B) shows the 
equivalent experiments in untreated (PS) plates (Adapted from Taylor, 2016).  
 
The efficiency of the TTR binding and inhibition of Aβ fibrillisation remains questionable 
in the absence of a detailed characterisation of the inhibition of fibril formation in the 
presence of different surfaces. This chapter is a study to further investigate binding 
affinity and inhibition of Aβ fibrillisation by TTR in the presence of two different 
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surfaces, widely used for the in vitro studies of Aβ1-42 whether for biophysical analysis, 
cell assays or ELISA. Polystyrene (non-treated or binding) and polyethylglycate (PEG) 
treated (non-binding) microplates were used to show the influence of these two surfaces 
on TTR binding and Aβ fibrillisation inhibition intensity. The chemical structures of these 
molecules are shown in Figure 3.2. 
 
 
Figure 3.2. The structures of polystyrene (PS) and polyethyl glycol (PEG). The highly 
hydrophobic nature of PS and more hydrophilic nature of PEG.  
 
3.2. Materials and Methods 
Preparation of monomeric Aβ, fibrillisation and EM were performed as described in 
chapter 2. 
3.2.1. Addition of TTRs to Aβ  
TTR stocks were kept in PBS (50 mM Na2HPO4/NaH2PO4, 150mM NaCl, 2mM NaN3, 
pH 7.4) at -20 °C. TTR stocks were thawed at room temperature, then filtered through 
100KD filters to remove any aggregated structures. TTR solutions were then diluted by 
adding PBS to the correct final concentration then added directly to the lyophilised Aβ, 
to prevent the peptide from forming low molecular weight species before the addition of 
TTR. 100 μl of the mixture was then added to 96 half-well plates and incubated in 
minimal shaking conditions as previously mentioned in section 2.8.2. 
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3.3. Results 
 
3.3.1. Aβ Fibrillisation  
 
Aβ1-42 fibril formation was monitored using thioflavin T fluorescence. Thioflavin T is an 
amyloid-specific dye that displays a characteristic shift of its emission spectrum as it 
binds to mature amyloid fibrils, and thus allows the time-dependent monitoring of 
fibrillisation. The dye binds only to mature fibrils, but not to monomers, oligomeric 
intermediates or protofibrils. The Aβ fibrillisation reactions monitored by thioflavin T 
assays (Figure 3.3) are consistent with the nucleation-dependent elongation model of 
amyloid assembly (Chapter 1; section 1.9). They exhibit a characteristic sigmoidal curve 
with an initial lag phase in which the amount of amyloid proteins turned into fibrils is not 
detectable, an exponential growth phase in which fibril concentration increases rapidly 
and eventually, a final equilibrium phase when most soluble proteins are converted into 
fibrils (Lee et al., 2007).  
 
Our aim was to use physiological conditions regarding pH, ionic strength and 
temperature. Salt accelerates and promotes the transformation of Aβ to β-sheet as it 
weakens electrostatic forces and as the hydrophobic interaction becomes the dominant 
driving force (Lin et al., 2008), it enhances aggregation. Higher temperatures also 
accelerate Aβ aggregation (Wolff et al., 2015).  Figure 3.3 shows the time course Aβ1-42 
fibrillisation under our optimised conditions. In both polystyrene and PEG-coated plates 
the general features of the fibrillisation reaction are preserved but the reaction is 
noticeably faster in the PEG-treated plates. Most inhibition studies to date have compared 
these data using t50 values because of their greater reproducibility. From the Aβ growth 
curves, the half time (t50) or the time for mid-growth phase when the fluorescence reaches 
  
82 
 
its 50% value was determined. The t50 for Aβ fibrillisation curve was 4.2 ± 0.6 and 1.33 
± 0.15 hrs in the polystyrene and PEG plates, respectively. 
The morphology of produced Aβ1-42 fibrils was analysed using transmission electron 
microscopy. Electron micrographs of Aβ1-42 fibrilisation reactions in the presence of PEG 
and PS plate surfaces after 24 hours are shown in Figure 3.3c & d respectively. The 
formation of mature fibrils confirmed in all of the samples. The fibrils are long, straight 
and unbranched. Little structural variations were between the two different preparations 
were observed. 
 
 
 
Figure 3. 3. Thioflavin T curves and EM images of Aβ1-42 fibrillisation in PS and PEG plates. Aβ1-
42 fibrilisation curves with error bars displaying the standard error of the mean (SEM) to give 
an indication of the spread of the data. t50 is indicated as a large red spot. a) Aβ1-42 in PEG and 
b) Aβ1-42 in polystyrene plates. Electron micrographs of Aβ (11µM) after 24 hrs of incubation. 
c) Aβ1-42 (11µM) in the PEG plate, d) Aβ1-42 in the presence of polystyrene plate. The scale bars 
are indicated. 
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3.3.2. Addition of WT-TTR to the Aβ1-42 fibrillisation reaction 
Thioflavin T time-course 
The kinetics of Aβ1-42 fibrillisation were monitored in the presence of different molar 
concentrations of WT-TTR in the standard conditions described earlier, with a fixed Aβ1-
42 concentration of 11 µM, and shown in Figure 3.4. In the PEG plates, different 
concentrations of TTR were tested ranging from 22 µM (twice the stoichiometric 
concentration of Aβ1-42) to 1 µM (11 times less than the concentration of Aβ1-42). Low 
levels of WT-TTR (1 μM) do not appear to have any effect on Aβ aggregation with the 
curves showing a similar t50. Equimolar (11µM) and lower concentrations (4µM) of WT-
TTR produced an increased t50 in a concentration-dependent manner, although the effect 
is very small. Surprisingly, higher concentrations of WT-TTR (22 μM) do not appear to 
have a greater effect than equimolar (11 μM) with respect to the t50 of Aβ aggregation 
(see Table 3.1.).  
In the polystyrene plates, a fixed Aβ1-42 concentration of 11 µM, with different 
concentrations of TTRs were tested ranging from 11 µM (stoichiometric concentration of 
Aβ1-42) to 1 µM (11 times less than the concentration of Aβ1-42). Near equimolar 
concentrations (9µM) of WT-TTR were able to completely suppress thioflavin T 
fluorescence, suggesting a complete inhibition of fibril formation. Smaller ratios of WT-
TTR (2, 4 and 7.5 μM) lengthened the Aβ fibrillisation time in a concentration dependant 
manner, producing changes in t50 far more significant than for the PEG treated plates. 
Low concentrations of WT-TTR (1 μM) do not appear to have a significant effect on Aβ 
aggregation with the curves showing similar t50 to the control reaction.  
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WT 
TTR 
conc 
(μM) 
Normalized t50 (hrs) Amplitude (as a fraction of 
control fluorescence) 
PEG  Polystyrene PEG Polystyrene 
Mean± sem 
p> 0.05* 
p<0.01* Mean± sem 
p> 0.05* 
p<0.01* 
0 1.33(1)± 0.15 n. a. 3.6 (1) ± 0.6 n. a. n. a. n. a. 
1 0.95 ± 0.19 0.2 n. s. 1.1 ± 0.13 0.15 n. s. 1.1± 0.06 1.22 ± 0.23 
2 n. d. n. d. 1.7 ± 0.5 0.007** n. d. 1.53 ± 0.29 
4 1.1 ± 0.15 0.08 n. s. 2.1 ± 0.5 0.006** 1.2 ±  0.1 1.58 ± 0.4 
7 n. d. n. d. 2.95 ± 0.8 0.045** n. d. 1.9 ± 0.45 
11 1.32 ± 0.33 0.80 n. s. n. d. n. d. 1.07 ± 0.12 n. d. 
22 1.3 ± 0.42 n. s. n. d. n. d. 1.29 ± 0.42 n. d. 
n. a. = not applicable, n. s. = non-significant, n. d. = no data 
Table 3.1. Normalised t50 and amplitude values for Aβ1-42 fibrillisation in the presence of WT 
TTR in PEG and PS microplates. 11 µM of Aβ1-42 and in the presence of different 
concentrations of WT-TTR with standard errors of mean (sem). The significant differences were 
calculated using t test and those with p< 0.05 (n. s.), p> 0.05 (*) and p> 0.01 (**) are indicated. 
 
At the end of the reaction (after reaching plateau), in the PEG plates, the amplitude of 
thioflavin T signal was slightly higher in the presence of the different concentrations of 
TTR. However, in the polystyrene plates, the amplitude was slightly higher in the 
presence of (1µM) of TTR than in its absence and significantly higher in the presence of 
(2, 4 and 7.5 µM) of TTR (Figure 3.4D). Only in the polystyrene plates could the reaction 
be supressed completely and no fibrils observed even after months of incubation 
suggesting the reaction is unable to proceed under these conditions. The increase in 
thioflavin T fluorescence at lower TTR could not be attributed to the independent 
formation of TTR amyloid because, when incubated alone in these conditions, WT TTR 
does not form fibrils and there is no increase in thioflavin T fluorescence.  
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Figure 3. 4. Thioflavin T curves of Aβ1-42 in the presence of WT TTR in both PS and PEG plates. 
Each colour coded line represents a different concentration of TTR with 11 µM of Aβ (1µM 
TTR, brown; 2 µM TTR, yellow; 4 µM, green; 7.5 µM, ocean; 9 µM, purple, 11 µM; black, and 
22 µM; red), with SEM bars representing 3 different experiments. a) Aβ1-42 with WT-TTR in 
PEG microplate b) Aβ1-42 with WT-TTR in polystyren microplate.  c) normalized t50 and d) 
amplitude values calculated for the Aβ1-42 with different concentrations of WT-TTR, in PEG 
(red) and polystyrene (orange) plates, with error bars showing the sem. 
 
Electron Microscopy 
While the thioflavin T fluorescence changes suggest that WT TTR affected Aβ fibril 
formation differently in the presence of PEG and polystyrene microplates, direct 
observation of the morphology of the structures was still necessary to confirm thioflavin 
T results. TEM was employed to investigate the morphology of the structures produced 
at the end of the incubation of Aβ in the presence of equimolar concentration (11µM) of 
WT-TTR in both PEG and polystyrene microplates. Figure 3.5 shows representative 
examples of electron micrographs of these different preparations after 24 hours. In PEG 
microplates, along with mature fibrils, only small amounts of amorphous aggregates also 
  
86 
 
formed, however in the polystyrene microplates large amounts of amorphous aggregates 
were found with very small amounts of fibrils observed in some images. 
 
 
 
 
Figure 3.5. Electron micrographs of Aβ1-42 in the presence of equimolar concentrations of 
WT-TTR after 24 hrs. a) in PEG and b) in polystyrene microplates. The scale bars are indicated. 
  
3.3. Discussion 
 
Several studies have suggested an interaction between TTR and Aβ peptides. 
Transthyretin is one of the amyloidogenic proteins found co-deposited in the plaques. 
Animal model and cell line studies suggest a protective role for TTR in the 
pathophysiology of AD. In vitro analyses of direct interactions also suggest that sub-
stoichiometric concentrations of TTR inhibit Aβ fibrillisation.  
In order to study TTR interaction with Aβ fibrillisation, a typical condition was developed 
for Aβ fibrillisation in both polystyrene and PEG microplates. Under the conditions used 
in this study Aβ peptides make typical straight, unbranched, thioflavin T positive amyloid 
fibrils and the aggregation kinetics follow a typical sigmoidal shape with a lag time, 
a 
b 
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growth phase and then plateau. This pattern fits with a nucleation dependant mechanism 
of aggregation which is a characteristic of Aβ aggregation. In PEG plates, Aβ1-42 exhibits 
a t50 of 1.33 ± 0.15hrs. These results are different from Aβ aggregation rates obtained in 
polystyrene plates where the aggregation rate is slower, the t50 value is about 4.2 ± 0.6 
hrs. However, it is consistent with the t50 for Aβ aggregation by (Meisl et al., 2016). They 
found a t50 of 0.7 hr for Aβ1-42 incubated in 96 well black polystyrene coated with PEG, 
in 20 mM sodium phosphate, 200 mM EDTA, 2mM NaN3, pH 7.4. The differences in the 
aggregation rate in both plates are most likely down to the difference in the Aβ interaction 
with the different surfaces. As previously mentioned, the deposition of an Aβ film and its 
nucleation on hydrophobic surfaces is well-supported in the literature. My lab colleague 
Alex Taylor found evidence for the formation of a tightly bound monolayer of Aβ on 
polystyrene which enhances Aβ nucleation. However, the lose binding of Aβ on PEG is 
likely to accelerate Aβ nucleation and aggregation more than the polystyrene plate, 
presumably because the nuclei can easily come off the surface to the solution and start 
aggregation. The acceleration of nucleation through loose binding of Aβ to surfaces have 
been suggested as the local concentration increases upon binding and loose binding 
allows mobility of the peptide and the ability to aggregate (Shen et al., 2012). 
In an attempt to study the binding and inhibition of Aβ by TTR in the presence of different 
surfaces, thioflavin T experiments were performed using PEG and polystyrene 
microplates. Results obtained in this study show that the intensity of WT-TTR to inhibit 
Aβ fibrillisation is significantly lower in the presence of PEG compared to polystyrene 
surfaces. In the presence of polystyrene plates low concentrations of TTR significantly 
lengthened the t50 of the Aβ fibrillisation and slightly lower than equimolar concentrations 
were sufficient to completely inhibit Aβ fibrillisation. However, in the presence of PEG 
surface even twice the equimolar concentration of WT-TTR does not inhibit Aβ1-42 
  
88 
 
fibrillisation. Electron microscopy showed no difference between the morphology of 
fibrils formed in the presence of an equimolar amount of TTR after 24 hrs in the PEG 
plates, suggesting no inhibition in Aβ fibrillisation by TTR. However, EM showed that 
near equimolar concentration of TTR prevented the formation of fibrils by Aβ in the 
polystyrene plates, and large amounts of amorphous aggregates were observed instead. 
The results obtained in the presence of PEG disagreed with previous studies suggesting 
Aβ1-42 fibrillisation can be inhibited by sub-stoichiometric amounts of TTR. Li et al. 
(2013a) found the complete inhibition of Aβ1-40 by 3µM WT TTR. Our results imply 
strongly that TTR can only inhibit Aβ1-42 fibillisation at these concentrations when it is 
immobilized on a surface. Indeed, while Aβ1-42 forms a tightly bound monolayer on the 
polystyrene surface, its binding to the PEG-treated plate is very weak suggesting it can 
only nucleate Aβ aggregation without forming a monolayer. 
This interpretation is supported by solution measurements of TTR binding to Aβ1-40 
monomers: the KD for TTR tetramer binding to Aβ1-40 is 24µM (Li et al., 2013a). 
However, the KD for TTR binding to Aβ1-42 is much stronger (28 nM) once the Aβ is 
immobilized as shown by ELISA based studies (Costa et al., 2008).  
Aβ forms a monolayer on the surface of the plate which enhances Aβ nucleation to happen 
faster than it would otherwise occur in solution. The binding occurs on the monolayer 
surface which enhances nucleation and formation of larger aggregates and then fibrils. 
Our results imply that disturbance of this layer by TTR prevents nucleation from 
occurring. On the other hand, nuclei and solution monomer can directly form fibrils as 
well but this may be extremely slow. It has been found that elimination of both air-liquid 
interfaces or reactive solid-liquid interfaces can extend nucleation of Aβ1-40 for extended 
periods of time (Garai et al., 2008, Morinaga et al., 2010) and presumably the critical 
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concentration for primary nucleation may be higher than 11μM in the absence of a 
polystyrene and/or air water interface. 
As the rate of aggregation of Aβ in our conditions was independent of monomer 
concentration, the increase in lag time and t50 in the presence of polystyrene plates cannot 
be interpreted as the result of TTR binding to Aβ monomer.  
It is plausible therefore that TTR binds weakly to the monomer or aggregated structure in 
the solution and binds much tighter to a rare species of Aβ aggregated structure on the 
monolayer, causing a delay in the lag time because it delays nucleus formation. However, 
the fibril formation reaction is more favourable and can drive the species bound to TTR 
(because the binding is weak) and the same amount of fibrils will form because all the Aβ 
can convert to fibrils and the final amplitude will be the same or greater than the control 
as the amount of Aβ1-42 which would otherwise bind to the surface is disturbed and able 
to fibrillise. When the concentration of TTR is higher but not high enough to inhibit Aβ 
completely, the amplitude becomes lower because a larger amount of TTR will be 
available at each time point to stay bound to the rare species and not all Aβ will be 
available to form fibrils. When the concentration of TTR is higher, the on-pathway fibril 
reaction will no longer be available and the amorphous aggregation will be more 
favourable.  
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Chapter Four: Transthyretin and Aβ interaction 
 
4.1. Introduction 
 
The hallmark of Alzheimer’s disease is the accumulation of Aβ peptide aggregates into 
extracellular amyloid plaques in the brain. This leads to major neurodegeneration and the 
consequent pathology. Whereas in the past, it was believed that Alzheimer’s plaques 
contained only Aβ peptides, recent findings suggest the involvement of multiple amyloid-
forming proteins in the plaques and in the pathophysiology of Alzheimer’s disease. In 
vitro, the aggregation behaviour of the Aβ peptide has been characterised extensively but 
the effect of co-deposited proteins on Aβ aggregation is not well established. Different 
amyloid forming proteins including transthyretin, neuroserpin and cystatin C have been 
found within amyloid plaques along with Aβ. Although these proteins have similar effects 
in vitro by reducing Aβ toxicity, it seems to be that the different proteins use different 
mechanisms to do this, as illustrated in Figure 4.1. Perhaps it is unsurprising that nature 
has evolved alternative natural mechanisms for the modulation of amyloid formation at 
different stages.  
Protein binding to Aβ monomers prevents the formation of nucleating species thus 
inhibiting fibril formation at the very early stages. Given that the nucleus formation is a 
rate limiting step, small decreases in protein concentration can significantly reduce the 
rate of fibril formation under some conditions (Jarrett and Lansbury, 1993). Nucleus 
stabilisation or restriction of monomer addition may also inhibit fibril formation. Binding 
to the surface of fibrils and preventing Aβ monomers from using it as a template in 
secondary nucleation reactions can also limit formation of new fibrils (Cohen et al., 
2015). Other factors might defibrillise mature fibrils into smaller aggregates which are 
susceptible to proteolysis (and therefore can be cleared by the body) or remodel on-
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pathway oligomeric species to non-toxic aggregates through transient bi-molecular 
collisions (Eichner et al., 2011), thus abolishing the potential for amyloid formation. 
Some other modulator acts as a catalyst by causing the formation of non-toxic species 
without itself being incorporated into the final product. A better understanding of these 
natural mechanisms, and how to mimic them, would lead to the development of a 
therapeutic strategy against AD. 
 
 
Figure 4.1. The Aggregation of Aβ1-42 and Different Methods of Modulation. Schematic 
illustrating the assembly pathway of Aβ1-42 into amyloid fibrils, from the formation of a nucleus 
through the production of oligomeric species before the assembly of protofibrils and finally 
mature fibrils, demonstrating the presence of both fibrils and oligomers in advanced AD. 
Mechanisms for reducing Aβ1-42 toxicity at different points in the aggregation process are 
highlighted, including the formation of a 1:1 complex (green), binding to nuclei (red), binding to 
oligomers (yellow), dissociation of amyloid (purple) and covering the fibril surface to prevent the 
use of its surface as an aggregation template (brown) (Adapted from Williams, 2015 with 
modifications). 
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Transthyretin and Aβ 
Transthyretin is one of several proteins which have been found inside Alzheimer’s 
plaques along with Aβ, is a major constituent of the CSF and can sequester Aβ 
(Schwarzman et al., 1994). Several studies using either animal models or cell culture 
supported the TTR’s interaction and protective ability against Aβ cytotoxicity. In vitro 
studies then showed a direct inhibitory effect of wild type and mutant TTRs on Aβ 
aggregation. Although there is clear evidence for the interaction between WT TTR and 
Aβ, in vitro studies have given contradictory results regarding which species of Aβ and 
TTR are interacting when different methodologies are used. In general, methodologies 
depending on immobilising one of the proteins like surface plasmon resonance (SPR) and 
ELISA show that TTR tetramers bind all forms of  Aβ (Costa et al., 2008) with 
preferential binding of TTR tetramers to Aβ aggregates compared to Aβ monomers (Du 
and Murphy, 2010) and fibrils (Yang et al., 2013a). However, liquid phase NMR 
experiments showed that TTR tetramers but not monomers bind to Aβ monomers and 
both TTR tetramers and monomers bind to Aβ aggregates (Li et al., 2013a).  
The efficiency of the inhibition remains questionable in the absence of a detailed 
characterisation of the inhibition of fibril formation in the liquid phase. This chapter is a 
study of the inhibitory effect of WT and mutant TTRs on Aβ monomers, oligomers and 
fibrils. To achieve these goals, a number of TTR mutants with different kinetic and 
thermodynamic stabilities were chosen and their inhibitory effect against different species 
of Aβ were investigated and compared to the human cystatin C mechanism of inhibition 
of Aβ fibrillisation (chapter 5). 
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TTR mutants used in the study 
More than 100 natural TTR mutants have been described. Most of these mutants are less 
stable as tetramers and more amyloidogenic than the wild-type (McCutchen et al., 1995). 
Four mutants have been used in this study, 3 natural and 1 model (Figure 4.2). All the 
mutants used exhibited a less stable tetramer and monomer to different degrees, except 
V122I which has more stable monomers. TTR mutants with unstable tetramers have been 
shown to be the best inhibitors of Aβ fibrillisation. However, it is not clear whether it is 
unstable tetramers that are effective or unstable monomers. In order to find whether only 
unstable tetramers are necessary for inhibition or unstable monomer as well is an 
important factor. The available data on the stability of WT TTR and its mutants is often 
difficult to compare due to the difficulty in resolving different unfolding and refolding 
transitions in this multimeric protein and the different cooperativity of folding observed 
in different mutants. A summary of the characteristics of the mutants chosen as a result 
of their different multimeric stabilities is described below (Table 4.1). 
1. S85A, is a model mutant TTR which assembles into less stable tetramers (Yang et al., 
2013). S85 is one of the retinol binding residues on the EF loop. CD spectra and 
tryptophan fluorescence data show that S85A retains a native or near-native secondary 
and tertiary structure. In contrast, ANS fluorescence indicates a loss of the thyroxine-
binding channel in this mutant. S85A assembles into a tetramer but these tetramers are 
less stable than their WT counterparts (Du et al., 2012). Size-exclusion chromatography 
shows a significant population of monomers at 10-5M.  
 
2. The V122I TTR variant causes a form of late onset familial amyloid cardiomyopathy. 
The V122I mutant protein is again less stable as a tetramer compared with WT TTR 
(ΔGdiss = +7 ± 1 kcal mole-1) whereas monomers are at least as stable as for the WT TTR. 
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V122I tetramer destabilisation and monomer stability counteract each other to some 
extent, leading to the observed similar overall thermodynamic stability of V122I and WT 
TTR. At physiological concentrations the amount of unfolded V122I monomer (0.15 nM) 
is 3-fold higher than for WT TTR (0.05 nM). The rate of V122I dissociation is 2-fold 
faster than WT (t½= 19 h vs. 41 h for WT TTR) (Hurshman Babbes et al., 2008).  
 
3. V30M is the most common cause of familial amyloid polyneuropathy (FAP) in 
heterozygotes (Sanchez-Ruiz, 2010). The V30M stability is lower than WT and this 
perhaps accounts for its greater capacity to inhibit fibrillogenesis (Li et al., 2013a).  The 
formation of a V30M tetramer happens at a much slower rate than for WT-TTR t1/2 is 68 
h, compared with 41 h for WT TTR (Hurshman Babbes et al., 2008), which could enhance 
monomer accumulation (Jesus et al., 2012), resulting in a higher inhibitory effect against 
Aβ aggregation. V30M monomer is destabilized by ∼2.5 kcal/mol relative to WT TTR 
monomer, with a ∆GunfoldH2O of 3.0 ± 0.2 kcal/mol and compared with a ∆GunfoldH2O for 
WT TTR monomer of 5.5 ± 0.8 kcal/mol under the same conditions (Hurshman Babbes 
et al., 2008).  
 
4. A25T is a mutant which causes central nervous system (CNS) amyloidosis. A25T is 
one of the most unstable known tetramers of TTR.  The A25T TTR protein exhibits a kdiss 
of 5.4 x 10-3 s-1, which equates to a half-life (t1/2) of only 2.1 minutes, 1200-fold faster 
than that of WT TTR. The A25T tetramer is the least stable of all other TTR variant 
published to date. The A25T mutation significantly destabilises both the TTR quaternary 
and tertiary structure compared with WT and the other FAP variants (Sekijima et al., 
2003). A25T monomer ΔGunfoldH2O = 1.8 ± 0.2 kcal mol-1 (M urea)-1, and –munfold = 1.1 
kcal mol-1 (M urea)-1 (Hurshman Babbes et al., 2008). The free energy of monomer 
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unfolding of A25T is 2.80 kcal/mol (Cm = 2M urea), which indicates that the A25T 
tertiary structure is less stable than that of WT TTR (Cm = 3.4 M urea) (Sekijima et al., 
2003). 
 
Figure 4.2. The crystal structure of tetrameric TTR with the mutated residues coloured 
and labelled. The structure adapted from (Klabunde et al., 2000). The structure made by using 
Pymol (DeLano, UK). 
 
 
Parameters WT V122I V30M A25T S85A 
ΔGDiss (kcal mole-
1) -32.8 ± 2.2 (a) -25.6±1.0 (a) 
1.5 M Urea vs 
3M for WT at 
1.44 µM [TTR] 
Very 
aggregation 
prone 
n. a. 
kdiss (s-1) 
t½ (min) 
4.67*10-6 ± 
2460 (41hrs) 
10-5 ± 
1140 (19hrs) 
(a) 
2.8 * 10-6 ± 
4080 (68hrs) 
5.4 * 10-3 
2.1 (4) (c) n. a. 
kass (s-1 M-3),  
k1 U→D and  
k2 D→T (both M-
1s-1) 
 
2.2*106  (a) 
8.1*103 (a) 
 
n. a.  
 
1.8*103 (b) 
1.9*102 (b) 
n. a. n. a. 
KDiss (M3) 
10-24 (a) 10-18 (a) 
Very slow to 
dissociate 
n. a. 10-16 
mDiss (kcal mole-1 
M-1) 
-2.7± 0.1 (a) -1.5± 0.1 (a) n. a. n. a. 
Very unstable 
monomers, 
probably 
unfolded, open 
door for Aβ 
binding site 
CmDiss (M) 3.3 M at 1.44 
µM (a) 
n. a. 
1.5 M at 1.44 
µM 
n. a. 
ΔGunf (kcal mole-1) -4± 0.5 (a) 
M-TTR is  
-5.5±0.8 
-5.1± 0.2 (a) 
stable 
monomers 
-1.5 
(M-TTR equiv is 
-3±0.2) 
-1.8± 0.2a (at 
low [TTR], 0.7-
7µM) Or -2.8 (c) 
KU/F 1.3*10-3 2.0*10-4 8.2*10-2 5.0*10-2 n. a. 
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munf (kcal mole-1 
M-1) 
-1.4±0.4 (a) -1.6±0.5 (a) n. a. n. a. n. a. 
Cmunf (M urea) 3.4 (a) n. a. n. a. 2 n. a. 
ΔGoverall (kcal 
mole-1) 
-48.8 -56.1 n. a. n. a. n. a. 
Koverall 10-27 10-23 n. a. n. a. n. a. 
n. a. = not available 
Table 4.1. A summary of the characteristics of the WT and mutant TTRs chosen as a result of 
their different multimeric stabilities. (a) (Hurshman Babbes et al., 2008), (b) (Jesus et al., 2012), (c) 
(Sekijima et al., 2003). 
 
4.2. Materials and Methods 
 
Aβ monomers for thioflavin T experiments were prepared and fibrillised as described in 
chapter 2. 
4.2.1. Addition of TTRs to Aβ  
 
TTR stocks were kept in PBS (50 mM Na2HPO4/NaH2PO4, 150mM NaCl, 2mM NaN3, 
pH 7.4) at -20 °C. TTR stocks were thawed at room temperature, then filtered through 
100KD filters to remove any aggregated structures. TTR solutions were then diluted by 
adding PBS to the correct final concentration then added directly to the lyophilised Aβ, 
to prevent the peptide from forming low molecular weight species before the addition of 
TTR. 100 μl of the mixture was then added to 96 half-well plates and incubated at 37C° 
with shaking for 10 seconds before taking readings at 5 minutes intervals. 
4.2.2. Addition of TTR at different time points 
 
Aβ fibrillisation was started as described previously. After 5 minutes or 1 hr of incubation, 
5 µl aliquots of 220 µM of TTRs were added to 95 µl of 11 µM Aβ at each of the time-
points to produce a 100 µl sample of 11 µM TTRs and 11 µM Aβ. Controls where PBS 
buffer was added to the Aβ reactions were also run. The aggregation reaction was then 
left to proceed by incubation of the plate in the plate reader. 
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4.2.3. Purification of fibrillar Aβ1-42 fibril 
After one day of incubation, the produced Aβ1-42 aggregates were pelleted by 
centrifugation at 13, 000 rpm for 20 minutes. The pelleted fractions were re-suspended in 
2% SDS to dissolve any non-fibrous aggregates (amorphous and oligomers). The SDS 
re-suspended fibrils were pelleted again, and then washed twice by re-suspension in PBS, 
to remove any residual SDS. The fibrils were then re-suspended in a small amount of 
phosphate buffer and used directly. The concentration of the Aβ fibril fraction was 
determined by measuring the concentration of soluble Aβ in the supernatant after the 1st 
and 2nd centrifugation steps and subtracting it from the total monomer concentration of 
Aβ used at the start of fibrillisation (This method is adapted from Davis, 2013, with 
modifications). 
4.2.4. TTRs binding to Aβ1-42 fibrils 
Different molar concentrations of TTRs were incubated with different amounts of 
purified Aβ fibrils for 20 minutes at 37°C.  Then the mixture was centrifuged at 13, 000 
rpm for 20 minutes to pellet down the fibrils and bound TTR. The concentration of TTR 
in supernatant was measured at 280 nm. The percentage of disappeared TTR was 
determined by subtraction of the TTR concentration in the supernatant from the initial 
TTR concentration. 
4.2.5. Defibrillisation of Aβ fibrils by TTRs 
Different molar concentrations of TTRs were mixed with different amounts of purified 
Aβ fibrils. 10µM of ThT was added to the mixture then 100 µl of the mixture was added 
to microplate wells and incubated at 37ºC for 24 hrs. The ThT fluorescence was recorded 
as described in chapter 2. 
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4.2.6. TTR addition to Aβ seeds 
Aβ fibrils were purified as described previously then fibril sonicated for 30 minutes to 
create short fibrils (seeds). The concentration of seeds was determined from the initial Aβ 
monomer concentration used for making the fibrils. The seeds were mixed with different 
concentrations of TTR in PBS. Then Aβ monomers added to the mixture. The mixture 
was added to the plate reader and the thioflavin T fluorescence followed as described 
previously.  
4.2.7. Analytical Size Exclusion Chromatography (SEC) 
The Aβ1-42 aggregation was monitored in both the absence and presence of TTR by using 
size-exclusion chromatography in PBS on an analytical gel filtration column Superdex 
200 (GE Healthcare, UK). The protein exclusion limit Superdex column is 1,300 kDa, 
with a separation range between 10 and 600 kDa. 180 μl samples were analysed and the 
column was run at 0.5ml/minute for 1hr. Samples from thioflavin T experiments 
performed using the plate reader were collected and analysed after 24 hrs from starting 
the reaction. The OD was measured at either 280 nm or 230 nm. 
 
4.3. Results 
4.3.1. Aβ Fibrillisation  
Aβ1-40 and Aβ1-42 fibril formation was monitored using thioflavin T fluorescence (Figure 
4.3). The Aβ fibrillisation reactions monitored by thioflavin T assays are consistent with 
the nucleation-dependent elongation model of amyloid assembly (Chapter 1; section 1.9) 
but do not show the concentration dependence implied by this model. Instead the 
polystyrene surface of the microplates drives the reaction in a manner which is dependent 
on the available surface area and thus unchanging for all the reactions observed (chapter 
3 and Taylor et al., manuscript in preparation).   
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Figure 4. 3. Thioflavin T curves and EM micrographs of Aβ1-40 and Aβ1-42 fibrillisations. A) Aβ1-40, 
B) Aβ1-42. Error bars displaying the standard error of the mean (SEM). tlag, t50 and tgrowth times are 
indicated. C) EM micrographs of Aβ1-40 after 24hrs of fibrillisation, D) EM micrographs of 
fibrillised Aβ1-42 after 24hrs of incubation, scale bars are indicated. 
 
Most published studies have extracted only the half times (t50) for the Aβ fibrillisation 
reactions. Despite the greater reproducibility of t50, t50 is a mix of the lag time (tlag) and 
growth time (tgrowth) and these two phases are completely different in their nature. In the 
current study we calculated lag time, t50 and growth times separately, in order to be able 
to show the effect of TTRs on the primary and secondary nucleation mechanisms and t50 
to be comparable to the literature. From the Aβ growth curves, the tlag, t50 and tgrowth were 
determined. The tlag for aggregation is the time when the initial nuclei of aggregation are 
forming, which is calculated here as the time point when the fluorescence reaches 5% of 
its final amplitude. t50 corresponds to the time for mid growth phase and is the time when 
the fluorescence reaches its 50% value, this value calculated depending on the lowest and 
highest fluorescence points during the path of Aβ aggregation. The tgrowth is the time from 
A B 
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the start of fibrillisation (or end of tlag) to the end of fibrillisation (or reaching equilibrium 
or plateau), calculated by subtracting tlag from the time when the fluorescence reaches 
95% of its maximum value. tgrowth represents the time needed by Aβ monomers to reach 
equilibrium with fibrils. The tlag for Aβ1-40 fibrillisation were much longer than for Aβ1-42, 
and were 10 ± 2.8 hrs and 1.54 ± 0.3 hrs, respectively under our standard conditions at 
11µM peptide. The Aβ1-40 t50 value was 13.0 + 3.0 hrs while for Aβ1-42 was about 4.2 ± 
0.6 hrs. The tgrowth for Aβ1-40 was 4.5 ± 0.7 hrs compared to 4.7 ± 0.7 hrs for Aβ1-42. This 
suggests that nucleation events are rarer for Aβ1-40 compared with Aβ1-42 peptides but that 
once growth is under way, both elongation and secondary nucleation events must be 
similar. It is worth mentioning that at the begining of Aβ1-42 fibrilisation the fluorescence 
is decreasing for about 30 minutes which might be due to the formation of  non-fibrous 
but thioflavin T positive species which dissolve and then start aggregation to take 
fibrillisation pathway.   
The morphology of the produced Aβ1-40 and Aβ1-42 fibrils was investigated by 
transmission electron microscopy. Electron micrographs showed that mature fibrils had 
formed in both preparations after 24 hours (Figure 4.3C&D). The fibrils are long, straight 
and unbranched. There appeared to be very little structural variation between different 
preparations shown throughout this chapter. 
4.3.2. Addition of WT TTR to Aβ1-42 Fibrillisation 
Thioflavin T Time-course 
The kinetics of Aβ1-42 fibrillisation were monitored in the presence of different molar 
ratios of WT TTR in the standard conditions described earlier, with a fixed Aβ1-42 
concentration of 11 µM, as shown in Figure 4.4. Different concentrations of TTR were 
tested ranging from 11 µM (stoichiometric concentrations of Aβ1-42) to 1 µM (11 times 
less than the concentration of Aβ1-42). Near equimolar concentrations (9µM) of WT TTR 
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were needed to completely supress thioflavin T fluorescence, suggesting complete 
inhibition of fibril formation. Smaller ratios of WT TTR lengthened the Aβ fibrillisation 
time in a concentration dependant manner. Low concentrations of WT TTR (1 μM) do 
not appear to have a significant effect on Aβ aggregation with the curves showing a 
similar tlag (1.56 ± 0.12 hrs p= 0.105 ns), t50 (3.34 ± 0.30 hrs p=0.15ns) and tgrowth values 
(5.84 ± 1.48 hrs p<0.05=0.024*). Intermediate concentrations of WT TTR (2, 4 and 7.5 
μM) appeared to have a significant effect on Aβ aggregation with the curves showing a 
significant increase in tlag, t50 and tgrowth in a concentration dependant manner (Figure 4.4 
and table 4.2). Compared with the tlag, the tgrowth did not increase to the same extent, 
although it did increase with concentration. The tgrowth increased by a factor of 1.2-2.2 
times the control in the presence of 1 to 7.5 µM TTR. 
 
 
 
 
Figure 4. 4. a) ThT fluorescence time 
course of Aβ1-42 titrated with WT TTR. 
Each colour coded line represents a different 
concentration of TTR with 11 µM of Aβ 
(0µM control, blue; 1µM TTR, brown; 2 µM 
TTR, orange; 4 µM, green; 7.5 µM, ocean; 9 
µM, purple), with SEM bars for 3 different 
experiments. b) The tlag  (blue), t50 (green) and 
tgrowth  (purple) values represented as 
histograms for the Aβ1-42 control and with 
different concentrations of WT TTR 
normalised, with error bars showing the sem. 
c) The amplitude of the growth curves in the 
presence of different concentrations of WT 
TTR normalised to one (Aβ control) with sem 
bars. 
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WT TTR 
conc. (µM) 
Normalized tlag (hrs) Normalized t50 (hrs) Normalized tgrowth (hrs) 
Mean± 
SEM 
p> 0.05 Mean± 
SEM 
p> 0.05* 
p<0.01* 
Mean± 
SEM 
p> 0.05 
1 1.56 ± 0.12  0.105 ns 3.34 ± 0.30 0.15ns 1.2 ± 0.2 0.024* 
2 3.0 ± 0.9 0.0739 ns 5.3 ± 1.1 0.007** 1.8 ± 0.37 0.039* 
4 3.2 ± 0.6 0.0252* 5.9 ± 1.0 0.006** 2.1 ± 0.5 0.02* 
7.5 6.8 ± 1.35 0.0215* 9.9 ± 1.7 0.045** 2.2 ± 0.4 0.113ns 
 
Table 4.2. The mean of Normalized tlag, t50 and tgrowth values of Aβ fibrillisation (11µM) in the 
presence of different concentrations of WT-TTR with the calculated standard errors and p-values. 
 
Unexpectedly, at the end of reaction (after reaching plateau), the amplitude of thioflavin 
T signal was slightly higher in the presence of the different concentrations of TTR. The 
intensity was slightly higher in the presence of (1µM) of TTR than in its absence and 
significantly higher in the presence of (2, 4 and 7.5 µM) of TTR (Figure 4.4 C). The 
increase in thioflavin T fluorescence could not be attributed to the independent formation 
of TTR amyloid because, when incubated alone in these conditions, WT TTR does not 
form fibrils and there is no increase in thioflavin T fluorescence. Past a threshold TTR, 
Aβ1-42 no longer fibrillises and the amplitude therefore drops to 0. 
4.3.3. Electron Microscopy  
Although the reductions in thioflavin T fluorescence suggest that WT TTR inhibits Aβ 
fibril formation, these changes could also be due to other factors such as changes in 
morphology and production of thioflavin T negative species.  TEM was employed to 
analyse the morphology of the produced structures at the end of the incubation of Aβ in 
the presence of a near equimolar concentration (9µM) of WT TTR. Figure 4.5 shows 
representative examples of electron micrographs of these different preparations after 24 
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hours. Along with mature fibrils, small amounts of amorphous aggregates also form in 
the Aβ control samples. The fibrils are long, straight and unbranched. 
Although changes in thioflavin T fluorescence suggest that TTR is completely inhibiting 
Aβ1-42 fibril production at equimolar concentration of WT TTR, a small number of single 
fibrils are present along with large amounts of amorphous aggregates. Re-investigation 
of this reaction mixtures after long periods of time (months) did not show the formation 
of large quantities of mature fibrils. Instead a large amount of amorphous aggregate is 
present along with small amounts of fibrils. In the presence of WT TTR, the most likely 
explanation is that an off-pathway species is formed and further associates to form large 
unstructured aggregates. The lack of fibrils even after extended periods of incubation 
suggests these species are no longer thermodynamically favoured. 
 
 
 
 
Figure 4.5. Electron micrographs of Aβ1-42 in the presence and absence of near equimolar 
concentrations of WT TTR after 24 hrs. a) Aβ control (11µM), b) Aβ in the presence of 9 µM of 
WT TTR. The scale bars are indicated. 
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4.3.4. Analytical Size Exclusion Chromatography (SEC) for Aβ1-42 and 
WT TTR  
Figure 4.6 shows SEC elution traces of samples obtained from the fibrillisation reactions 
of Aβ1-42 in the presence of different concentration of wild type TTR after 24hrs of 
incubation. There are several peaks observable in addition to the tetrameric TTR peak at 
28 min and the small monomeric Aβ peak just about detectable at 38.6 min, which is just 
within the separation range for the column: although Aβ is only a 4KDa peptide, the 
unfolded nature of the monomer means that it behaves more like a 15 KDa globular 
protein and is resolvable here. In all reactions, a large peak is observed at the void volume 
of the column (13min) and represents species in excess of 600kDa but that are not filtered 
out by the in-line filter, which suggests it was smaller than 13 MDa. This peak represents 
the aggregated structure larger than 600 KDa, wich could be pure Aβ fibrils or amorphous 
aggregates or any of them bound to TTR. A further peak at 36.7 mins is representative of 
large oligomeric species which adhere to the column and are retarded (Williams, 2014). 
DMSO and buffer peaks appeared at 40.3 and 44 minutes. Aβ monomer, DMSO and 
buffer peaks were characterised by loading monomeric Aβ and DMSO separately on the 
column.   
The height of the 13 min peak is 50% higher in the Aβ1-42 control reaction compared to 
reactions in the presence of 4 and 7µM concentrations of TTR, and about twice the height 
of the aggregated structure peak in the presence of 1µM WT TTR. This is consistent with 
the thioflavin T data which indicates that the proportion of fibril produced by Aβ was 
relatively higher in the presence of the higher concentrations of TTR, and further 
confirmed that TTR only delays the lag time of the Aβ aggregation but unless the 
fibrillisation is started a large amount of fibrils produced at the end. Even in the presence 
of near equimolar (9 µM) concentration of TTR, the height of the aggregated structure 
peak was still nearly half of the control. 
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Figure 4.6. SEC of Aβ1-42 fibrillisation reactions in the presence of different concentrations 
of WT TTR. (A) SEC elution profiles of Aβ1-42 fibrillisation in the presence of different TTR 
concentrations after 24 hours. The peak at 13 minutes indicates aggregated structures, and the 
peak at 28 minutes indicates TTR tetramer. Colours represent different TTR concentrations (0µM 
control, red; 1µM TTR, green; 4µM, magenta; 7.5µM, orange; 11µM, black), the insert is TTR 
tetramer peaks. B) Variation of peak heights (absorbance) from incubations with different 
amounts of WT TTR. Peaks represented are aggregates at 13min (blue), TTR tetramers at 28min 
(purple), Aβ1-42 monomers at 38.6 (brown) and Aβ1-42 oligomers at 36.7min (dark green). 
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This supports the EM observation that even in the absence of a thioflavin T signal 
increase, there are still some aggregates formed, although the nature of these aggregates 
may be amorphous rather than fibrous.  
This conclusion is supported to some extent by the presence of a concomitant increase in 
the height of peaks from smaller molecular weight species, which elute at 36 min and 38 
min respectively and are likely representative of large oligomeric species which adhere 
to the column and are retarded (Williams, 2014). It is clear however that there is a large 
amount of optical density present in the 13 min peak that is not compensated by an 
increase in the 36 and 38 min peaks, so we examined the profiles for evidence of a TTR-
Aβ complex. Tetrameric TTR elutes at 28 min and the observed peak heights are within 
error of the expected peak heights for the relative amounts of TTR in the absence of Aβ. 
This suggests that, while most of the TTR remains soluble, most of the Aβ species remain 
aggregated in one form or the other, but at a smaller molecular weight on average.  
4.3.5. Addition of mutant TTRs to Aβ1-42 fibrillisation reactions 
V122I 
The V122I mutant exhibits a less stable tetramer compared with WT TTR while the 
monomers are at least as stable as WT TTR. This mutant exhibits a 2 fold faster rate of 
tetramer dissociation compared to WT and so was used to investigate the efficacy of 
folded monomer in inhibition. The impact of V122I on the Aβ1-42 fibrillisation was 
studied using thioflavin T fluorescence assays, where 11μM samples of Aβ1-42 were 
fibrillised in PBS in the presence of different concentrations of V122I (1, 2, 4, 7.5, 10 and 
11µM) (Figure 4.7 A). tlag, t50 and tgrowth values were calculated for all reactions (Figure 
4.7 B). The results show that equimolar amounts of V122I are needed to completely 
inhibit Aβ fibril formation. Smaller ratios of V122I TTR increased the tlag and the t50 of 
Aβ fibrillisation in a concentration dependant manner.  
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Figure 4. 7. a) ThT fluorescence data from 
V122I TTR titration into 11 µM of Aβ1-42 
fibrillisation reactions with different 
concentrations of TTR (0µM control, blue; 
1µM TTR, brown; 2 µM TTR, orange; 4 
µM, green; 7.5 µM, ocean; 10 µM, grey; 11 
µM, black), with SEM bars. b) The tlag 
(blue), t50 (green) and tgrowth (purple) values 
represented as histograms for Aβ1-42 control 
and with different concentrations of V122I 
TTR normalised, with error bars (sem). c) 
The amplitude of the growth curves in the 
presence of different concentrations of 
V122I TTR, normalised to the Aβ control, 
with error bars (sem). 
 
As shown in table 4.3, the normalised tlag increased in the presence of 1, 2, 4, 7.5 and 10 
µM V122I as well as the normalised t50, indicating a similar efficacy for inhibition as WT 
TTR. However, unlike with the WT, Aβ1-42 fibrils still grow in the presence of 10 µM 
V122I (Figure 4.7). This result suggests that V122I is slightly less effective compared to 
WT TTR. 
The amplitude of Aβ fibrillisation in the presence of V122I (Figure 4.7C) was slightly 
different for the Aβ control compared with the different concentrations of V122I. The 
amplitude increased in the presence of 1 µM (1.27 ± 0.13), and 2 µM (1.14 ± 0.12) of 
V122I. However, in the presence of higher concentrations 4 µM (1.0 ± 0.15), 7.5 µM (0.9 
± 0.2), 10 µM (0.8 ± 0.12) of V122I the amplitude generally decreased with the increase 
in V122I concentration, indicating that the bulk of fibril produced was different from 
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control Aβ. As with the WT, the amplitude shows a dramatic drop past a critical 
concentration of TTR, in this case at 10µM V122I, which is slightly higher than for WT. 
 
V122I 
TTR conc. 
(µM) 
Normalized tlag Normalized t50 Normalized tgrowth 
Mean± 
SEM 
p>0.05*  
p<0.01** 
Mean± 
SEM 
p> 0.05* 
p<0.01** 
Mean± 
SEM 
p> 0.05 
1 1.5 ± 0.3 0.225ns 1.6+_0.3 0.19ns 1.58± 0.24 0.125ns 
2 2.7 ± 0.9 0.18ns 2.0+_0.25 0.04* 1.6 ± 0.2 0.084ns 
4 5.2 ± 1.0 0.041* 3.3+_0.4 0.94ns 3.1 ± 0.9 0.14ns 
7.5 11.7 ± 1.1 0.002** 6.0+_0.52 0.0096** 2 ± 0.57 0.22ns 
10 16 ± 2.0 0.005** 7.5+_1.8 0.042* 4.15 ± 1.0 0.085ns 
 
Table 4.3. The mean of tlag, t50 and tgrowth normalized values of Aβ fibrillisation (11µM) in the 
presence of different concentrations of V122I-TTR with the calculated standard errors and p-
values. 
 
V30M 
V30M is less stable than wild type transthyretin, perhaps accounting for its greater 
capacity to inhibit fibrillogenesis (Li et al., 2013a).  The formation of V30M tetramers 
also happens at a much slower rate than for WT-TTR, which will enhance monomer 
accumulation (Jesus et al, 2012), resulting in a higher inhibitory effect against Aβ 
aggregation. However, the lack of stability of the monomer (table 4.1.) may imply that 
the predominant species populated apart from the tetramer is an unfolded monomer. 
The fibrillisation of 11 µM Aβ1-42 was monitored in the presence of different 
concentrations of V30M (0.5, 1, 2, and 2.5µM) (Figure 4.8). The results show that 
substoichiometric concentrations (less than 1:4, 2.5 µM) of V30M are enough to 
completely inhibit Aβ fibril formation, which is 3-4 times less than the concentration of 
WT or V122I TTR needed to achieve the same effect. Smaller amounts of V30M TTR 
increased the tlag and t50 of Aβ fibrillisation in a concentration dependent manner. While 
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the tlag in the presence of 0.5 µM V30M was not significantly increased (table 4.4), in the 
presence of 1, 1.5 and 2 µM V30 µM, the lag times were significantly different from the 
control. This result shows that V30M is significantly more effective than both WT and 
V122I TTR.  
 
  
 
Figure 4. 8. a) ThT  fluorescence time 
course of 11 µM Aβ1-42 in the presence of 
different concentrations of V30M (0.5µM 
TTR; red, 1 µM TTR; brown, 1.5 µM; 
purple, 2 µM; orange, 2.5 µM; black). b) 
The tlag (blue), t50 (green) and tgrowth (purple) 
values represented as histograms for the 
Aβ1-42 control and with different 
concentrations of V30M TTR normalised 
with respect to the control, with error bars 
(sem). c) The amplitude of the growth 
curves in the presence of different 
concentrations of V30M TTR normalised to 
the Aβ control, with error bars (sem). 
 
The effect of V30M was greater on the tlag compared with its effect on the t50 and tgrowth 
(Figure 4.8.b) and (table 4.4). The increase in growth time was between 1.8 and 2.7 times 
the control in the presence of 0.5, 1, 1.5 and 2 µM V30M. However, these rates were not 
significantly different from the control. The results so far concur to say that the effect of 
TTR on the fibrillisation of Aβ1-42 is principally on the nucleation phase and is enhanced 
greatly when TTR is unfolded rather than simply dissociated to monomers. 
 
  
110 
 
V30M 
TTR conc 
(µM) 
Normalized tlag (hrs) Normalized t50 (hrs) Normalized tgrowth (hrs) 
Mean± 
SEM 
p> 0.05 Mean± 
SEM 
p> 0.05* 
p<0.01* 
Mean± 
SEM 
p> 0.05 
0.5 1.63± 0.13 0.024* 1.75 ± 0.5 0.26ns 2.0 0.7 0.23ns 
1 2.7 ± 0.26 0.0037** 2.16 ±0.2 0.08* 1.9 0.3 0.06ns 
1.5 5.8 ± 1.1 0.02* 4.8 ±1.4 0.11ns 2.7 ±0.9 0.19ns 
2 9.0 ± 0.9 0.0083** 6.9 ±1.6 0.044* 2.5 ± 0.83 0.2ns 
 
Table 4.4. The mean of normalized tlag, t50 and tgrowth values of Aβ fibrillisation (11µM) in the 
presence of different concentrations of V30M-TTR with the calculated standard errors and p-
values. 
 
The amplitude of Aβ1-42 fibrillisation in the presence of V30M was also marginally 
different from the Aβ1-42 control (Figure 4.8 C). While the yield was higher in the presence 
of 0.5 µM V30M, at higher concentrations of the inhibitor, it generally decreased until a 
cut-off value of 2µM beyond which no fibrillisation occurs.  
 
A25T  
A25T is one of the most unstable known tetramers of TTR (Table 4.1) and causes CNS 
myloidosis. A25T has a half-life (t1/2) of only 2.1 minutes, with a kdiss of 5.4 x 10
-3 s-1, 
some 1200-fold faster than that of WT TTR (Hammarström et al, 2002). The A25T 
mutation significantly destabilises both the TTR quaternary and tertiary structure 
compared with WT and the other FAP variants (Sekijima et al., 2003). 
11 µM Aβ1-42 was fibrillised in the presence of different concentrations of A25T (0.5, 1, 
1.5, 2, and 2.5µM) (Figure 4.9). Similarly to V30M, the results show that 
substoichiometric concentrations (2.5 µM) of A25T TTR were enough to completely 
inhibit Aβ fibril formation, 3-4 times less than the concentration of WT or V122I TTR 
needed to achieve the same effect. Smaller ratios of A25T TTR increased the tlag and t50 
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of Aβ fibrillisation in a concentration dependant manner. The tlag was increased by a factor 
of 2 to 9 times in the presence of 0.5, 1, 1.5 and 2 µM A25T (Figure 4.9 b) and (table 
4.5). t50 were increased accordingly to up to 7 times the control. This result shows that 
A25T TTR is far more effective than WT and V122I TTR.  
 
 
 
 
 
Figure 4.9. a)  ThT fluorescence of 11 µM 
Aβ1-42 titrated with different concentrations 
of A25T (0µM control, blue; 0.5µM TTR, 
red; 1 µM TTR, brown; 1.5 µM, purple; 2 
µM, orange; 2.5 µM, black). b) The tlag 
(blue), t50 (green) and tgrowth (purple) values 
represented as histograms for the Aβ1-42 
control and with different concentrations of 
A25T TTR normalised with respect to the 
control. c) The amplitude of the growth 
curves in the presence of different 
concentrations of A25T TTR normalised to 
the Aβ control. All error bars are sem. 
 
Slightly different to WT and all other mutants, the amplitude of Aβ fibrillisation in the 
presence of A25T TTR was lower than that of the Aβ control for all concentrations (table 
4.5), and it generally decreased with the increase in A25T TTR concentration (Figure 4.9 
C).  
A25T 
TTR conc. 
(µM) 
Normalized tlag (hrs) Normalized t50 (hrs) Normalized tgrowth (hrs) 
Mean± 
SEM 
p> 0.05 
p<0.01**  
Mean± 
SEM 
p> 0.05* 
p<0.01** 
Mean± 
SEM 
p> 0.05* 
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0.5 2.2 ±0.42 0.16 2.3 ±0.1 0.0035** 2.8 ± 0.3 0.04* 
1 5.4 ±0.7 0.015* 4.3 ±0.3 0.0042** 2.7 ±0.43 0.048* 
1.5 6.8 ±0.58 0.005** 5.5 ± 0.17 0.0001*** 2.0 ± 0.45 0.16ns 
2 9.17 ±1.9 0.14ns 7.2 ± 0.7 0.06* 3.9 ± 1.17 0.2ns 
 
Table 4.5. The mean of normalized tlag, t50 and tgrowth values of Aβ fibrillisation (11µM) in the 
presence of different concentrations of A25T-TTR with the calculated standard errors of mean 
and p-values. 
 
S85A TTR 
S85A is a model mutant TTR with the mutation in the EF loop. This mutant assembles 
into less stable tetramers. The EF loop has been suggested as a binding site to Aβ and as 
an Aβ sensor (Yang et al., 2013a).  
11 µM Aβ1-42 was fibrillised in the presence of different concentrations of S85A (0.5, 1, 
1.5, 2, and 2.5µM) (Figure 4.10). Similarly to V30M and A25T, the results show that 
substoichiometric concentrations (2.5 µM) of S85A TTR were enough to completely 
inhibit Aβ fibril formation, which is 3-4 times less than the concentration of WT and 
V122I TTR needed to achieve the same effect. However, smaller ratios of S85A TTR 
increased the tlag and the t50 of Aβ fibrillisation in a concentration dependent manner, even 
more effectively compared to A25T and V30M. The tlag increased by a factor of 4, 6, 8 
and 11 times in the presence of 0.5, 1, 1.5 and 2 µM S85A respectively (table 4.6). The 
t50 increases accordingly between 1.5 and 3.5 times the control as S35A TTR 
concentrations rise to 2 µM. This result shows that S85A TTR is the best inhibitor in 
terms of increasing the tlag. Even more strikingly than for the other TTRs, the tgrowth stays 
unchanged compared to the control and in the presence of different amounts of S85A. 
These data show that S85A affects only the tlag, with only a very small effect on the tgrowth.  
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Figure 4. 10. a) ThT time courses for 
fibrillisations of 11 µM Aβ1-42 in the presence 
of different concentrations S85A (0.5µM 
TTR, red; 1 µM TTR, brown; 1.5 µM, 
purple; 2 µM, orange; 2.5 µM, black). Error 
bars are sem. b) The tlag (blue), t50 (green) and 
tgrowth (purple) values represented as 
histograms for the Aβ1-42 control and with 
different concentrations of S85A TTR 
normalised with respect to the control, with 
error bars (sem). c) The amplitude of the 
growth curves in the presence of different 
concentrations of S85A TTR normalised to 
the Aβ control, with error bars (sem). 
 
The amplitude of Aβ fibrillisation in the presence of S85A TTR was higher than the 
control in the presence of 0.5 µM of S85A, however it then decreased with increasing 
S85A concentration (Fig. 4.10C and table 4.6).  
S85A 
TTR conc. 
(µM) 
Normalized tlag (hrs) Normalized t50 (hrs) Normalized tgrowth (hrs) 
Mean± 
SEM 
p> 0.05*  
p<0.01** 
Mean± 
SEM 
p> 0.05* 
p<0.01** 
Mean± 
SEM 
p> 0.05 
0.5 4.15 ±1.0 0.08 1.5 ±0.16 0.09 0.65 ±0.12 0.09ns 
1 6.5 ±0.67 0.0076** 2.14 ± 0.07 0.0006*** 0.9 ±0.09 0.44ns 
1.5 8.4 ± 1.1 0.016* 2.8 0.18 0.0035** 1.25 ±0.25 0.44ns 
2 10.5 ± 1.8 0.031* 3.5 ±0.35 0.015* 1.3 ±0.21 0.27ns 
 
Table 4.6. The mean of normalized tlag, t50 and tgrowth values of Aβ fibrillisation (11µM) in the 
presence of different concentrations of S85A-TTR with the calculated standard errors and p-
values. 
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4.3.6. Comparing WT and mutant TTRs 
tlag, t50 and tgrowth of Aβ1-42 in the presence of different concentrations of WT and mutant 
TTR were calculated and plotted together to show the difference between the inhibition 
intensity of different mutants compared with WT (Figure 4.11).  
The tlag of Aβ1-42 aggregation increases in a concentration dependent manner as a result 
of the addition of WT and all mutants. Near stoichiometric concentrations of WT and 
V122I were needed to completely inhibit Aβ aggregation, however 3-4 times less (only 
2.5µM) of V30M, A25T and S85A were needed to do so. S85A was the most effective 
mutant for extending the lag time, followed by A25T> V30M> WT> V122I. This result 
indicates that, with the exception of V122I, all other mutants were more effective 
compared to WT TTR.  
Regarding growth time, the results show that in general the TTRs are not as effective on 
growth time as they are on lag time. The order of effectiveness remains the same, however 
S85A has no any obvious effect on growth time and is less effective compared with WT 
and all other mutants. The observed t50s of aggregation reflect a contribution from both 
lag and growth times, with the pattern of inhibition intensity generally the same except 
for S85A, which is less effective than A25T and V30M. 
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Figure 4.11. Lag, t50 and growth times for Aβ1-42 fibrillisation in the presence of TTRs with respect 
to control Aβ1-42 (in blue, 11 µM), for Aβ1-42 in the presence of different concentrations of TTR 
(Red-WT, Green-V122I, Purple-V30M, Orange-A25T, Black-S85A) with error bars representing 
sem. Values are normalised with respect to the Aβ1-42 control mean. a) Normalized lag time (tlag), 
b) Normalised half time (t50). c) Normalised growth time (tgrowth).  
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4.3.7. Addition of TTRs to Aβ1-40 Fibrillisation 
Thioflavin T Time-course 
The kinetics of Aβ1-40 fibrillisation were monitored in the presence of different molar 
ratios of WT TTR in the standard conditions described earlier, with an Aβ1-40 
concentration of 11 µM (Figure 4.12). Different concentrations of WT TTR were tested 
ranging from 4 µM (33% of the concentration of Aβ1-40) to 0.1 µM (~100 times less than 
the concentration of Aβ1-40). A molar ratio of 1:5 WT TTR to Aβ1-40 caused a complete 
reduction in thioflavin T fluorescence, suggesting that the fibril formation is completely 
inhibited in the presence of WT TTR. Smaller ratios of WT TTR to Aβ (~1:20 and ~1:10) 
have an effect on Aβ1-40 aggregation with the curves showing significant increases in tlag, 
and a delay in t50.  
 
 
Figure 4.12. TTRs inhibit Aβ1-40 fibril formation. WT (green), V122I (red) and V30M (purple) 
TTRs increased the aggregation t50 (i.e. decreased fibril formation) of 11 μM solution of 
monomeric Aβ1-40 monitored by ThT fluorescence, in a concentration dependent manner within 
concentration ranges (0.2– 4 μM). The blue dashed line shows the t50 of Aβ1-40 aggregation under 
the same conditions in the absence of TTR. 
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In order to investigate different inhibitory behaviours of different TTR mutants on Aβ1- 
40 aggregation and obtain data comparable with Aβ1-42, two of the mutants with different 
inhibitory effects on Aβ1-42 fibrillisation were used. The V122I and V30M mutants were 
chosen. V122I was the least effective and V30M was the most effective (equally to 
A25T). The order of inhibition of WT and mutants are similar to that of TTRs on Aβ1-42, 
except that the difference in the inhibitory effect of V122I with WT is more obvious. The 
inhibitory effect of V122I is significantly less than wild type TTR. In the case of Aβ1-40, 
the inhibitory order is V30M>WT>V122I compared to V30M> WT≥ V122I in Aβ1-42. 
Compared to WT TTR, a higher concentration of V122I (5 µM) was needed to completely 
inhibit Aβ1- 40 fibrillisation. Lower concentrations of V122I (1, 2, 4 µM) significantly 
lengthened the t50 of Aβ fibrillisation in a concentration dependant manner, however, the 
intensity of inhibition was smaller compared to WT and the difference between the effect 
of V122I and WT was significant. V30M was significantly more effective than WT. Only 
1.5µM is needed to completely inhibit 11 µM of Aβ1-40. Lower concentrations (0.25, 0.5 
and 1 µM) extended the t50 for much longer time compared to WT TTR (Figure 4.12). 
4.3.8. Addition of TTRs at different time points 
In order to reveal whether TTRs bind to already aggregated species of Aβ, TTRs were 
added to Aβ1-40 aggregation reactions at different time points and the reaction followed 
by ThT fluorescence (Figure 4.13). These time points were chosen to be at the beginning 
of the elongation phase or lag time (5 minutes) and later after (1 hr), where Aβ1-40 
aggregates are formed.   
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Figure 4.13. Addition of TTRs to Aβ1-40 
fibrillisation at different time points: 
0.5µM of different TTRs added to Aβ1-40 
fibrillisation reaction at different time points 
(0, 5 minutes and 1hr). The blue curve 
represent Aβ1-40 control (11 µM), violet 
represent time zero (0), brown represent TTR 
addition after 5 minutes of Aβ1-40 addition to 
the buffer and  green represent TTR addition 
after 1 hr of Aβ1-40 addition to the buffer a) 
WT TTR,  b) V122I TTR, c) V30M TTR. 
 
The addition of TTRs after both 5 minutes and 1 hour caused differences in their 
inhibitory effects compared to their addition to fresh monomeric Aβ. The inhibitory 
capacity of WT TTR was nullified when added after 5 minutes and 1hr. The ability of the 
V122I variant to delay Aβ1-40 aggregation markedly decreased when added after 5 
minutes or 1hr. However, its addition after 5 minutes and 1hr were very similar. The 
inhibitory effect of V30M mutant reduced when added after 1 hr, however, its addition 
after 5 minutes did not reduce its inhibitory effect and was similar to its addition to fresh 
Aβ. These results indicate that WT affects Aβ aggregation mainly through monomers or 
very early events. The effect of the V122I mutant on aggregated structures is very small, 
while V30M can still affect smaller Aβ1-40 species but not larger ones. 
4.3.9. TTRs and Aβ fibrils 
4.3.9.1. TTR binding to Aβ1-42 fibrils 
The surface of Aβ fibrils can catalyse production of new aggregates through working as 
a secondary nucleation template for the formation of new fibrils. Prevention of this 
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secondary nucleation process is of particular importance in the prevention of toxic 
oligomer production (Cohen et al., 2015). In order to investigate the ability of WT and 
mutant TTRs to bind to pre-made Aβ fibrils, the co-pelleting of TTRs with Aβ1-42 fibrils 
was measured. TTRs were incubated with equimolar amounts of Aβ1-42 fibrils (monomer 
equivalents) for 20 minutes. After incubation the mixtures were centrifuged at 13, 000 
rpm for 20 minutes to pellet the fibrils and any bound TTR. The amount of TTR remaining 
in the supernatant was measured and the pelleted fraction of TTR calculated by 
subtracting the remaining amount from the original TTR concentration. The same 
concentrations of TTR were incubated separately without Aβ1-42, centrifuged and TTR 
concentrations were checked in the supernatant to be used as controls. A25T showed the 
largest fraction of protein co-pelleting with Aβ1-42 fibrils, followed by V30M> WT> 
S85A> V122I (Table 4.7. and Figure 4.14).  
 
TTRs Decrease in TTR 
concentration in TTR 
controls % 
Decrease in TTR 
concentration in TTR+ 
Aβ1-42 mixtures % 
The fraction of TTR co-
pelleted with Aβ1-42 % 
WT 0% 8% 8 ± 1.2 % 
V122I 5% 7% 2 ± 0.6 %  
V30M 7% 16% 9 ± 1.4 %  
A25T 38% 56% 18 ± 3.1 %  
S85A 2% 8% 6 ± 0.9 % 
 
Table 4.7. The mean percentage of the bound (co-pelleted) TTRs in the presence of equimolar 
concentrations of purified Aβ1-42 fibrils. 
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Figure 4. 14. Histogram representation of the percentage of TTRs co-pelleted with Aβ1-
42 fibril. 
 
4.3.9.2. Aβ1-42 defibrillisation by TTRs 
Disaggregation of amyloid fibrils is an important step towards its clearance. TTRs can 
alter the Aβ fibrillisation kinetics and we found evidence on its ability to bind to pre-made 
fibrils. The ability of WT and mutant TTRs to defibrillise pre-made Aβ fibrils was 
investigated applying thioflavin T technique. Equimolar amounts of TTRs were incubated 
with purified Aβ1-42 fibrils and the thioflavin T signal monitored to detect any changes. 
Generally, the addition of TTRs to Aβ fibril shows no difference in thioflavin T 
fluorescence compared to the control. An initial decrease in the Thio T fluorescence 
intensity is noticed in the Aβ1-42 control and similarly in the presence of TTRs, this could 
be due to either temperature adjustment or dissociation of the fibrils because of dilution 
as the reaction started by adding highly concentrated stock of fibrils to the reaction buffer. 
As no significant differences are detectable with TTR compared with in its absence, these 
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results suggest that TTRs do not dissolve pre-formed mature Aβ fibrils, but rather have 
an effect on their formation.  
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Figure 4.15. Thio T curves of Aβ1-40 defibrillisation by TTRs. Thio T curves of (11 
µM-monomer equivalent) of purified Aβ1-42 fibrils in the absence, control (blue) and 
the presence of equimolar amount of WT TTR (red), V122I (green), V30M (purple), 
A25T (black), S85A (orange). The error bars represent (sem).  
 
4.3.9.3. TTRs inhibition of Aβ1-42 seeding 
It has been shown that formation of amyloid fibrils by Aβ1-42 happen by a nucleated 
growth mechanism (Evans et al., 1995). In the absence of an aggregate, a nucleus has to 
be formed in situ in a process that needs a relatively high concentration of the peptide and 
significant dead time. When an aggregation seed is present due to addition of exogenous 
aggregates, the nucleation time of the reaction is reduced and the fibril extension step is 
more quickly started (Evans et al., 1995). The addition of WT and mutant TTRs to such 
seeded reactions does not extend the lag time, except for A25T which extends the lag 
time similarly in the presence and absence of seeds. This result indicates that only the 
  
122 
 
A25T variant inhibits the ability of added fibrils to act as seeds for fibril formation, 
suggesting that A25T can prevent addition of monomers through binding to the extension 
sites of an amyloid fibril and, probably these sites are similar to the binding sites on an in 
situ generated nucleus in an unseeded reaction (Wood et al., 1996). 
 
 
Figure 4. 16. Thiofavin T curves showing the inhibitory effect of WT and A25T TTRs 
on seeded reaction of Aβ fibrillisation. Aβ1-42 monomer (4µM) without (blue) and with 
0.4µM Aβ1-42 seeds (light blue); 0.4µM WT TTR added to Aβ monomers without (red) and 
with (orange) seeds; 0.4µM A25T TTR added to Aβ monomers without (dark green) and 
with (light green) seeds.  
 
4.4. Discussion 
 
Several studies have suggested a protective role for TTR in the pathophysiology of AD 
and a direct interaction between TTR and Aβ peptides. In vitro data suggest that sub-
stoichiometric concentrations of TTR inhibit Aβ fibrillisation. However, the species of 
Aβ which TTR binds to prevent its aggregation is still not clear. ELISA based methods 
suggested that TTR binds to all forms of Aβ including fibril, oligomers and monomer, 
preferentially to oligomer. However HSQC NMR showed that TTR and specifically the 
residues around and including the thyroxine binding pocket of the TTR tetramer bind to 
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Aβ1-40 monomers. Most of the studies mentioned above have been performed on Aβ1-40. 
Aβ1-40 is 4 times more abundant in the brain, however Aβ1-42 is more aggregation prone 
and pathogenic. This study is an attempt to reveal the species of Aβ which TTR binds to. 
In this study, conditions were optimized to make both Aβ1-40 and Aβ1-42 fibrillise, in order 
to compare the effect of TTRs on the peptides under similar conditions. Under the 
conditions used in this study both Aβ peptides makes typical straight, unbranched, 
thioflavin T positive amyloid fibrils and the aggregation kinetics follow a typical 
sigmoidal shape with a lag time, growth phase and then plateau. This pattern fits with a 
nucleation dependant mechanism of aggregation which is a characteristic of Aβ 
aggregation. Our results showed that Aβ1-42 is the more aggregation prone and exhibits a 
lag time of 1.5 hrs, t50 of 4.2 hrs and reaches a plateau after 6.2 hrs. Aβ1-40 takes 5 times 
longer to start fibrillisation, with a lag time of 10hrs, a t50 of 13hrs and then reaches a 
plateau after 14.5 hrs. Results obtained by this study show that near equimolar 
concentrations of WT TTR are needed to completely inhibit Aβ1-42 fibrillisation, while a 
3-4 times lower concentration was sufficient to completely inhibit Aβ1-40 fibrillisation. 
These results are in agreement with those from Kelly and co-workers (Li et al., 2013) 
regarding the complete inhibition of Aβ1-40 by 3µM WT TTR. However, in the current 
study, lower concentrations of TTR extended the t50 of Aβ1-40 for longer compared with 
the t50 times found by Kelly and co-workers. This is most probably due to the later 
addition of TTR to Aβ by their group, where the peptide is dissolved in buffer before 
addition of TTR instead of our method which is to dissolve the peptide into a solution 
already containing TTR. This is validated by our observation that addition of TTR to Aβ1-
40 after addition of buffer significantly lowers the strength of TTR inhibition, as measured 
by the fibrillisation lag time (section 4.3.8). 
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4.4.1. The stoichiometry of transthyretin inhibition implies that it binds 
to more than just monomeric Aβ. 
While TTR binding to immobilised Aβ is strong (28nM), TTR binding to Aβ monomers 
in solution is relatively weak. The KD of TTR tetramer binding to Aβ1-40 in solution is 
24µM (Li et al., 2013a), meaning that only 1/3 of TTR and Aβ monomers are bound at 
any particular time in an 11μM mixture of equimolar amounts of both TTR and Aβ. 
Despite this, equimolar concentrations of WT TTR were enough to inhibit Aβ1-42 
fibrillisation completely. In addition, under our experimental conditions, the lag time is 
not concentration dependent, so binding of TTR to Aβ monomers can’t explain the delays 
in the lag time of Aβ fibrillisation. At the same time, TTR only significantly increased 
the tlag and t50 rather than tgrowth which suggests TTR mainly affects the monomeric Aβ or 
early oligomeric / nucleating species. There are a number of models which can explain 
these observations. Inhibition may occur in this way due to the fact that both TTR 
tetramers and monomers can bind to Aβ aggregates as well as monomers. TTR tetramers 
may inhibit Aβ aggregation through binding to small aggregates (shown by ELISA based 
methods) and enhancing the formation of off-pathway species rather than fibrils. The 
observation of large amounts of amorphous aggregates in EM images in the presence of 
TTR further supports this interpretation. Monomers of TTR may also contribute 
significantly to this process: at physiological concentrations of TTR, tetramer is in 
equilibrium with small but significant amounts of monomer (table 4.1.). TTR monomers 
are more effective than tetramers in inhibiting Aβ fibrillisation and bind preferentially to 
Aβ aggregates. It has also been suggested that addition of Aβ enhances the destabilisation 
of the TTR tetramer which then leads to an increase in the observed monomer population. 
Monomers subsequently bind to newly formed Aβ oligomers to inhibit further 
fibrillisation. This could explain, why less stable mutants are more effective under our 
conditions (4 times more effective). Because this mechanism does not depend on 
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interactions with the monomeric species of Aβ, it permits to inhibition of Aβ fibrillisation 
at lower than stoichiometric ratios of TTR to Aβ1-42 monomers. The implication here is 
that these secondary mechanisms may be responsible for the segregation of at least 2/3 of 
the Aβ molecules down alternative pathways. 
A further interpretation of this effect would be surface effects given that we found that 
Aβ binds to the surface of the polystyrene microplates and forms a monolayer. This 
monolayer can nucleate Aβ aggregation, however, the TTR binding to Aβ on this 
monolayer is stronger than to Aβ in solution. The TTR stays bound to aggregated Aβ and 
prevents it from nucleating the fibrillisation reaction. 
4.4.2. Mutant TTRs exhibit different inhibitory mechanisms on Aβ 
fibrillisation. 
Aβ1-42   
The 4 variant TTRs compared in this study exhibited two different types of behaviour. 
While the inhibitory effect of the V122I mutant is not significantly different from wild 
type, other mutants were significantly more effective. Nearly four times less V30M, 
A25T and S85A were required to completely inhibit Aβ1-42 fibrillisation, compared with 
WT and V122I. The S85A mutant was significantly more effective in extending the lag 
time of Aβ aggregation compared to A25T and V30M. The rank of inhibitory effect of 
TTR mutants was S85A> A25T>= V30M> V122I>=WT. These results indicate that the 
inhibitory capacity of mutants is conversely related to their stability, with the less stable 
mutants acting as the better inhibitors. Even if V122I tetramer is less stable as tetramer 
compared to wild-type, this mutant is equally effective or even slightly less. This could 
be because V122I has a more stable monomer compared to other mutants and possibly its 
binding site to Aβ is not as exposed as other mutants which have unstable monomers as 
well as tetramers. It has been suggested that addition of Aβ can lead to the dissociation of 
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TTR tetramers, indicating that both the dissociation of tetramer the unfolded nature of the 
monomer are important to inhibit Aβ fibril formation.  
Costa and colleagues (2009), found that the affinity of V30M for immobilised Aβ is only 
60% of WT TTR binding. However, NMR data have shown that V30M binding to soluble 
Aβ1-40 is stronger than WT TTR in solution (Li et al., 2013)  and these effects are likely 
to dominate our experiments. The stronger inhibitory efficacy of the less stable TTR 
mutants (V30M, A25T and S85A) may be due to the increased exposure and therefore 
accessibility of their hydrophobic residues to Aβ. Another possibility could be that more 
than one Aβ molecule can fit within the TTR hydrophobic pocket if these mutants exhibit 
a more open tetrameric structure (Figure 4.2). For example, with regards to the S85A 
mutant, it has been suggested that mutation of S85 to alanine leads to better access of 
other hydrophobic residues to Aβ and consequently a better inhibition of Aβ fibrillisation 
is achieved (Du and Murphy, 2010). The idea that Aβ destabilises the TTR tetramer and 
that the increased monomer population can then bind to Aβ oligomers and inhibit 
fibrillisation may provide a further explanation for the 4-fold greater than WT inhibitory 
effect of mutants observed here. The observed high efficacy of M-TTRs even at highly 
substochiometric ratios by (Li et al., 2013) supports this theory.  
 
Aβ1-40 
The Aβ1-40 is less aggregation prone and exhibits a much longer lag time compared with 
Aβ1-42. Results obtained by this study show that only 3 µM WT TTR were needed to 
completely inhibit Aβ1-40 fibrillisation. This results is consistent with published data (Li 
et al., 2013a). However, in the current study, lower concentrations of TTR extended the 
Aβ1-40 t50 time for longer compared to the t50 times found by (Li et al., 2013). This could 
be due to the addition of buffer to Aβ before adding TTR by (Li et al., 2013), considering 
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that Aβ can form small aggregates rapidly in physiological buffers. This is validated by 
the addition of TTR to Aβ after addition of buffer which significantly lowered the 
intensity of TTR inhibition. We found the V122I variant to be less effective at inhibiting 
Aβ1-40 fibrillisation compared with WT and 5 µM was needed to completely inhibit 
fibrillisation instead of 3μM. This finding is different to the result reported by Li and 
colleagues (2013), where they found that the V122I mutant was more effective than WT 
TTR. This could also be due to the late addition of WT TTR to Aβ (their addition of buffer 
to Aβ before adding TTR) by (Li et al., 2013). This makes the WT inhibition appear far 
less efficient as it allows the formation of oligomers that the WT TTR cannot reverse. 
Interestingly, we found that V122I was more effective at lengthening the lag time of Aβ 
aggregation when added after 5 minutes or 1hr of addition of buffer to Aβ. This could be 
due to the fact that V122I can also bind to small Aβ aggregates and delay fibrillisation. 
V30M mutant is even more effective, and compared with both WT and V122I only needs 
1.5 µM to completely inhibit Aβ1-40 fibrillisation for at least 200 hrs.  
 
4.4.3. Transthyretin did not reduce the fibril yield once a threshold 
concentration is reached 
The amplitude of the ThT fluorescence signal from Aβ and TTR reactions is most likely 
to represent the amount of fibril produced during the reaction. The intensity is largely the 
same until it reaches a threshold concentration, then no fibrils are observed. This means 
that below a certain concentration of TTR, amyloid β fibrillisation is only delayed and 
the final yield of fibril remains essentially the same. Once a threshold concentration is 
reached, the reaction is prevented from occurring and the amplitude is 0. The fluorescence 
amplitude of Aβ and WT TTR mixtures was slightly higher and increased with WT TTR 
concentration. However, for all mutants, the amplitude was higher than the control in the 
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presence of lower TTR concentrations and then decreased with further increases in TTR 
concentration, indicating a possible decrease in the formation of Aβ fibrils. The most 
obvious idea would be that transthyretin may be co-aggregating and contributing directly 
to the increase in fluorescence observed. However, the size-exclusion analysis presented 
in section 4.3.4 suggests this is not true and supports a model where most of the TTR 
remains in solution. Another explanation is that the increase in fluorescence does not 
represent an increased yield, rather it could be due to TTR enhancing the formation of 
morphologically different ThT positive Aβ fibrils with a higher intrinsic fluorescence. 
However, in the case of higher concentrations of TTR, the same thing is not happening 
making this hypothesis less likely.  
4.4.4. The nature of the growth phase of Aβ fibrillisation – a clue to 
interpreting the mechanism of inhibition of transthyretins? 
From our tlag, t50 and tgrowth calculations, it would appear that the effect of TTRs on tgrowth 
is smaller compared with their effect on tlag and is not concentration dependent (i. e. 7.5 
µM of WT TTR extends the tlag 7-fold, however the same amount of TTR extends tgrowth 
by only 2-fold compared with the control reaction). The nature of the growth phase is 
controversial and in our conditions has only a very shallow concentration dependence on 
Aβ concentration, if at all, suggesting that the molecular processes that dominate in this 
phase are not affected by the concentration of monomer. If TTR exerts most of its effect 
through monomer binding, then its effect will be to decrease monomer concentration, 
which is therefore unlikely to have a significant effect on tgrowth. Given the above 
discussions, this seems unlikely. 
A simpler explanation would be that, despite the importance of other effects, the main 
impact of TTRs is still to affect Aβ aggregation through delaying the formation of primary 
nuclei rather than by affecting secondary nucleation. The S85A variant is an extreme case 
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of this where the effect on tgrowth is negligible, in spite of the fact that it had the greatest 
impact of all TTRs on lag time. The Aβ fibril binding assays presented here further 
support this: S85A was also the odd one out in showing no significant binding to Aβ 
fibrils. This would indicate that S85A inhibits Aβ fibrillisation entirely through binding 
to monomers or very early species not present in the growth phase, and not oligomers or 
fibrils. Experiments performed on TTRs binding to Aβ fibrils and the effects on seeding 
showed that only in the case of A25T mutant can a relatively large percentage bind to Aβ 
fibrils and neutralise the seeding effect. These results again shows that most TTRs cannot 
affect secondary nucleation reactions. As A25T is very unstable and aggregation prone, 
addition of fibrils can further destabilise and make it aggregate and precipitate during 
pelleting, however it was effective in controlling the seeding. This could be due to 
increase in monomer population as monomers suggested to bind Aβ aggregates better. 
Conversely, mutants which had the greatest impact on growth rate were A25T and V30M, 
which are most likely to be binding to alternative species of Aβ.  
4.4.5. Transthyretin interacts with more than monomers, but does it 
interact with fibrils? 
The current hypothesis of Aβ fibrillisation supports the idea that secondary nucleation 
plays a key role in fibrillisation. Aβ1-42 fibrils are not directly toxic themselves. However, 
they can help continuous generation of toxic oligomers as they can provide a catalytic 
surface for this. Consequently the produced oligomeric species can grow and form 
additional fibrils, which further promoting the production of more toxic species in a 
catalytic cycle. Accordingly, the fibrils, play a big role in the toxic oligomer by lowering 
the kinetic barriers. Because of the prominent role of the catalytic cycle in the generation 
of new toxic oligomers, identification of inhibitors to prevent the catalytic activity of the 
fibril surfaces would be of a valuable importance.  
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To explore the potential of this strategy, TTRs were incubated with purified Aβ fibrils 
and monitored using ThT fluorescence. The data obtained show that TTRs do not exhibit 
any obvious defibrilisation effect on Aβ1-42 fibrils. However, co-pelleting assays showed 
that a large fraction of the A25T TTR variant protein co-pelleted with Aβ fibrils. This 
could be due to either binding to Aβ fibrils or destabilisation of A25T by Aβ and 
consequently amorphous aggregate formation, followed by precipitation of the A25T. Aβ 
seeding inhibition assays show that only A25T can inhibit seeding of Aβ1-42. This result 
would support the idea that it binds to Aβ fibrils and prevents the fibril surface from acting 
as a secondary nucleation template for the formation of new fibrils. A25T can inhibit both 
primary and secondary nucleation processes for generating oligomers. Additionally, 
because the targets are the catalytic sites on the fibrils, and does not depend on 
interactions with the monomers, it is possible that even substoichiometric ratios of TTR 
would be efficient to inhibit the catalytic process.  
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5 Chapter Five: Human Cystatin C and Aβ interaction 
 
5.1. Introduction 
The importance of human Cystatin C (hCC) in Alzheimer’s disease is presented in the 
introduction to this thesis. Here, we consider available data on the direct interaction of 
hCC with Aβ in vitro. The first investigations into the direct interaction between hCC and 
Aβ revealed a high affinity binding between the two proteins at physiological pH and 
temperature. ELISA assays revealed a specific, concentration dependant and high affinity 
binding of hCC to both Aβ1-40 and Aβ1-42 (Figure 5.1 A) (Sastre et al., 2004b). This study 
also showed a nanomolar KD for both proteins. The same study found that hCC inhibited 
in vitro fibril formation by both Aβ1-40 and Aβ1-42, and promoted the formation of 
amorphous aggregates rather than mature fibrils (Figure 5.1D). TEM detected that 
substoichimetric concentrations of hCC can prevent fibril formation by Aβ1-40, as no 
fibrils were observed when 3.75 µM hCC was incubated with 22 µM of Aβ1-40. However 
near stoichiometric amounts of hCC were needed to completely inhibit amyloid fibril 
formation by Aβ1-42 (15 µM hCC for 22 µM Aβ1-42) in a 10 µl volume. The binding site 
of hCC to the extracellular N-terminal region of Aβ was mapped employing co-
immunoprecipitation experiments with deletion mutants of APP and in vitro binding 
assays with GST-Aβ.  
Selenica et al. (2007a), probed the effect of hCC addition to Aβ1-42 ADDL and protofibril 
preparations using western blotting and gel filtration (Figure 5.1 B&C). The authors 
suggested that the formation of both small and large Aβ1-42 oligomers decreased in the 
presence of hCC, as a decrease in the amount of Aβ trimers, tetramers and high molecular 
weight oligomers (98-38 kDa) was detected by SDS-PAGE when Aβ1-42 was incubated 
with an equimolar amount of hCC (Figure 5.1B).  
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Figure 5.1. The Interaction between hCC and Aβ in the Literature 
The binding of hCC to Aβ was studied by ELISA (A) Different concentrations of wild-type 
(solid line, solid circles), L68Q variant (dashed line, open squares) and urinary hCC (dotted 
line, solid triangles) were incubated for 3 h at 37°C with Aβ1-40 or Aβ1-42 coated wells. Anti-
hCC antibody was used to detect bound hCC, and the means and standard deviations were 
calculated from three independent experiments (image taken from Sastre et al. (2004a). (B) 
Western blot of Aβ1-42 oligomers with and without hCC (taken from Selenica et al. (2007a). 
SDS-PAGE of the oligomeric preparations was analysed using the anti-Aβ monoclonal 
antibody 6E10. Lanes 1-6 show different volumes of the supernatants of mixtures in the 
absence (lanes 1-3) and presence (lanes 4-6) of equimolar hCC after 24 h incubation. Lanes 8-
10 represent different volumes of the supernatants of mixtures with preformed Aβ-oligomers 
to which 100 μM has been added and incubated for a further 24 h. Lane 7 (veh.) is a control of 
the incubation solution with no proteins present. (C) The elution profile  of gel filtration of  0.6 
nM 125-I-labelled hCC (solid circles) and a solution of 0.6 nM 125I-labelled hCC in the presence 
of a slight molar excess of Aβ1-40 (open squares) (taken from Selenica et al. (2007a). The shift 
in the peak of radioactivity to a volume thought to correspond to a molecular mass of ~17 kDa 
is explained as the formation of an equimolar complex between 125I-labelled hCC (13 kDa) and 
Aβ1-40 (4 kDa). D)  Electron micrographs of assemblies formed by (a) Aβ42 (1 µg) or (b) Aβ42 
(1 µg) incubated with hCC (2 µg). Scale bars represent 100 nm (taken from Sastre et al. 
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(2004a). 
They also found that the amount of precipitate increased in the presence of hCC: TEM 
revealed that this precipitate was mainly composed of amorphous aggregates with few 
oligomers and fibrils present. SEC-HPLC was employed to show a reduction in Aβ1-42 
protofibril formation when Aβ1-42 was incubated with both equimolar and 2 x 
concentrations of hCC. A sephadex G-50 gel filtration column (Amersham) was used to 
detect Radio-labelled 125I-hCC-Aβ1-40 complex after for 35 minutes of incubation of the 
two proteins. The radioactive peak of hCC (13 kDa) shifted as seen in Figure 5.1C and 
this was believed to resemble a complex with a molecular weight of 17 kDa, i.e. a 1:1 
complex formation between hCC and Aβ1-40 (4 kDa). These data are difficult to explain, 
given the insufficient resolution of Sephadex G-50 and the abnormal behaviour of 
oligomeric species during gel filtration. The nature of any complex formed in solution is 
still debatable. 
As mentioned above, it has been suggested that there is a single binding site between the 
two proteins, with a nanomolar range dissociation constant. The hCC binding halts further 
Aβ aggregation to form amyloid fibrils, and alternatively diverts the assembly pathway 
to the formation of amorphous aggregates. Despite the fact that hCC interaction with Aβ 
has been investigated through several different methods, however, the structural details 
of this association is no well-established yet. In our lab, previously the interaction 
between hCC and amyloid beta peptide (Aβ) has been studied by Williams (2015). 
Amyloid β fibrillisation time courses were performed with and without hCC and showed 
that hCC will inhibit the amyloid fibrils formation by Aβ1-42 in a concentration-dependent 
way, requiring a 2:1 molar ratio of hCC to Aβ to completely inhibit this reaction where 
complete reduction in the intensity of thioflavin T  fluorescence was noticed. At 
equimolar concentrations, a significant decrease in thioflavin T fluorescence, but not a 
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complete loss, indicates that a small amount of amyloid fibrils is still present (Figure 5.2). 
  
 
Figure 5.2. Aβ and hCC Dose Dependence  
Thioflavin T fluorescence time-courses of Aβ1-42 fibrillisation at 11 µM with the addition of 
different molar ratios of hCC. Each curve is the average of 5 replicates, with error bars indicating 
the standard error of the mean (SEM). Three separate experimental series done at different times 
and with different protein stocks are shown for comparison (Adapted from Williams, 2015). 
1H 15N-HSQC NMR experiments were also performed for 15N labelled hCC and Aβ to 
find the binding surface of hCC to Aβ. Despite the fact that hCC inhibited Aβ fibril 
formation, no chemical shift in amide cross-peaks was observed in 1H 15N-HSQC NMR 
spectra of hCC incubated with Aβ1-40 (Keeley, 2007, Elshawaihde, 2012), and Aβ1-42 both 
in its monomeric and oligomeric forms (Williams, 2015).  These data suggest that folded 
hCC monomers do not interact with Aβ1-42 monomers, yet they still effectively inhibit Aβ 
fibril formation. This was surprising, as it has been shown that hCC tightly binds to 
monomeric Aβ1-40 as determined by ELISA (Sastre et al., 2004a). It is believed that these 
variations could be accounted for by the fact the ELISA experiment is performed on a 
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surface, while the NMR experiment is in solution.  This is a strong indication that hCC 
binds non-monomeric species of Aβ1-42, most probably some form of the oligomer 
(Williams, 2015).  
In order to identify the species in the Aβ aggregation reaction to which the hCC was 
binding, hCC was added to Aβ fibrillisation at different time points. These points were 
the start of the initiating the Aβ fibrillisation, at the mid-elongation phase, and at the 
plateau. Addition of hCC at the start of the initiating the Aβ fibrillisation, at the mid- 
elongation phase have also caused inhibition of the aggregation and a reduction in 
thioflavin T fluorescence intensity, however, hCC addition at these points was not as 
effective as when it was added at the start of the aggregation reaction. This however 
indicates that hCC still has an effect on Aβ aggregation at these time-points, suggesting 
that the hCC binding species are still present. The addition of hCC at the plateau shows 
no difference in thioflavin T fluorescence compared to the control. This suggests that hCC 
needs to be present early on in the reaction to have an effect, and hCC does not dissolve 
pre-formed mature Aβ fibrils, but rather has an effect on their formation. This suggests 
the interacting Aβ species are likely to be a protofibrillar species present early on in the 
reaction. 
Formation of domain-swapped dimers is one of the characteristics of the cystatin 
superfamily. As demonstrated by Ekiel & Abrahamson (1996), dimerisation of hCC can 
be induced by de-stabilising the protein using temperature, pH or chemical denaturants. 
Dimerisation causes hCC to lose its protease inhibition activity as the active site is 
included in the process. As oligomeric forms of an intracellular homolog of hCC, cystatin 
B had been shown to interact with amyloid β (Skerget et al., 2010b), the ability of hCC 
dimers to inhibit Aβ fibrillisation was also examined. Unlike monomer, the addition of 
equimolar concentrations of hCC dimer has no effect on the fibril yield, but instead caused 
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an increase in lag phase, compared to Aβ1-42 incubated in the absence of hCC. This 
suggests a different mechanism of inhibition by the dimer, where it is able to interfere 
with the reaction progress but not affect its outcome. The notable difference between the 
inhibitory effect of monomer and dimer gives a strong indication that the region involved 
in protease binding is responsible (Williams, 2015). The surface of the monomer and the 
dimer are basically similar in all regions of the molecule except for the loops involved in 
protease binding (Ekiel et al., 1997a). The hydrophobic nature of this region of the hCC, 
which is essential for protease binding, makes it a typical surface for interactions with the 
Aβ peptide.  
Given the above findings, the next step in this study was to understand the chemical nature 
of the binding site and the binding Aβ species. However, re-examination of the 
concentration dependence of the hCC inhibition and hCC: Aβ complex formation by 
NMR was necessary. Residue-specific mutagenesis is a powerful technique in the study 
of protein–protein interactions, allowing identification of key residues in protein–protein 
interactions. The unusually hydrophobic nature of the protease binding site suggested that 
hydrophobic residues may be key candidates for the binding of Aβ species. This chapter 
describes the biochemical identification of the binding interface of hCC with Aβ through 
mutation of hydrophobic residues to alanine. The interaction between wild-type and 
variant hCC and different species of Aβ is assessed applying thioflavin T fluorescence 
assays and electron microscopy techniques.  1D and 1H 15N-HSQC NMR were used to 
monitor fibrillisation time-courses of Aβ1-42 with hCC and detect complex 
formation/monomer disappearance. A key part of this work is also to validate/rectify 
previous measurements which I show to be affected by the presence of an E. coli 
contaminant, with a significant anti-amyloid activity (chapter 6). 
Establishing the molecular mechanism of how this process works would then allow a 
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comparison of this with other Aβ-modulating systems to discover if there is a general 
mechanism for in vivo protection which could be exploited for the identification of a 
therapeutic peptide.  
Materials and Methods 
5.2.1 Monomeric Aβ preparation and fibrillisation 
Monomeric Aβ preparation, fibrillisation and inhibitor addition assays were performed as 
described in (Chapter 2), except that two different shaking conditions used. First; 
continuous shaking at 300 r.p.m. Second: minimal shaking at 100 r.p.m for only 10 
seconds before each reading.  
5.2.2 Purification of fibrillar Aβ1-42 fibril 
Fibrillar Aβ was prepared, hCC binding to Aβ fibrils, defibrillisation and seeding 
inhibition assays were performed as described in section (4.2.). 
5.2.3. Preparation of hCC Dimer 
100 µM hCC in 10 mM sodium phosphate pH 6.0, 100 mM NaCl was incubated for 30 
minutes at 68 °C, then loading onto a semi-preparative Superdex 200 (GE Healthcare) gel 
filtration column equilibrated in 50 mM sodium phosphate pH 7.4, 150 mM NaCl. 0.5 ml 
fractions were collected and the dimeric peak were collected and quantified by measuring 
the absorbance at 280 nm, before immediate use in thioflavin T assays. 
5.2.4. Nuclear Magnetic Resonance Spectroscopy 
Protein preparations.  
15N-labelled hCC was expressed and purified as described in section 2.4.3. Before the 
NMR experiments, the purity and monomeric state of the protein was established through 
analysis by mass spectrometry and SEC-HPLC. 
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Lyophilised HFIP-treated Aβ1-42 was purchased from rPeptide. 1 mg Aβ1-42 was dissolved 
in 1 ml HFIP and sonicated for 10 minutes in a DECON Ultrasonics sonicator bath 
(Sussex, UK). The solution was split into 0.1 mg aliquots and HFIP was evaporated under 
a stream of N2. Samples were lyophilised to remove any residual HFIP and stored at -20 
°C. Monomeric Aβ1-42 for subsequent NMR experiments was prepared by dissolving 0.2 
mg of HFIP-treated Aβ1-42 in 176 µl of 10 mM NaOH, with sonication for 30 minutes. 50 
µl of deuterium oxide (D2O) and 340µl of phosphate buffer saline were added to 100 µl 
of NaOH dissolved Aβ1-42 stock. The final concentration of Aβ1-42 was brought to 50 µM 
in 50 mM phosphate buffer (Na2HPO4/NaH2PO4), 150mM NaCl, 2mM Sodium azide. 
The pH was adjusted to 7.4 by adding 10 µl of 100 µM HCl and adjusting the final volume 
to 500 µl. The concentration of Aβ was quantified by measuring the absorbance at 280 
nm, and where necessary adjusted to 50 µM by the addition of Phosphate buffer pH 7.4, 
10% D2O. A 1D 
1H spectrum was recorded at 330 K.  
 
NMR Spectroscopy.  
All NMR spectra described in this chapter were recorded on a Bruker DRX spectrometer 
operating at 600 mHz with a cryogenically cooled probe, and controlled using 
XWinNMR (Bruker). Spectra were processed and analysed using Felix 2004 (Accelrys) 
with in-house macros. All heteronuclear single quantum coherence (1H 15N-HSQC) 
experiments were acquired using 1024 increments in the proton dimension and 512 
increments in the nitrogen dimension. The spectral widths of the proton and nitrogen 
dimensions were 7507.5 Hz and 2128.6 Hz respectively. 
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1H-15N HSQC Spectrum of HCC. 
A backbone assignment for hCC at the required experimental conditions of 50 mM 
phosphate buffer (Na2HPO4/NaH2PO4), pH 7.4, 150mM NaCl, 330 K, has been 
determined through salt titration. This assignment was based on a published assignment 
for 200 μM hCC in 15 mM Tris-TFA pH 7.5, 278 K (Keeley, 2007). In turn, this 
assignment was based on a published assignment for 200 μM hCC in 50 μM sodium 
phosphate pH 6.0, which was recorded at 303 K (Ekiel et al., 1997b).  
Salt Titration for 15N-labelled HCC. 
The backbone assignment of hCC under the desired experimental conditions, 50 mM 
phosphate buffer (Na2HPO4/NaH2PO4), pH 7.4, 150mM NaCl, 330 K was determined by 
tracking changes in the 1H-15N HSQC spectra as conditions were gradually changed from 
the previously assigned conditions 15 mM Tris-TFA pH 7.5, 278 K (Keeley, 2007). This 
assignment was based on a published assignment for 200 μM hCC in 50 μM sodium 
phosphate pH 6.0, which was recorded at 303 K (Ekiel et al., 1997b). The new assignment 
was determined in three steps by gradually increasing NaCl concentration, as described 
below. A 500 µl sample of 50 mM phosphate buffer (Na2HPO4/NaH2PO4), pH 7.4, was 
prepared for NMR by the addition of 10% D2O. The initial spectrum was recorded once 
the sample was equilibrated to 303K.  The assignment of 15 mM Tris-TFA pH 7.5, 278 
K transferred well onto this spectrum.  Following this, the sample was removed from the 
NMR tube so that the NaCl concentration could be increased to 20 mM and 150 mM by 
the addition small aliquots of 5M NaCl stock.  At each new NaCl concentration, a 1D 1H-
spectrum of the sample was recorded prior to recording the 1H-15N HSQC spectra. 
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Time-course of unlabelled Aβ1-42  
1D time course - 50 µM of Aβ1-42 in 50 mM phosphate buffer (Na2HPO4/NaH2PO4), pH 
7.4, 150mM NaCl, 2mM Sodium azide, was prepared as previously described, and 50 µl 
of deuterium oxide (D2O) was added to bring the final the final volume to 500 µl. The 
concentration of Aβ1-42 was quantified by measuring the absorbance at 280 nm, and where 
necessary adjusted to 50 µM by the addition of Phosphate buffer pH 7.4, 10% D2O. A 1D 
1H spectra were recorded at 15 minute intervals at 303K. The disappearance of Aβ1-42 
monomer was followed by the reduction in the overall spectral intensity as a function of 
time by comparing to the 1st time point.  
Time-course of unlabelled Aβ1-42 with 15N-hCC 
1D and 1H-15N HSQC Time Courses -  15N-labelled hCC in phosphate buffer saline were 
added to monomeric Aβ1-42 to achieve 50 µM of both Aβ and hCC in 50 mM phosphate 
buffer (Na2HPO4/NaH2PO4), pH 7.4, 150mM NaCl, 2mM Sodium azide and 50 µl of 
deuterium oxide (D2O) was added to bring the final volume to 500 µl. The 1D and 2D 
HSQC spectra of the sample were obtained every 85 minutes for 24 hours at 303 K.  
Results 
5.3.1 Design of Mutations 
The fact that dimerisation of hCC causes the loss of its inhibitory action implies that the 
dimerisation interface is the same interface as for binding (Williams, 2015). Given the 
hydrophobic nature of this site and the affinity of Aβ for hydrophobic surfaces, six 
hydrophobic residues with large solvent accessible surfaces were selected from different 
parts of hCC and mutated to alanine (Figure 5.3). Three large hydrophobic patches were 
identified at the surface of the molecule including the protease binding site, which 
contains the hCC N-terminal, previously implicated in Aβ binding (Sastre et al., 2004b).  
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Figure 5.3. Crystal surface structure of hCC showing, A) mutated residues, and B) all 
hydrophobic residues in red. On the left, view as in A), right, rotated through 180o. Images 
made using Pymol (Delano, UK). 
 
NMR titrations of hCC with Aβ1-40 and Aβ1-42 had shown that flexibility in this region 
is gained during the titration: peaks (G4, K5, R8, L9, V10, G11, and G12) from residues 
at the N-terminal sharpen and increase in intensity (Keeley, 2007). In the N-terminal 
region, Proline number 6 (P6) was thus mutated, although it is not shown in figure 5.3. 
as the flexible N-terminal does not appear in the crystal structure. As well as the N-
terminal, residue V57 at the first, then P105 and W106 from the second loop of hCC 
protease inhibition active site were selected. A second hydrophobic patch through the 
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middle part of the protein was identified and V50 made up a large part of its surface so 
was chosen. In the third patch, residue L80 from the large loop between strands 3 and 
4 was also mutated to Alanine (Figure 5.3.). The total solvent accessible surface area 
of hCC is 6819 Å2, and the solvent accessible hydrophobic surface area is 2036 Å2. The 
percentage of solvent accessible surface area of each residue to the total accessible 
hydrophobic surface area of the protein was calculated and presented in table 5.1. 
 
 
* P6 residue is not included in the crystal structure, so its surface area calculated form Miller et al. (1987). 
Table 5.1. Total surface area and solvent accessible surface area of each mutated residues 
calculated from hCC PDB file in PYMOL (Blake et al., 1978).  The percentage of accessible 
surfaces for each residue is calculated with respect to the total solvent accessible 
hydrophobic surface of hCC. 
Mutated 
residue 
Total surface area 
(Å2) 
Solvent accessible 
surface area (Å2) 
% of solvent accessible 
surface area (Å2) 
P6 143* 143 7 
V50 96.6 96.6 3.62 
V57 95.8 95.8 3.4 
L80 117.8 117.8 7.86 
P105 84 84 3.93 
W106 166.8 163 8 
 
 
5.3.2. Aβ1-42 Fibrillisation  
Previously in our lab, the effect of wild-type hCC on Aβ1-42 aggregation kinetics was 
studied with continuous shaking of the reaction mixture at 300 r.p.m. In this study the 
same continuous shaking method was used to reproduce comparable data to those 
obtained from the previous study as shaking is known to affect the reaction both in terms 
of acceleration of nucleation (Morinaga et al., 2010, Lee et al., 2012), growth rate (Cohen 
et al., 2013) and changes in fibril structure (Buttstedt et al., 2013). However, in order to 
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produce comparable data to the data obtained in the study of the TTR effect on Aβ, the 
minimal shaking condition was also used as presented in section 3. Fibrillisation curves 
under both conditions are shown in figure 5.4 for comparison. 
    
 
 
Figure 5.4. Thio T curves and TEM of Aβ1-42 fibrillisation in minimal and continuous shaking 
conditions. Thioflavin T fluorescence curves showing Aβ1-42 fibrillisation reactions. Aβ1-42 was 
incubated at 11 μM in 50 mM sodium phosphate pH 7.4, 150 mM NaCl in an Omega plate-reader 
at 37 °C either with A) continuous shaking at 300 r.p.m. or B) minimal shaking at 100 r.p.m. for 
only 10 seconds before each reading. The increase in fluorescence intensity at 482 nm was 
monitored over several hours. The mean of 3 different experiments with 5 replicates from each 
experiment was plotted. C and D: Aβ fibrils produced during thioflavin T experiments at different 
shaking conditions in 50 mM sodium phosphate pH 7.4, 150 mM NaCl show a similar structural 
morphology after 24 hours.  Scale bars are indicated. 
 
From the Aβ growth curves obtained in continuous and minimal shaking conditions, the 
lag time (tlag), half time (t50) and growth times (tgrowth) were determined (as discussed in 
section 4.3) and presented in table 5.2. The tlag and t50 times are much shorter in the case 
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of continuous shaking, probably due to the fact that shaking can cause fragmentation of 
the fibrils. Fibril fragmentation can thus accelerate the rate of secondary nucleation. As 
amyloid aggregation is an autocatalytic process, monomer addition to the ends of 
preformed fibrils is more favourable and faster than the formation of new fibrils from the 
monomers and, consequently, the aggregation rate depends on the number of fibril ends. 
 
Conditions \Values tlag (hours) t50 (hours) tgrowth (hours) 
Continuous shaking 0.6 ± 0.14 1.3 ± 0.23 2.2 ± 0.4 
Minimal shaking 1.54 ± 0.3 4.2 ± 0.2 4.7 ± 0.7 
 
Table 5.2. The mean and sem of tlag, t50, tgrowth values of Aβ fibrillisation curves in both continuous 
and minimal shaking conditions. 
 
The morphology of produced Aβ1-42 fibrils were analysed by transmission electron 
microscopy of the fibrils produced. Electron micrographs of the Aβ1-42 fibrils in these 
different conditions after 24 hours are presented in figure 5.4 C&D. TEM confirmed that 
mature fibrils had formed in all of the samples. The fibrils are long, straight and 
unbranched. There appeared to be very little structural variation between Aβ1-42 fibrils 
produced in these two different preparations. 
 
5.3.3. Addition of hCC to Aβ1-42 Fibrillisation 
5.3.3.1. Thioflavin T Time-course 
The kinetics of Aβ1-42 fibrillisation were monitored in the presence of different molar 
ratios of hCC, with 11 µM Aβ1-42, as shown in Figure 5.5. Each curve is the average of 3-
5 different experiments, each experiment with 5 replicates.  
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Figure 5.5. Concentration dependence inhibition of Aβ1-42 in minimal and continuous 
shaking conditions. Thioflavin T fluorescence time-courses of Aβ1-42 fibrillisation at 11 µM with 
the addition of different molar ratios of hCC; blue (0 µM), green (5.5 µM), red (11 µM), black 
(13 µM), purple (22 µM), brown (33 µM) and dark blue (44 µM). Each curve is the average of 5 
replicates, with error bars indicating the standard error of the mean (SEM). A) In minimal shaking 
and B) Continuous shaking conditions. C) and D) normalized data from A) and B), respectively. 
E) The relative amplitude of thioflavin T curves of Aβ fibrillisation (11µM) in the presence of 
different concentrations of hCC in minimal shaking (green) and continuous shaking (black) 
conditions. The error bars represent SEM. 
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In minimal shaking conditions slightly higher than equimolar concentrations of hCC 
caused complete inhibition of thioflavin T fluorescence, suggesting complete inhibition 
of fibril production. hCC concentrations of 11 µM and 5.5 µM caused a reduction in 
thioflavin T fluorescence of 90% and 40% respectively. However, in continuous shaking 
conditions, 4 times the equimolar concentration was needed to completely inhibit Aβ 
aggregation (Figures 5.5.B&E). Equimolar concentration of hCC only slightly reduced 
the amplitude of Aβ aggregation curves. This suggests that hCC only binds to a subset of 
Aβ1-42 species and that these are less highly populated under shaking conditions.  
Unlike TTR, hCC did not show any effect on the shape of the curves of Aβ aggregation 
time courses with the curves showing similar tlag, t50 and tgrowth. It was not any increase in 
thioflavin T fluorescence upon incubation of hCC alone, indicating that hCC did not form 
fibrils in these conditions. Normalisation of the curves shows that superficially there is 
very little difference in either the lag phase or the elongation rate of the reactions under 
all conditions (Figures 5.5.C&D).  
5.3.3.2. Electron Microscopy 
In spite of the fact that reductions in thioflavin T fluorescence suggested that hCC was 
inhibiting Aβ1-42 fibril production, this reduction in fluorescence intensity could be down 
to other factors such as the formation of different Thioflavin T species or changes in 
morphology. TEM was employed to investigate the structural morphology of the 
structures formed at the end of the incubation of Aβ1-42 in the presence of inhibitory 
concentrations of hCC. Figure 5.6 shows electron micrographs of Aβ1-42 after at least 24 
hours of incubation in the presence of inhibitory concentrations of hCC in two different 
conditions. In the absence of hCC, Aβ1-42 produces long straight unbranched fibrils 
(Figure 5.4.) while in its presence, a large amount of amorphous aggregate was observed 
in both conditions (Figure 5.6).  
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Figure 5.6. TEM of incubated Aβ1-42 in the Presence of hCC  
Electron micrographs of Aβ1-42 (11 µM) in the presence of inhibitory concentrations of hCC 
after at least 24 hours. A) Aβ1-42 in the presence of 13 µM of hCC in minimal shaking conditions 
and B) Aβ1-42 in the presence of 44 µM of hCC in continuous shaking conditions. The scale 
bars re indicated. 
 
5.3.4. hCC binding to Aβ1-42 fibres 
Equimolar amounts of purified Aβ1-42 fibrils and WT hCC were incubated at 30°C for 2 
hrs. The mixture was centrifuged for 20 minutes at 13,000 rpm to co-pellet Aβ1-42 fibrils 
and bound hCC. The concentration of the co-pelleted fraction of hCC was determined by 
subtracting the hCC concentration left in the supernatant from the original hCC 
concentration at the start. hCC alone was also incubated, spun down and pelleted as a 
control. 
18% of WT hCC co-pelleted with the Aβ1-42 fibrils suggesting that 18% of hCC was 
bound to Aβ1-42 fibrils, which is nearly a ratio of 1:5 of hCC to Aβ1-42. This result is 
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consistent with 18% disappearance of hCC when incubated with the equimolar amounts 
of Aβ1-42 after 24 hrs and monitored by 1D 1H NMR (section 5.3.8.4). 
5.3.5. Aβ1-42 defibrillisation by hCC 
Equimolar amounts of hCC were incubated with purified Aβ1-42 fibrils and the thioflavin 
T signal monitored. Only a very small reduction in thioflavin T fluorescence is observed 
in both the Aβ control and in the presence of hCC (Figure 5.7.), which might be due to 
temperature adjustment or dilution of the fibrils. This suggests that WT hCC does not 
dissolve pre-formed mature Aβ1-42 fibrils in the time course of this experiment, but rather 
has an effect on their formation.  
 
Figure 5.7. Aβ1-42 defibrillisation by WT hCC. Thioflavin T curves for the Aβ1-42 
defibrillisation assay, where blue represents 11µM purified Aβ fibrils in standard phosphate 
buffer and brown is the same amount of purified fibrils in the presence of an equimolar 
amount of monomeric WT hCC. The initial decrease is most likely a temperature adjustment. 
 
5.3.6. Inhibition of seeding 
Aβ1-42 seeds were generated by sonication of purified fibrils for 30 minutes. Addition of 
10% of these seeds significantly shortened or removed the lag time of monomeric Aβ1-42 
aggregation. Compared with WT TTR, which had no impact on seeding, addition of 
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equimolar amounts of hCC completely inhibited the seeding effect. It has been shown 
that formation of amyloid fibrils by Aβ1-42 happen by a nucleated growth mechanism 
(Evans et al., 1995). In the absence of an aggregate, a nucleus has to be formed in situ in 
a process that needs a relatively high concentration of the peptide and significant dead 
time. When an aggregation seed is present due to addition of exogenous aggregates, the 
nucleation time of the reaction is reduced and the fibril extension step is more quickly 
started (Evans et al., 1995). Low concentration (equimolar to Aβ seeds) did not delay the 
lag time of Aβ fibrillisation. However, higher concentration of WT hCC extended the lag 
time to what it was in the absence of seeds. This result indicates that WT hCC inhibits the 
ability of added fibrils to act as seeds for fibril formation only when it is present in excess 
to seeds. This suggests that despite WT hCC’s ability to bind and presumably cover the 
surface of fibrils, it is not very effective in preventing addition of Aβ monomers to the 
extension sites of an amyloid fibril.  
 
Figure 5.8. Thioflavin T curves of inhibition of Aβ seeding by WT hCC. Red is 6µM of Aβ1-42 
monomers in phosphate buffer, green is 6µM of Aβ1-42 monomers seeded with 1 µM of Aβ1-42 seeds, 
blue is 6µM of Aβ1-42 monomers seeded with 1 µM of Aβ1-42 seeds in the presence of 1 µM of hCC, 
purple is 6µM of Aβ1-42 monomers seeded with 1 µM of Aβ1-42 seeds in the presence of 6 µM of hCC. 
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5.3.7. Addition of Dimer 
Dimers of hCC were produced and characterised and their ability to inhibit Aβ 
fibrillisation was investigated using thioflavin T fluorescence. An investigation into the 
effect of cystatin B on amyloid fibril formation by Aβ suggested that tetramers of this 
wild-type cystatin completely inhibit Aβ fibrillisation, as showed by thioflavin T and 
TEM, whereas the monomer, dimer and higher oligomeric species do not have this 
inhibitory effect (Skerget et al., 2010a). Similarly, it has been found that non-native 
species of transthyretin and neuroserpin are more effective inhibitors, possibly as this 
favours exposure of the active binding site (Du and Murphy, 2010, Chiou et al., 2009).  
Dimers were produced by heating 50 µM hCC in 50 mM sodium phosphate pH 7.4, 150 
mM NaCl at 68°C for 30 minutes before purification using a Superdex 200 (GE 
Healthcare, UK) size exclusion column in 50 mM sodium phosphate pH 7.4, 150 mM 
NaCl. Figure 5.9. shows the change in thioflavin T fluorescence when the hCC dimer 
preparation was incubated with 11 µM Aβ1-42 at two different dimer concentrations, 11 
µM and 22 µM. Unlike the monomers, the addition of dimer has no effect on the final 
yield of fibrils produced. This confirms the previous work by Abigail Williams in our 
group (Williams, 2015).  
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Figure 5.9. Addition of hCC Dimer to Aβ1-42 fibrillisation reaction. Molar ratios of 1:2 
(brown) and 1:1 (red) Aβ1-42 to hCC dimer and 1:1 molar ratio of Aβ with hCC monomers 
(orange) were incubated and monitored by thioflavin T fluorescence. Each curve is the average 
of 4 or 5 replicate reactions with the standard error of the mean indicated by the error bars.  
 
5.3.8. NMR Spectroscopy 
The nature of the interaction between hCC and Aβ1-40 (Keeley, 2007, Elshawaihde, 2012) 
and Aβ1-42 (Williams, 2015) has been investigated by previous lab members through 1H 
15N HSQC titration experiments. These studies showed that there are no major chemical 
shift changes when Aβ1-40 or Aβ1-42 is titrated into a sample of hCC up to 1:1.2 
equivalences, despite the observed inhibition of Aβ fibril formation by hCC. These 
experiments were performed in different buffer conditions to the Thio T experiments 
presented here. 1H-15N HSQC NMR experiments were performed in 15mM Tris buffer, 
pH 7.4, 278K for hCC and Aβ monomer binding in order to prevent oligomerisation of 
the peptide during the experiment (Williams, 2015). In order to investigate the interaction 
between hCC and Aβ in the same buffer as used for our thioflavin T experiments, the 1H-
15N HSQC spectrum of hCC was first assigned under these buffer conditions based on 
previous assignments and then the Aβ1-42 titrated into hCC. 
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5.3.8.1. Assignement of the 1H 15N HSQC of hCC in 50 mM phosphate buffer, pH 
7.4, 150mM NaCl.  
 
Previously, the 1H 15N hCC HSQC spectrum was assigned in 15 mM Tris-TFA, pH 7.5, 
with no added salt (Keeley, 2007). This spectrum was used to assign hCC spectra in (50 
mM phosphate buffer, pH 7.4, 150mM NaCl) by salt titration and tracking the shifts in 
the amide peaks.  
An 1H 15N HSQC experiment measures the chemical shift of the nitrogen and amide 
proton. This is attained by modulating each proton signal with the signal of the attached 
nitrogen. Employing software to deconvolute the two frequencies can generate a two-
dimensional plot of the spectrum with a peak for every amide at the intersection of the 
proton and nitrogen chemical shifts. As each amino acid contains a backbone amide, each 
peak in the 1H 15N HSQC spectrum will correspond to a specific residue within the protein 
structure. The chemical shift in amide is directly correlated to its local chemical 
environment. As a result factors that alter the chemical environment of the amide can be 
revealed by changes in the 1H 15N HSQC spectral property.  Accordingly, peaks may 
show a shift in position or a change in intensity. Alternatively, they can broaden or fade 
away completely. It is important to know which amide, and therefore residue, corresponds 
to which peak in the spectrum to allow changes in the chemical environment to be mapped 
onto the protein structure. This is achieved through a process known as resonance 
assignment. The chemical shift is expressed in parts per million (ppm), which accounts 
for the field strength at which it is measured. 
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Salt titration 
Changes in the 1H 15N HSQC spectrum were successfully tracked as the salt concentration 
was increased from 0 to 150 mM.  The salt concentration was increased from 0 to 20 and 
then 150mM Figure 5.10. shows the change in chemical shift of each amide in the 1H 15N 
HSQC spectrum.  The majority of peaks can be tracked from their position at no salt to 
their position at 150 mM NaCl as they showed only very small shifts during the course 
of the titration. Intensity changes were also only minor for the majority of residues, the 
gentle decrease that is observed can be attributed to the minor dilution factor caused by 
addition of salt to the sample.  The distribution of amide peaks corresponds well with the 
established assignment in the conditions used by (Keeley, 2007) and (Williams, 2015). 
As even small changes in the chemical environment are reflected in the 1H 15N HSQC 
spectrum, this validates the reproducibility of the sample preparation. There is no 
evidence for the characteristic shifts in the peaks that are attributed with dimerisation in 
either the 1D or 2D spectra, confirming that the protein is in the required monomeric state. 
Out of 120 residues, 87 were successfully; the ones that were excluded were either not 
present (prolines), significantly overlapped or very weak. 
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Figure 5.10.  1H-15N HSQC spectrum of hCC salt titration. The associated chemical shift 
changes observed in the 1H-15N HSQC spectra of hCC as the NaCl concentration increased 
from 0  (blue) to 150 mM (red positions).  The spectra were recorded at 303K using 50 µM 
hCC in 50 mM phosphate buffer, pH 7.4, 2 mM sodium azide.  F1 represents the 1H 
dimension, F2 represents the 15N dimension.   
 
5.3.8.2. 1H 15N HSQC Spectrum of hCC 
The 1H 1D spectrum of 50 µM hCC in 50 mM phosphate buffer, pH 7.4 at 303 K shows 
a wide dispersion of amide proton resonances (6-10 ppm) and up-field aliphatic proton 
peaks (below 0 ppm) indicating that hCC is folded. This is reflected in the 1H 15N HSQC 
spectrum where the amide chemical shifts are also well dispersed (Figure 5.11).  
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Figure 5.11. 1H 15N HSQC Spectrum of hCC at 303 K. An 1H 15N HSQC spectrum of 50 
μM hCC incubated in 50 mM Phosphate buffer, pH 7.4, 150 mM NaCl at 303 K, showing 
the amide assignment. F1 represents the 1H dimension and F2 represents the 15N dimension. 
 
5.3.8.3. Titration with monomeric Aβ1-42  
Aβ1-42 was added to a monomeric hCC sample. As has been previously observed 
(Elshawaihde (2012); Williams, 2015) there are only very minor chemical shift changes. 
The lack of chemical shift changes at equimolar concentrations (1:1 of Aβ1-42: hCC) 
indicates that there is no change in the local chemical environments of any of the residues. 
This suggests that there is no binding between hCC and Aβ monomers. The solution 
conditions of the two proteins were the same (no change in pH and salt caused artefacts). 
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Figure 5.12. Titration of hCC with Aβ1-42. A reference 1H 15N HSQC spectrum of 15N labelled 
50 µM hCC in 50 mM phosphate buffer, pH 7.4, 150  mM NaCl at 303 K (blue) was overlaid 
with the spectrum of hCC where an equivalent amount of Aβ1-42 has been added (shown in red). 
F2 represents the 1H dimension and F1 represents the 15N dimension.  
 
5.3.8.4. 1D 1H NMR Time course of the fibrillisation reaction 
Measuring the reduction in the 1H 1D NMR spectral intensity of Aβ1-42 peptide and hCC 
over time can give information on the rate of their monomer disappearance, as the 
intensity of the spectral signal corresponds to the monomer population. Because NMR is 
unable to detect large molecules, Aβ1-42 monomer signal intensity reduces as it forms 
large aggregates and hCC monomer signal intensity reduces as it binds to large Aβ1-42 
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aggregated structures. 1D 1H spectra of both Aβ1-42 and hCC were recorded separately 
and in the mixture over the time course of the reaction for 24 hrs. The Aβ1-42 and hCC 
spectra were subtracted from the mixture spectrum and the reduction in signal of the 
spectra was measured (Figure 5.13). In the presence of equimolar amounts (50 µM) of 
hCC the intensity of the Aβ1-42 spectrum was reduced by only 52% compared with the 
control Aβ1-42 which was reduced by 89%. This indicates that in the presence of hCC, 
30% more of the Aβ1-42 samples is maintained monomeric or as small structures and 
prevented from going to form large enough aggregates to be invisible by NMR. This 
result indicates that the hCC prevents Aβ1-42 aggregation despite the fact that the 1H 15N 
HSQC fails to show binding to monomers of Aβ1-42. Investigating the hCC 1D 1H 
spectrum showed that during the same time period, 18% of the hCC disappeared in the 
mixture with the Aβ compared to 1% in the absence of Aβ, this could be due to hCC 
molecules binding to the Aβ1-42 aggregated structures while they are forming and 
becoming no longer visible to NMR. The rate of the hCC disappearance was simultaneous 
with Aβ1-42 disappearance further confirming that hCC was binding to the Aβ1-42 
aggregated structures (figure 5.13B). This result was consistent with the centrifugation 
results reported here (section 5.3.4.) and the chromatography results obtained by 
(Williams, 2015) where a percentage (10%) of the monomeric hCC was observed to 
disappear during incubation with Aβ1-42, presumably to go and form a large molecular 
weight complex with Aβ1-42. Both these later experiments were performed at considerably 
lower concentrations of protein suggesting this binding is significant at micromolar 
concentrations. 
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Figure 5.13. The time course of monomer disappearance of both Aβ and hCC obtained 
by 1D NMR. A) The percentage of  Aβ monomer disappearance in  Aβ control (blue), Aβ 
monomer disappearance in the presence of equimolar amount of hCC (red), and hCC 
disappearance in the Aβ and hCC mixture (purple), hCC disappearance in hCC control (black). 
The error bars represent (sem). B) The same data normalized to show simultaneous 
disappearance of Aβ and hCC. 
  
The nature of the species produced in these titrations was verified using TEM and is 
shown in figure 5.14 where amorphous aggregates are seen in the presence of hCC 
compared with fibrils in the control. This suggest despite that hCC cause larger fraction 
of Aβ to stay as monomer or small aggregates, it is also bind to Aβ aggregates and 
disfavours the fibrillisation pathway of Aβ by leading to the formation of amorphous 
aggregates. 
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Figure 5.14. TEM of 1D 1H NMR Time-course samples after 24 hrs. Electron micrographs 
of the 1D 1H NMR time-course experiment where 50 µM Aβ1-42 is incubated in the absence 
(A) and presence (B) of 50 µM hCC in Phosphate pH 7.4, 150 mM NaCl, 2 mM Sodium Azide, 
at 30°C after 24 hours. The scale bars are indicated. 
 
5.3.9. Addition of different hCC mutants 
Aβ1-42 fibril formation was monitored in the presence of hCC mutants employing 
thioflavin T fluorescence in minimal shaking conditions. Slightly higher than 
equimolar concentrations of wild type hCC caused a complete reduction in thioflavin 
T fluorescence, suggesting complete inhibition of Aβ1-42 fibril formation. All other 
mutants were less effective compared with wild type hCC. Four times the equimolar 
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concentration of W106A and three times the equimolar concentration of P6A were 
needed to completely inhibit Aβ1-42 fibrillisation. Around twice the equimolar 
concentrations of V57A and V50A were needed to inhibit Aβ1-42 fibrillisation. Despite 
their large exposed hydrophobic surfaces, L80A and P105A mutant were very similar 
to WT hCC. Half molar ratios of hCCs were also used against Aβ1-42 to confirm the 
reproducibility of the results obtained with equimolar concentrations of hCC, and these 
data confirm that the inhibitory pattern is same.  
 
Figure 5.15. Aβ1-42 aggregation in the presence of hCC mutants. Linear regression of the 
amplitudes of thioflavin T curves of Aβ aggregation in the presence of different concentration 
of WT hCC and mutants, as indicated.   
 
The inhibitory order of mutants compared to WT was WT > L80A> P105A> V50A> 
V57A> P6A> W106A. These results indicate that hydrophobic residues like P6 which 
is located in the unstructured N-terminal region and W106 from the protease inhibition 
part of the protein are mostly involved in Aβ inhibition. Other nearby residues from the 
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active site region, V57 and V50, were significantly less effective than WT, indicating 
a lesser involvement in the inhibition. Interestingly, although V50 is well away from 
the protease binding site, mutation of this residue does affect inhibition suggesting this 
second hydrophobic patch may be involved, either directly or indirectly, by 
destabilising the protease binding site. P105, despite its large solvent accessible 
hydrophobic surface and proximity to W106 is not significantly different from the WT. 
The last mutated residue, L80, is least involved in Aβ1-42 binding suggesting this third 
hydrophobic region is not involved.  
 
5.4 Discussion  
5.4.1. hCC inhibition is strongly affected by shaking the fibrilliation reactions 
The kinetics of Aβ1-42 fibrillisation was monitored in two different shaking conditions; 
minimal and continuous shaking. The Aβ fibrillisation was faster in the continuous 
shaking conditions. The explanation for this could be that shaking accelerates Aβ1-42 
nucleation (Morinaga et al., 2010, Lee et al., 2012) and fragmentation of the fibrils 
(Cohen et al., 2013). Accelerating primary nucleation shortens the time Aβ1-42 needs to 
start fibrillisation and fibril fragmentation can accelerate the rate of secondary nucleation. 
Amyloid aggregation is an autocatalytic process which means that the monomer addition 
to the ends of preformed fibril is more favourable and faster than the formation of new 
fibrils from the monomers and, consequently, the aggregation rate depends on the number 
of fibril ends. 
 
Amyloid β fibrillisation time courses with hCC were carried out and presented in this 
thesis. We showed that in minimal shaking conditions hCC will inhibit the amyloid fibril 
formation by Aβ1-42 in a concentration-dependent manner, requiring a 1.3:1 molar ratio of 
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hCC to Aβ1-42 to inhibit this reaction completely, where no increase in thioflavin T 
fluorescence intensity is detected. Equimolar concentrations significantly reduced 
thioflavin T fluorescence, but not completely, indicating that a considerable amount of 
amyloid fibre is still present. In continuous shaking conditions a much higher amount of 
hCC is needed to completely inhibit Aβ1-42 fibrillisation; 4 times more than equimolar 
concentration was needed. Equimolar concentrations only reduced the amplitude of 
thioflavin T signal by a small percentage. These differences could be due to the fact that 
shaking either causes acceleration of nucleation and consequently more hCC will be 
needed to prevent growing nuclei or causes fragmentation and consequently more fibril 
ends forming - more hCC is then needed to inhibit enhanced secondary nucleation arising 
from the fragmentation. Another explanation is that shaking might cause formation of a 
different morphology of Aβ1-42 fibrils which hCC can’t bind to and therefore stop from 
fibrillising. Generally, in all conditions, hCC has no measurable effect on the fibrillisation 
kinetics of the Aβ peptides that escape inhibition as the tlag, t50 and tgrowth measurements 
showed no significant differences in the presence and the absence of lower than inhibitory 
amounts of hCC, however the effect of hCC is purely on the yield of amyloid fibrils. As 
in our conditions, the Aβ1-42 aggregation was not concentration dependant, even a small 
amount of hCC which escapes inhibition will still aggregate at the same rate as a larger 
amount in the absence of hCC.  
It has previously been suggested that ratios of 1:1 hCC to Aβ1-42 are needed to completely 
inhibit the amyloid fibrils formation by Aβ1-42 (Sastre et al., 2004a). However, 
substoichiometric concentrations of hCC (0.3 μM) have been shown to protect both N2a 
neuroblastoma cells and rat primary hippocampal neurons from Aβ-induced cell death 
when incubated with 30 μM of Aβ1-42. Our results from minimal shaking conditions were 
consistent with the above study as near equimolar amount of hCC inhibited fibrillisation 
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completely. It has been previously found in our lab that ratios of 2:1 hCC to Aβ1-42 are 
required to completely inhibit the formation of amyloid fibres by Aβ1-42 in continuous 
shaking conditions (Williams, 2015). The results obtained in the current study were 
different from the previous results obtained by (Williams A, 2015), as 4 times more than 
an equimolar amount of hCC was required to completely inhibit Aβ fibrillisation under 
similar continuous shaking conditions. This might be due to the impurities in the hCC 
batch used by (Williams A, 2015) as shown by SDS PAGE and HPLC experiments. This 
is explained in detail in chapter 6. 
 
5.4.2 Aβ forms amorphous aggregates in the presence of hCC 
Observation of the sample by TEM indicated that instead of amyloid fibrils, large 
amounts of amorphous aggregates had been produced through the incubation of Aβ1-42 
with near equimolar amounts of WT-hCC in minimal shaking conditions and 4 times 
equimolar concentration in the continuous shaking conditions. It is possible that hCC is 
stabilising off-pathway states and preventing their further aggregation to produce mature 
fibrils. This result was consistent with the results obtained by Sastre et al. (2004), when 
they found that Aβ1-42 formed amorphous aggregates in the presence of twice equimolar 
amounts of hCC. Studies have showed a remarkable reduction in cytotoxicity when hCC 
is incubated with Aβ (Kaeser et al., 2007a, Mi et al., 2007b, Tizon et al., 2010a), 
demonstrating that the species forming do not exhibit the toxic activity that is observed 
with Aβ alone. 
One of the challenges in this study was variability in the inhibitory efficacy of WT hCC 
and variants through different experiments even when the same batch of the inhibitor was 
used. This variability could be due to the fact that hCCs inhibit Aβ fibrilisation not 
through binding to monomeric Aβ hence through binding to aggregated structures, like 
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oligomers and protofibrils of Aβ.  As Aβ oligomers are very heterogeneous, different 
results could be obtained in different experiments, when the pathway of Aβ aggregation 
is different from one experiment to another. Another explanation of this variability is that 
handling of the Aβ during the experiment is likely to introduce air to the Aβ: hCC mixture 
during pipetting, this will enhance Aβ aggregation and reduce hCC efficacy to inhibit 
aggregation, as the air-water interface is known to interfere with Aβ nucleation (Garai et 
al., 2008, Morinaga et al., 2010). As the hCC yield was very low, the probability for the 
presence of contaminants was higher, this could be another reason for the variabilities 
found in hCCs effects. An E. coli protein contaminant co-purifiy with hCC and was later 
found to have inhibitory effects on Aβ fibrillisation, the details of this can be found in 
chapter 6. 
 
5.4.3. Aβ and hCC do not bind as monomers but hCC does inhibit Aβ assembly 
Previously in our lab, the effect of Aβ addition on the NMR 1H 15N-HSQC spectrum of 
hCC was investigated to look for clues to possible binding sites. The time course of the 
interaction was followed in a Tris buffer pH 7 with no added salt, to keep Aβ monomeric 
for a longer time to detect binding to monomer. Despite the inhibition of Aβ fibril 
formation, no shifted amide cross-peaks were observed in 1H 15N-HSQC spectra of hCC 
incubated with Aβ at 30°C (Williams, 2015). In order to exclude the possibility of buffer 
interference (effects) on hCC binding to Aβ, the same 1H 15N-HSQC NMR experiments 
were repeated in an identical buffer condition to that used for thioflavin T experiments. 
No significant chemical shifts in any of the amide cross-peaks were observed in 1H 15N-
HSQC spectra of hCC incubated with Aβ1-42. Titration results were similar to previous 
results obtained in our lab confirming no complex formation between monomeric hCC 
and Aβ. However, this result was inconsistent with published data which suggested the 
formation of a high-affinity complex between the two proteins as investigated by ELISA 
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(Sastre et al., 2004a). It is believed that the inconsitency in these results could be due to 
the fact that the ELISA experiment is carried out on a surface, whereas the NMR 
experiment is in solution. A similar variation has been showed in experiments with 
transthyretin, indicating solid-phase binding assays may not be entirely consistent with 
binding characteristics or inhibition of fibril formation observed in the liquid-phase (Li et 
al., 2013b). We have also found variations in the inhibitory effect of transthyretin on Aβ 
fibrillisation in the presence of different surfaces (chapter 3). 
1D 1H NMR spectra of both Aβ1-42 and hCC were investigated to monitor the reduction 
in the amount of monomer over the time period of 24 hrs. In the Aβ1-42 control 89% of 
monomers disappeared compared to 52% in the presence of equimolar amounts of hCC. 
The hCC spectral signal intensity reduced by 18% in the mixture with the Aβ1-42 
compared to 1% in the absence of Aβ1-42. This indicates that hCC reduces the formation 
of large structures by Aβ1-42 and causes a larger fraction of Aβ to stay as monomer or 
small aggregates. Despite that, the 1H 15N-HSQC fails to show hCC binding to Aβ1-42 
monomers, the simultaneous disappearance of hCC with Aβ1-42 suggests that hCC bind 
to Aβ1-42 aggregated structures in the ratio of 1:3 hCC to Aβ1-42, as 18% of hCC disappear 
compared to 52% of Aβ1-42 at the same time. These results are consistent with the 
chromatography results obtained by (Williams, 2015) as a percentage (10%) of the 
monomeric hCC was observed to disappear during incubation with Aβ1-42. This suggested 
that hCC forms a large molecular weight complex with Aβ1-42.  
5.4.4. Does hCC bind to Aβ1-42 fibrils? 
In order to identify the nature of the Aβ1-42 species that interacts with hCC, the inhibitor 
was added to Aβ1-42 fibrils. The hCC incubated with purified Aβ1-42 fibrils and the fraction 
of hCC co-pelleted with fibrils by centrifugation was measured. Nearly 20% of the hCC 
co-pelleted with the equimolar amount of fibrils (calculated as monomer equivalent). This 
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result shows that hCC bind and cover the surface of the fibrils in 1 to 5 molar ratio of 
hCC to Aβ1-42. Despite hCC binding to the Aβ1-42 fibrils, co-incubation of hCC with Aβ1-
42 fibrils and monitoring the fibril disaggregation applying thioflavin T did not show 
disaggregation of Aβ1-42 fibrils, at least in the time course of the thioflavin T experiment. 
Addition of a large amount of hCC was needed to inhibit seeding of the Aβ1-42 
fibrillisation reaction. Presumably, hCC can only cover the surface of the fibrils as 
showed by co-pelleting assays, however, it is not active in inhibition of elongation of the 
seeds from the ends. Overall, results so far suggest that WT hCC can bind and cover the 
surface of fibrils and prevent Aβ1-42 monomers from starting aggregation using the fibril 
surface as a template. Similar behaviour by another amyloidogenic protein has been 
suggested. Brichos is an amyloidogenic protein domain which is also found highly 
concentrated in Aβ amyloid plaques in the brain. It have been showed that Brichos can 
bind to Aβ1-42 fibrils without defibrillising, however, it can prevent the use of the fibre 
surface as a secondary nucleation template for the formation of new fibrils (Cohen et al., 
2015). These findings suggest a different role for hCC and Brichos in preventing amyloid 
plaque formation in the brain by preventing secondary nucleation.  
5.4.5. The hCC interface 
The different forms of hCC were also investigated in terms of their inhibitory activity. 
The addition of an equimolar concentration of hCC dimer to the Aβ1-42 aggregation 
reaction has no effect on the thioflavin T fluorescence changes, showing no decrease in 
fibril yield, compared to Aβ1-42 incubated in the presence of hCC monomer. This 
reinforced the view that the dimer interface is crucial to the inhibitory activity of hCC. 
In order to find the binding surface of the hCC to Aβ1-42 protofibrils or fibrils, several 
hydrophobic residues chosen from 3 identified hydrophobic patches were mutated to 
alanine. Mutated hCCs were tested for Aβ1-42 fibrillisation inhibition. In region 1, 
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corresponding to the dimer interface the P6 residue from the unstructured N-terminal 
region of hCC and another residue, W106 from the active site of protease inhibitor 
significantly reduced the hCC inhibitory effect. V57A in region 1, from the active site 
and V50A from the second part also reduced hCC’s inhibitory effect but to a smaller 
degree.  L80 exhibits a large accessible hydrophobic surface area, however it did not 
significantly reduce the hCC’s ability to inhibit Aβ fibrillisation suggesting that this 
loop’s site of hCC is not involved in the binding. The P105 residue was also unaffected 
by hCC’s inhibitory action despite its large solvent accessible hydrophobic surface and 
its proximity to the most affected W106 region, this could be due to the direction of the 
P105 hydrophobic surface which is away from the binding site. These results together 
suggest that the N-terminal unstructured part and residues with large accessible 
hydrophobic surface areas located in or close to the active site and the hydrophobic 
surface facing outward are effectively involving in the hCC binding to Aβ1-42 aggregated 
structures. 
A potential model for this system could be that hCC is binding to an aggregated structure 
of Aβ as the results obtained in this study and previous work in our lab strongly suggest 
that hCC binds a species of Aβ1-42 other than monomer. Presumably, this binding happens 
through its N-terminal unstructured part and residues with large accessible hydrophobic 
surface areas located in the active site as the results from mutant hCCs suggest. Our 
results suggest that the stoichiometry of the binding is about 1 hCC molecule to 3 to 5 
Aβ1-42 monomers in the aggregated structure. The hCC binding to Aβ1-42 aggregated 
structures diverting the assembly pathway and causing the formation of amorphous non-
toxic aggregates and this is consistent with previous studies, in which hCC is shown to 
cause the production of amorphous aggregates and non-toxic to the cells (Sastre et al., 
2004a).  
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Chapter Six: Variability in the observed activity of 
recombinant cystatin C on Aβ fibrillisation- Isolation of GLTI, 
an active inhibitor from E. Coli periplasm 
As mentioned in chapter 5, WT hCC showed inconsistent results to the previous study 
regarding the concentration of WT hCC needed for inhibition and the reproducibility of 
the data. Variable results were obtained using either the same batch of hCC or hCC from 
different purification preps. The aim of this chapter is to investigate the reasons behind 
this inconsistency in detail and characterise an active contaminating inhibitor protein 
from the Escherichia coli periplasm.  
6.1.   Materials and Methods 
 
For purification of hCC, preparation of Aβ monomers, thoflavin T assays and EM see 
chapter 2. 
 
6.1.1. hCC Re-purification 
Previously in our lab, the hCC was purified by periplasmic extraction through applying 
osmotic shock by 20% sucrose, then loading on a cation exchange chromatography 
column, and finally, gel filtration. The same purification method was used in this study, 
however, the observed hCC inhibitory action on Aβ fibrillisation was variable among 
hCC samples from different purification preps. In order to work out the reasons behind 
these inconsistencies in the hCC inhibitory action on Aβ fibrillisation, the purified hCC 
was re-purified by different methodologies. The techniques used for re-purification were 
anion exchange chromatography, hydrophobic interaction chromatography (HIC), and 
size exclusion high-pressure liquid chromatography (SEC-HPLC).  
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6.1.1.1.  Anion exchange chromatography 
The purified hCC was further purified using anion exchange chromatography. The hCC 
buffer exchanged to 10mM phosphate buffer pH 9.0 and loaded at a rate of 2 ml/min into 
the 100 ml Q-Sepharose column equilibrated with the same buffer. The column was 
washed with 10 mM sodium phosphate pH 9.0 until A280 of the eluent stabilized. The 
hCC was eluted using 10 mM sodium phosphate buffer, pH 9.0, 0.2 M NaCl, and 5 ml 
fractions collected. Any remaining bound protein was eluted with sodium phosphate 
buffer pH 9.0, 1 M NaCl.  Fractions were analysed by SDS-PAGE and those containing 
hCC were pooled and stored at -20°C. 
 
6.1.1.2.   Hydrophobic interaction chromatography (HIC) 
As re-purification with anion exchange chromatography was not successful in separating 
the contaminants from hCC, re-purification using a hydrophobic interactions column was 
performed using RESOURCE ETH (GE Healthcare, UK), prepacked with SOURCE™ 
15ETH, which are rigid, monodisperse 15 µm beads made of polystyrene/divinyl 
benzene. 
 
6.1.1.3.  Size-exclusion high-pressure liquid chromatography (SEC-HPLC) 
The purified hCC was further purified by size exclusion high-pressure liquid 
chromatography (SEC-HPLC). An analytical Superdex 200 (10/300) column (GE 
Healthcare, UK) was equilibrated with 50mM phosphate buffer pH 7.0, 100mM NaCl. 
180 μl samples of concentrated hCC were loaded on the column with a Perkin Elmer 
Series 200 HPLC system (Perkin Elmer, UK) equipped with a UV-visible absorbance 
detector. The OD of eluent monitored at 280nm. The column was run at 0.5ml/min and 
the 0.5ml fractions of the eluted peaks were collected in eppendorf tubes. 
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The Superdex column has a protein exclusion limit of 1,300 kDa, with a separation range 
between 10 and 600 kDa, and a matrix of cross-linked agarose and dextran.  
 
6.1.2. Nuclear Magnetic Resonance Spectroscopy 
15N-labelled GLTI was expressed and purified as well as 15N hCC. Before the NMR 
experiments, the purity of the protein was established through analysis by SDS-PAGE 
and SEC-HPLC. 
6.1.2.1.  1H 15N HSQC NMR for unlabelled Aβ1-42 and 15N GLTI 
1H 15N HSQC experiments were performed for 15N GLTI in the absence of Aβ and after 
adding Aβ monomers to GLTI. A final concentration of 50 µM of each protein was 
achieved in 50 mM phosphate buffer (Na2HPO4/NaH2PO4), pH 7.4, 150mM NaCl, 
2mM Sodium azide, and 50 µl (10%) of deuterium oxide (D2O) added to bring the final 
volume to 500 µl. The experiments were performed at 330 K.  
 
6.1.2.2. 1 D 1H NMR time-course of unlabelled Aβ1-42 with 15N-GLTI 
15N-labelled GLTI in phosphate buffer saline was added to monomeric Aβ1-42 to achieve 
50 µM of both Aβ and GLTI in 50 mM phosphate buffer (Na2HPO4/NaH2PO4), pH 7.4, 
150mM NaCl, 2mM Sodium azide and 50 µl of deuterium oxide (D2O) added to bring 
the final volume to 500 µl. A 1D 1H spectrum of the sample was obtained every 2hrs for 
24 hours at 303 K.  
 
6.2. Results 
 
6.2.1. Purification-elution profiles 
The hCC sample used throughout this study was purified from three different purification 
preps at different times. The elution profiles and SDS-PAGE from each prep is presented, 
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(Figures 6.1, 6.2, 6.3). The yield from the first and second prep was low, it was 1-2 mgs 
per litre of growth. The third prep yielded a much higher amount of hCC, three mgs per 
litre of growth. The higher yield caused the production of purer hCC, as the amount of 
contaminant became relatively lower. The first step of hCC purification was anion 
exchange chromatography. Some other contaminants were co-eluted with hCC form the 
SP-sepharose column and only a single peak was observed (see figure 6.1.). However, 
more than one protein appeared in SDS-PAGE in all fractions. The fractions from the 
peak were identified by SDS-PAGE and fractions (11-1) which contained hCC and less 
contaminant were pooled together and concentrated using a further step of purification.  
 
           
Figure 6.1. Elution profile and SDS-PAGE from loading periplasmic extract onto SP-sepharose. A) 
showing co-elution of hCC and GLTI as a single peak from fraction number 9 to 15. B) SDS-PAGE of the 
fractions 9-15 from the SP-sepharose.  
 
The most abundant contaminant was a protein with an apparent MW of 37KD which was 
later identified as a periplasmic E. coli protein; Aspartate/ Glutamate binding protein 
(GLTI) (section 6.2.5). 
The next step of purification was the loading of the co-eluted fractions from the SP-
sepharose column onto the gel filtration column. As hCC is smaller than all of the 
contaminants that co-elute from SP-sepharose, it elutes later from the gel filtration column. 
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hCC eluted at fraction 31-38 while the periplasmic E. coli protein (GLTI) was mostly eluted 
from fraction 25-28. Fractions 32-38 were pooled together and kept at 8°C. 
 
 
 
          
    
Figure 6.2. The elution profile and SDS PAGEs of 1st and 2nd hCC purification prep. A) The elution 
profile of hCC gel filtration and B) SDS-PAGE of the eluted fractions from first (B) and second (C) 
purification prep of hCC after gel filtration (final step of purification), showing hCC and GLTI proteins. 
 
The hCC yield from the third purification prep was much higher compared to the first and 
second one. The yield from 5L of broth was 13 mg from third prep compared to only 5-7 
from the first and second one. The high protein yield from the second prep led to obtaining 
more pure sample as the amount of contaminant was relatively lower, figure 6.3. Fractions 
pooled were 40-46 and the SDS-PAGE suggested only very small amounts of co-purified 
proteins. 
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Figure 6.3. The elution profile and SDS PAGE of 3rd hCC purification prep. A) The elution profile 
from the gel filtration of hCC and B) SDS-PAGE of the eluted fraction from the third purification prep 
of WT hCC after gel filtration (final step of purification), showing hCC and GLTI proteins. 
 
6.2.2. Re-purifying hCC and GLTI 
 
6.2.2.1.  Anion exchange chromatography 
Because the iso-electric points of both hCC (8.7) and GLTI (8.5) are very similar, this 
technique was unsuccessful in separating both proteins. Both proteins were eluted 
together as two overlapped peaks which are shown in figure 6.4. 
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Figure 6.4. Elution profile of hCC re-purification with anion exchange chromatography using 
Q-sepharose applying pH 9. Both hCC and the contaminant were eluted as two overlapping peaks. 
 
6.2.2.2. Hydrophobic interaction chromatography (HIC) 
Both hCC and GLTI are abundant in hydrophobic residues. Although a chemically 
distinct methodology, HIC did not efficiently separate the two proteins. In thioflavin T 
experiments, the effect of hCC before then after purification on the Resource ETH column 
showed no difference in inhibitory efficiency on Aβ1-42 fibrillisation (Figure 6.5). 
 
Figure 6.5. Thioflavin T curves for Aβ1-42 fibrillisation in the presence of re-purified hCC by 
Resource ETH. Blue: Aβ1-42 control, green: Aβ in the presence of equimolar amount of non-purified 
hCC, orange and black: Aβ1-42 in the presence of equimolar amount of hCC from the first and second 
parts of overlapped peaks, respectively. 
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6.2.2.3.  Size exclusion high-pressure liquid chromatography (SEC-HPLC) 
hCC was further purified by size exclusion high-pressure liquid chromatography (SEC-
HPLC). An analytical Superdex 200 column was a good choice to re-purify concentrated 
hCC without losing a significant amount of the protein and the two proteins were clearly 
separated and recovered. The E. coli periplasmic contaminant (GLTI) was eluted at 15.5 
ml and hCC eluted at 17.5 ml (Figure 6.7 A). The middle part of both peaks were collected 
as pure proteins.  
6.2.3. Addition of hCC to Aβ1-42 Fibrillisation 
 
Thioflavin T Time-course 
The kinetics of Aβ1-42 fibrillisation was monitored in the presence of different molar ratios 
of hCC to Aβ1-42, as shown in Figure 6.6. Each bar represents the amplitude of the 
thioflavin T curve of Aβ1-42 fibrilisation in the presence of equimolar and half equimolar 
amount of hCC in experiments, each experiment with 5 replicates. hCC samples used 
from all the different preps showed inconsistent results compared with previous results 
and even between different preps. Impure hCC samples exhibit the greater inhibitory 
action, purer hCC from the third prep was shown to be less effective on Aβ1-42 
fibrillisation: up to 3 times the equimolar concentration of the less pure (first and second 
preps) hCC (Figure 6.6 A&B) and 4 times the equimolar concentration of the purer (third 
prep) sample were needed to complete inhibition of Aβ1-42 fibrillisation as monitored by 
thioflavin T fluorescence (figure 6.6C). This contrasts with a 2-fold excess in the previous 
results obtained by (Williams, 2015). The results obtained in minimal shaking conditions 
(red bars in figure 6.6) were more consistent among different experiments using the same 
hCC sample and between different preps, indicating that continuous shaking (blue bars) 
is also one of the reasons behind these inconsistencies despite the presence of various 
amounts of contaminant in different hCC preps. 
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Figure 6.6. Amplitude of Aβ fibrillisation curves in the presence of WT hCC. The x axis 
represent different experiments and y axis is the relative amplitude of Aβ fibrillisation curves in the 
presence of equimolar (solid bars) or half equimolar (empty bars) concentrations of hCC. The blue 
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bar charts represent continuous shaking and red ones represent minimal shaking conditions. The 
hCC sample used during the study was from 3 different purification preps, first prep (A), second 
prep (B) and third prep (C). Showing the inconsistency between different experiments. In graph (B) 
the bar charts labelled with re-purified with Q-sepharose to represent purified hCC with cation 
exchange chromatography and bar charts labelled with re-purified with Resource ETH represent 
purified hCC with hydrophobic interaction chromatography. The dates of the experiments are shown 
to allow evaluation of the effect of sample age on the results obtained. 
 
6.2.4. Purification of GLTI 
GLTI co-purified with hCC through periplasmic extraction, cation exchange and size 
exclusion chromatography (FPLC). As reported in section 6.2.2.3, GLTI separated from 
hCC through another round of size exclusion using analytical HPLC superdex 200 colum, 
figure 6.7 A. The GLTI was eluted at 15.5 ml (31 minutes). SDS-PAGE of the collected 
0.5 ml fractions is shown in Figure 6.7 C. The purest fractions were collected and 
analysed by HPLC-SEC (Figure 6.7 B) and used for thioflavin T and NMR experiments. 
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Figure 6.7. SEC-HPLC Elution profile and SDS-PAGE of hCC and GLTI. A) Elution profile 
of the mixture of hCC and GLTI from size exclusion (HPLC), showing the peaks from GLTI 
and hCC, GLTI eluted at 15.1ml (31 mins) and hCC at 18ml (36 mins). B) Elution profile 
of the HPLC purified GLTI and hCC, showing the peaks from GLTI (blue) and hCC (black). 
C) SDS-PAGE of the eluted fractions form GLTI purification by HPLC. 
 
6.2.5. Characterisation of GLTI 
 
Mass spectrometry 
Purified GLTI and 15N GLTI were investigated by mass spectrometry. The size of GLTI 
was 31,170.5 Dalton. This mass was different from the theoretical mass of GLTI without 
the first 22 amino acid signal peptide (31229D when it’s 280 residues). 15N GLTI was 
31525 Dalton, but the protein contains 377 nitrogen atoms, which theoretically should be 
31607D. These differences might be due to a mutation in the protein like mutation of a K 
or Q to A or D to G as a small part of the sequence did not match the theoretical sequence: 
specifically residues number 240-246 (KDDPQFK) (see next section). Minor peaks of 
other contaminants were also observed.  
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A) 
 
 
 
 
 
B) 
 
 
 
 
 
Figure 6.8. Mass spectrometry results of purified A) GLTI which is 31170 D, and B) 15N GLTI 
which is 31525 D. 
 
Sequencing 
Purified GLTI was characterised by mass spectrometry. The protein identified by Peptide 
mass fingerprinting; in which the proteins digested by proteolytic enzymes, then the 
masses of the produced peptides are compared to a database of predicted masses that 
created from the digestion of known proteins. If a significant number of produced 
peptides masses matched the protein sequence in the reference list, this indicates that the 
protein was present in the original sample. 118 out of 121 peptides which generated from 
the enzymatic digestion of the protein sample were unique to GLTI (Figure 6.9). 84% of 
the GLTI sequence was identified and if we exclude the first 22 signal peptide amino 
acids, the percentage of coverage would be as high as 95%. The percentage coverage 
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refers to the percentage of found peptides matched to database peptides. The higher the 
coverage the greater the probability of the presence of particular protein.  
  
 
 
 
Figure 6.9. Mass Spec Results of GLTI Characterisation. A) List of the proteins identified 
in the sample. B) The sequence of GLTI (including first 22 signal peptide) with identified 
regions highlighted in green. 
 
6.2.6. Background information on GLTI 
 
The periplasmic contaminant was identified as the aspartate/glutamate binding protein 
(GLTI). GLTI is an E. Coli periplasmic protein which binds both glutamate (KD = 0.8 
pM) and aspartate (KD = 1.2 pM) (Willis and Furlong, 1975a) with only one binding site 
is indicated per molecule of protein.  
GLTI belongs to the DEBP family of binding proteins. DEBP is one of the constituents 
of ATP-binding cassette (ABC) transport systems. These systems transport solutes across 
membranes through coupling to ATP hydrolysis. These systems include a periplasmic 
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binding protein (PBP), an integral membrane protein, and two cytoplasmic nucleotide-
binding domains that hydrolyze ATP. The periplasmic protein, like GLTI, is responsible 
for ligand capture and then passes it to a transmembrane protein for transport into the cell. 
At the time of binding to their ligands, the DEBPs exhibits a remarkable conformational 
change that enhances the formation of a complex with a corresponding membrane-bound 
component of the transport system (Sun et al., 1998). 
Periplasmic glutamate/aspartate binding protein was first purified and identified from 
Escherichia coli K12 (Willis and Furlong, 1975b). A DEBP from Shigella flexneri 
(sfDEBP) has more recently been reported which is almost identical to the E. coli DEBP 
(GLTI) in amino acid sequence. The only difference is that a nonessential residue (Val5) 
in GLTI, is replaced with an Alanine in sfDEBP (Hu et al., 2008). The E. coli DEBP 
(GLTI) structure is not solved yet. However, its similarity to Shigella flexneri DEBP 
(sfDEBP) can provide information on its possible structure and role. 
DEBP structures consist of two asymmetric domains, and the two domains are similarly 
folded. Two antiparallel strands link the two domains together. The ligand binding site 
located at the intersection of two domains. The centre of each domain consist of a five-
stranded beta sheet surrounded by12 α-helices (Figure 6.10 A). 
The DEBP protein binding to ligands is achieved by hydrogen bonding and salt bridges 
between the side chains and the main chain of the DEBP protein and the ligand molecules. 
Hydrogen bonds form between the side chains of the Arg24, Ser72, Arg75, Ser90, 
His164, Thr92 and Thr140 and the ligand. The side chains of Arg75, Arg90 and Asp 182 
and the main chain carbonyl oxygen of Ser90 form salt bridges with the glutamate (Hu et 
al., 2008).  
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Figure 6.10. The crystal structure of Shigella flexneri DEBP (sfDEBP). A) cartoon structure; 
Domains I and II are colored yellow and red, respectively. The two β-strands that connect 
domains I and II are colored blue. The bound glutamate molecule is shown as ball-and-stick 
model Adapted from (Hu et al., 2008). B) the surface structure of sfDEBP with the hydrophobic 
residues coloured in red (drawn using pdb code 2VHA using Pymol). 
 
6.2.7. Interaction between Aβ1-42 and GLTI 
 
6.2.7.1.  Thioflavin T of Aβ1-42 and GLTI 
The kinetics of Aβ1-42 fibrillisation were measured in the presence of different molar 
ratios of GLTI in the standard conditions described earlier, with an Aβ1-42 concentration 
of 11 µM, as shown in Figure 6.11. Each curve is the average of 5 replicates with error 
bars displaying the standard error of the mean (SEM) to give an indication of the spread 
of the data. Different concentrations of GLTI were tested ranging from 5 µM (half the 
concentration of Aβ1-42) to 1.25 µM (8 times less than the concentration of Aβ1-42). Half 
equimolar concentrations of GLTI caused a complete reduction in thioflavin T 
fluorescence. In the presence of 3.75 µM GLTI the intensity of the thioflavin T curve is 
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about 17% of the Aβ1-42 control curve, suggesting that the amount of fibril being produced 
was significantly less than in the absence of GLTI. GLTI concentrations of 2.5 µM and 
1.25 µM caused reductions in thioflavin T fluorescence of 40% and 30% respectively. 
 
 
 
 
Figure 6.12. Dose Dependence of the inhibitory activity of GLTI on Aβ1-42 fibrillisation. A) 
Thioflavin T fluorescence time-courses of Aβ1-42 fibrillisation at 11 µM with the addition of 
different molar ratios of GLTI. Each curve is the average of 5 replicates, with error bars indicating 
the standard error of the mean (SEM). Eight separate experiments have been done at different 
times and with different protein stocks, the data summarized in two graphs. B) The amplitude of 
Thioflavin T curve in the presence of different concentrations of GLTI, normalised to the Aβ1-42 
control. 
 
6.2.7.2.  Electron Microscopy 
Although changes in thioflavin T fluorescence suggested that GLTI inhibits Aβ1-42 fibril 
production, this reduction in intensity could be attributed to other factors such as changes 
in morphology or the production of alternative species which also bind thioflavin T. TEM 
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was used to study the structural morphology of the structures produced at the end of the 
incubation of Aβ1-42 in the presence of half equimolar concentration of GLTI. Figure 6.12 
shows electron micrographs of equimolar concentrations of Aβ1-42 and GLTI in the same 
conditions after at least 24 hours of incubation. In the absence of GLTI, Aβ1-42 produces 
fibrils. In its presence, a large amount of amorphous aggregate observed with some curly 
structures is seen. 
 
Aβ1-42 Control  
 
Aβ1-42+ GLTI 
(1: 0.5)  
 
Figure 6.13. TEM micrographs of Aβ1-42 and GLTI after 24 hrs of A) Aβ control after 24hrs of 
aggregation. B) Aβ aggregation reaction in the presence of half equimolar amount of GLTI. 
 
6.2.7.3. NMR Spectroscopy 
 
6.2.7.3.1. 1H 15N HSQC Spectrum of GLTI 
The 1H spectrum of 50 µM GLTI in 50 mM phosphate buffer, pH 7.4 at 303 K shows a 
wide dispersion of amide proton resonances (6-10 ppm) indicating that GLTI is folded. 
This is reflected in the 1H 15N HSQC spectrum where the amide chemical shifts are also 
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well dispersed (Figure 6.13.). Out of 280 residues, 220 were observed, 12 are prolines, 
the rest of the peaks (48) were either not present, very weak or significantly overlapped. 
The peaks were dispersed between 6-11 ppm indicating proper folding of the protein. 
Aβ1-42 was then titrated to the GLTI to achieve equimolar concentration. The 1H 15N 
HSQC for 15N GLTI has not been assigned yet, so the observed residues are not identified. 
 
 
Figure 6.14. 1H 15N HSQC Spectrum of 15N GLTI at 303 K. An 1H 15N HSQC spectrum 
of 50 μM GLTI incubated in 50 mM Phosphate buffer, ph 7.4, 150 mM NaCl at 303 K 
showing the amide peaks. F1 represents the 1H dimension and F2 represents the 15N 
dimension. 
 
 
  
186 
 
6.2.7.3.2. Titration with monomeric Aβ1-42  
Figure 6.14 shows an overlay of a reference 1H 15N HSQC spectra overlaid with the 
spectrum that were obtained after addition of monomeric 15N-labelled GLTI with 
unlabelled monomeric Aβ1-42. Because the 1H 15N HSQC is not assigned yet and the 
intensity of the peaks was not uniform, it was difficult to find the amide chemical shifts. 
However, there were some shifts in the position of some of the residues and some other 
residues were completely disappeared.   
 
 
Figure 6.15. Titration of 1H 15N GLTI with Aβ1-42. A reference spectrum of 15N labelled 50 
µM GLTI in 50 mM phosphate buffer, pH 7.4, NaCl 150  mM at 303 K (blue) was overlaid 
with the 1H 15N HSQC spectrum of Aβ1-42 have been added (shown in red). F2 represents the 
1H dimension and F1 represents the 15N dimension. 
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6.2.7.3.3. 1D 1H NMR Time-course of GLTI with Aβ1-42 
 
1D 1H NMR can monitor the disappearance of Aβ1-42 monomers during the time course 
of Aβ aggregation as the intensity of the spectra reduces with the reduction of the amount 
of the monomer. 1D NMR spectra, a total of 12, were obtained over 24 hours, with each 
experiment lasting 2 hours and 8 minutes. The aim was to compare the reduction in Aβ1-
42 spectrum intensity in the absence and presence of GLTI. The substraction of the Aβ1-42 
spectra from the GLTI and Aβ1-42 mixture was not possible because of the change in the 
position of the peaks. It is clear therefore that large conformational changes in GLTI, Aβ1-
42 or both are occurring. The Aβ1-42 control (Figure 6.15) showed 87% reduction in the 
intensity of its spectrum over 24 hrs at 37°C, indicating that a significant fraction of Aβ1-
42 monomers participate in the formation of large aggregated structures. 
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Figure 6.15. The intensity of Aβ1-42 1D 1H NMR spectrum over the time course of 24 hrs. 
50 µM of Aβ1-42 in phosphate buffer, pH 7.4 and temperature 37°C. The reduction happens as 
the monomers form large structures. 
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6.3.  Discussion and Future work 
 
Confirmation of existing data and further characterisation of the inhibition of Aβ 
fibrillisation by WT hCC meant working with purer hCC samples. In the current study, 
attempts to replicate the same results as the previous study were confronted with some 
issues. Inconsistent results were obtained regarding the amount of hCC required to inhibit 
Aβ1-42 fibrillisation completely. Unlike the previous study, the current study demonstrates 
that twice equimolar concentration is not enough to completely inhibit the formation of 
amyloid fibrils by Aβ1-42 in the same continuous shaking conditions. Also, the thioflavin 
T data obtained from different experiments using either the same batch of hCC or hCC 
from different purification preps were variable, as the amplitude of thioflavin T curves 
was variable through using different experiments. 
Trying to work out the reasons behind these inconsistencies and keeping the possibility 
of contaminants in mind, some different purification strategies like repurifying through 
hydrophobic interaction chromatography and re-purifying by anion exchange 
chromatography at pH 9. These techniques were unsuccessful in resolving the 
inconsistency issues as they failed to separate the contaminant and the hCC, probably 
because of similar iso-electric point and similar abundance in hydrophobic residues in 
both proteins. Size-exclusion chromatography using an analytical superdex 200 column 
was successful in separating an E. coli priplasmic protein which showed an inhibitory 
effect on Aβ1-42 fibrillisation at a much lower stoichiometric concentration compared to 
hCC. 
These differences could be due to the fact that the amount of contaminant present was 
different between the various purification preps, as the contaminant had some ability to 
inhibit Aβ1-42 fibrillisation. Shaking might also be another reason for the inconsistency, 
as shaking leads to an increase in a species of Aβ1-42 aggregates that hCC is less able to 
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bind (chapter 5). Non-shaking conditions produced more consistent results and hCC was 
more efficient. 
Thioflavin T experiments performed with Aβ1-42 in the presence of GLTI showed that 
GLTI can inhibit Aβ1-42 fibrillisation at a much lower molar concentration compared to 
hCC. The stoichiometry of 1:0.45 of Aβ1-42: GLTI was sufficient to completely inhibit 
Aβ1-42 fibrillisation. The structure of GLTI has not been solved yet, however, the structure 
of the homologous Shigella DEBP protein has many hydrophobic patches (Figure 6.10B). 
These hydrophobic patches could be behind GLTI’s ability to bind to Aβ1-42 and inhibit 
its fibrillisation as Aβ1-42 binds to hydrophobic surfaces. Another explanation of this 
inhibition activity could be down to the ability of GLTI to bind to both glutamate and 
aspartate very tightly. The Aβ1-42 structure includes 3 aspartic acids and 3 glutamic acids 
(D1, E3, D7, E12, E23, and D24), and GLTI may bind to one or more of these residues 
with sufficient affinity to inhibit the peptide from aggregation, especially if it binds to the 
ones which take part in the fibril structure (Figure 1.3.)  
Observation of the sample by TEM indicated that instead of amyloid fibrils, large 
amounts of amorphous aggregates had been produced through the incubation of Aβ1-42 
with GLTI. It is possible that GLTI is stabilising off-pathway states and preventing their 
further aggregation to produce mature fibrils.  
The 1H 15N NMR HSQC spectrum of GLTI has not been assigned previously. The 1H 15N 
HSQC spectrum of the GLTI was measured. We observed chemical shifts in some 
residues and a complete disappearance of some other peaks. Because of the lack of GLTI 
HSQC assignment, it is very difficult to find any clue on which interface and residues of 
the GLTI bind to Aβ1-42. Future work has to be performed to find the species of Aβ1-42 the 
GLTI binds to and to identify residues of both GLTI and Aβ1-42 which form the interface. 
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In an attempt to assess the rate of Aβ1-42 monomer disappearance in the presence of GLTI, 
a 1D 1H NMR time course was performed. In the case of the Aβ1-42 control the intensity 
of the spectra was reduced by 87% in 24 hrs, suggesting that a big fraction of monomers 
were forming larger aggregates not visible by NMR. Since chemical shift changes were 
observed, subtraction of the Aβ1-42 spectra from the Aβ1-42 and GLTI mixture was difficult 
and the rate of Aβ1-42 monomer disappearance in the presence of GLTI was not deduced 
here. The large conformational changes which occur in this family of proteins on substrate 
binding suggest that similar events may be occurring on binding Aβ1-42. 
Further analysis will be required to understand the nature of interaction sites. The first 
step towards this goal is developing an overexpression system for GLTI to produce a 
sufficient amount of the protein. An 1H 15N HSQC assignment would then provide the 
ability to identify the binding sites of GLTI to Aβ1-42. 
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Chapter Seven: Final Conclusions and Future Work 
 
The initial aim of this project was to reveal the nature of interaction between the Aβ 
peptide and the proteins, transthyretin and human cystatin C (hCC). Both TTR and hCC 
have been found inside and in the periphery of Aβ plaques in the brains of people with 
Alzheimer’s disease (Deng et al., 2001). Animal models and cell assay experiments 
suggest a protective role for these two amyloidogenic proteins in the pathophysiology of 
Alzheimer’s (Stein et al., 2004, Tizon et al., 2010b). Direct interactions between these 
proteins and the Aβ peptide had been studied in vitro using techniques based mostly on 
the immobilisation of one of the proteins (Sastre et al., 2004b, Selenica et al., 2007b, 
Costa et al., 2008, Du and Murphy, 2010). However, the details of the direct interactions 
in solution were unknown. The main aim of this project was to study the details of the 
direct in vitro interactions between these proteins and the Aβ peptide.   
The deposition of an Aβ film and its nucleation on hydrophobic surfaces is well-supported 
in the literature (Kowalewski and Holtzman, 1999, Rocha et al., 2005, Shen et al., 2012). 
In our lab, we found evidence for the formation of a tightly bound monolayer of Aβ1-42 
on the surface of polystyrene microplates. We also found that both polystyrene (PS) and 
polyethyl glycate (PEG) surfaces enhance the nucleation of Aβ. However, the loose 
binding of Aβ on PEG is likely to accelerate Aβ nucleation and aggregation more than 
the polystyrene plate, presumably because the nuclei can easily come off the surface to 
the solution and start aggregation. 
 
Inhibition of Aβ firbillisation by TTR occurs at the surface 
Previous reports suggested that TTR tetramers bind to Aβ monomers in solution and 
inhibition mainly happen through binding to Aβ monomers (Costa et al., 2008, Li et al., 
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2013a). This was inconsistent with the low Kd of binding between TTR and Aβ monomers 
in solution (24µM) as this suggests that only one third of the Aβ molecules are bound to 
TTR tetramers in the solution with the equimolar amount of both proteins at 11µM. 
Despite this, we have found that an equimolar concentration of TTR is enough to inhibit 
Aβ aggregation. Additionally, as the rate of aggregation of Aβ in our conditions was 
independent of monomer concentration, the observed increase in lag time in the presence 
of polystyrene plates cannot be interpreted as the result of TTR binding to Aβ monomer.  
This study further confirmed the difference in TTR’s ability to bind Aβ when the second 
is in solution or it is immobilised on a surface. Results obtained in this study show that 
the ability of WT TTR to inhibit Aβ fibrillisation is significantly lower in the presence of 
PEG compared to polystyrene, indicating that TTR binding to solution Aβ is much 
weaker. These results suggested stronger binding of TTR to immobilised Aβ on PS. It is 
plausible therefore that TTR binds weakly to the monomer or aggregated structure in the 
solution and binds much tighter to a rare species of Aβ aggregated structure on the 
monolayer, causing a delayed nucleus formation. Given the above discussion, we suggest 
that TTR prevents the nucleation of Aβ on the surface. Our results imply that disturbance 
of this layer by TTR prevents nucleation from occurring. It follows that TTR may also 
prevent the binding of oligomeric Aβ to membranes and other surfaces in vivo. As it is 
well-known that oligomers are the most toxic forms of Aβ and these oligomers exert their 
toxicity via affecting the cell membranes, validating TTR binding to oligomeric species 
on surfaces would be of a particular importance for revealing the nature of TTR 
modulation of Aβ in vivo.  Performing Aβ inhibition experiments by TTR in the presence 
of other surfaces with different hydrophobicities, inert surfaces like glass and lipid bilayer 
coated surfaces would be invaluable to find clues to understanding the TTR inhibitory 
effect on Aβ fibrillisation in vivo. 
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WT TTR inhibits Aβ fibrillisation using a different mechanism to its amyloidgenic 
mutants 
In order to study TTR interaction with Aβ in detail, four different TTR mutants were 
chosen with different kinetic and thermodynamic stabilities in terms of their tetramer 
stability and the folded state of their monomers. It had been previously shown that the 
residues around and including the thyroxine binding pocket of the TTR tetramer bind to 
Aβ monomers and Aβ inhibition by TTR was suggested to occur through binding to 
solution Aβ monomers. However, our results suggest that WT TTR works through 
tetramer binding to a very early nucleating species, supported by the observation that late 
addition of WT TTR to Aβ fibrillisation reactions abolishes its ability to inhibit Aβ 
fibrillisation, and this interaction occurs mainly at the surface. The WT TTR and its 
mutants inhibit Aβ fibrillisation via different pathways. Mutants interact with larger Aβ 
aggregates via exposing hydrophobic patches on their monomers. TTR mutants used in 
this study showed two different types of behaviour. TTR mutants study showed that their 
ability to inhibit Aβ aggregation is inversely related to their stability as a tetramer and 
folding state of monomer. Less stable mutants as a tetramer with unfolded monomers 
were the strongest inhibitors. V122I tetramer V122I has a more stable monomer 
compared to other mutants yet even though its tetramer is strongly destabilised, it is 
similarly effective or even slightly less than WT TTR. This could be because its binding 
site to Aβ is not as exposed as that of other mutants which have unstable monomers as 
well as dissociating tetramers.  
Aβ1-42 fibrils are not directly toxic themselves. However, they can help the continuous 
generation of toxic oligomers as they can provide a catalytic surface for this. To explore 
the potential of TTRs to bind Aβ fibrils, TTRs were incubated with purified Aβ fibrils 
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and co-pelleted to show binding between TTRs and Aβ fibrils. The percentage of TTRs 
showed to bind Aβ fibrils was consistent with the instability of their tetramers and 
unfolded state of their monomers. Addition of TTRs to seeded Aβ fibrillisation reactions 
showed that the TTR mutant with the most unstable tetramer with significantly populated 
unfolded monomers (A25T mutant) was the only inhibitor of seeding, presumably via 
binding to the fibrils ends through its exposed hydrophobic patches of monomer. These 
results indicates that mutant TTRs bind to aggregated structures, seeds and fibrils in the 
same way by using exposed hydrophobic patches of their monomers.  
It has been suggested that TTR monomers are more effective than tetramers in inhibiting 
Aβ fibrillisation presumably through stronger binding to Aβ aggregates. It has been found 
that F78M/L110M (M-TTR) TTR mutant is unable to assemble to tetramers and it stays 
as monomers (Du and Murphy, 2010). Designing M-TTR mutants to produce TTR 
monomers with different folding states and investigation of its ability to inhibit Aβ 
fibrillisation could validate the relationship between the unfolding of TTR monomer and 
ability to inhibit Aβ aggregation. 
Monitoring the time course and size distribution of aggregates forming during Aβ 
fibrillisation in the presence and absence of TTRs and the effect of different TTRs on the 
formation of ADDLs would give an idea of the nature of the Aβ oligomers that TTRs 
bind. 
Cystatin C inhibits Aβ fibrillisation through binding of a specific type of oligomer 
The second part of this project was to study the interaction between human cystatin C 
(hCC) and Aβ. It had been suggested that monomer-monomer binding occurs between 
hCC and Aβ and this results in the prevention of Aβ fibrillisation (Sastre et al., 2004b, 
Selenica et al., 2007b). However, previously in our lab the interaction between WT 
cystatin C and Aβ1-42 was investigated and led to the proposal that monomeric hCC 
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inhibits the formation of amyloid fibrils by Aβ through binding to an oligomeric form of 
the peptide. hCC does not bind to monomeric Aβ but instead appears to be binding to an 
oligomeric species causing the formation of non-toxic assemblies. Similarly, PrPC 
selectively binds to oligomers (Lauren et al., 2009), however in this system the producing 
species are more toxic than those formed in the absence of PrPC. In the current study, 
again NMR experiments failed to find the interaction between monomeric Aβ and hCC. 
However, the concentration dependence of Aβ inhibition by hCC was confirmed by 
thioflavin T assays. Although the formation of the complex between Aβ and hCC was not 
observable using 15N 1H HSQC, it is possible that alternative NMR methods, for example 
relaxation experiments, could be performed to monitor this interaction.  
A major challenge in this part of the study was the insufficient production of hCC and co-
purifying of an E. coli protein mutants. This problem was solved by adding another round 
of size exclusion to separate out the contaminants. The concentration dependence 
confirmed, however in slightly different conditions, as it was found that in continuous 
shaking conditions hCC is less efficient in inhibiting Aβ fibrillisation. Slightly higher 
than equimolar concentration of hCC were enough to completely inhibit Aβ fibrillisation 
in minimal shaking conditions compared to about 4 times of the equimolar concentration 
in the continuous shaking conditions. This differences could be down to the acceleration 
of nuclei generation by Aβ or production of the different oligomeric forms that hCC is 
unable to bind (and thus avoid their growth to form fibrils). Another factor could be due 
to the fragmentation of the produced Aβ fibrils during shaking which causes generation 
of more ends and a faster rate of aggregation.  
Investigation of the morphology and size distribution of the Aβ oligomers forming in 
these two different shaking conditions is important to find the nature of oligomers that 
hCC can bind and its implication in vivo.  
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The inhibition interface of Cystatin C 
Mutagenesis of hydrophobic residues over different regions of the hCC structure was used 
as a crude biochemical method to find the binding interface to Aβ oligomers through their 
impact on the inhibition of Aβ fibrillisation measured through thioflavin T fluorescence 
assays. The addition of hCC dimers to the Aβ1-42 aggregation reaction has no effect on 
the fibril yield. This reinforced the view that the dimer interface is crucial to the inhibitory 
activity of hCC. The major limitation of this strategy were reproducibility of the 
inhibitory effect of WT and mutants, which could be due to binding of hCC to 
heterogenous oligomers, however an order of inhibitory effect of mutants were possible. 
The likely binding interface of Aβ binding on the hCC is the unstructured N-terminal 
region represented by P6 residue and protease inhibitor active site represented strongly 
by W106 residue and less intensely by V57. Close to dimer interface (V50A) also reduced 
hCC’s inhibitory effect but to a smaller degree. Despite its large hydrophobic surfaces 
L80 from the biggest loop’s site of hCC and P105A which is close to W106 is not 
involved in the binding. These results together suggest that the N-terminal unstructured 
part and residues with large accessible hydrophobic surface areas located in or close to 
the active site and the hydrophobic surface facing outward are effectively involved in 
hCC binding to Aβ1-42 aggregated structures. Presumably hCC bind to Aβ aggregated 
structures via this binding site and inhibit its further aggregation to form fibrils.    
A study using short peptides of hCC could also be employed to find which region of hCC 
is involved in binding Aβ, as has been successful in the transthyretin system (Du and 
Murphy, 2010). Additionally, it may be interesting to investigate the effect of mixtures 
of modulating proteins on Aβ fibril formation.  
As TTR’s effect was significantly different in the presence of different surface and all the 
hCC: Aβ experiments were performed in the presence of polystyrene microplates. 
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Preliminary work in our lab shows that unlike TTR, hCC does inhibit Aβ fibrillisation in 
the presence of PEG microplates. This result indicates that hCC can bind and inhibit Aβ 
oligomers both in the solution and on the surface which indicates the potential importance 
of hCC in the inhibition of Aβ aggregation in vivo in different compartments. This, in 
addition to its ability to prevent fibrillisation at later stages of assembly, makes cystatin 
C a particularly interesting regulator of amyloid formation. 
 
Identification of a novel inhibitor of Aβ fribrillisation from E. coli 
While trying to work out the reasons behind the variability in the intensity of hCC to 
inhibit Aβ fibrillisation. An E. coli contaminant was found to co-purify with hCC. This 
contaminant separated from hCC by adding another round of size exclusion. The purified 
contaminant was found to have an inhibitory effect against Aβ. Half equimolar amounts 
of the contaminant were enough to completely inhibit Aβ fibrillisation and EM 
observation confirmed the formation of amorphous aggregates instead of fibrils by Aβ. 
The contaminant identified and sequenced by mass spectrometry was the periplasmic 
glutamate/ aspartate binding (GLTI) E. coli protein. This protein is part of an amino acid 
transport system which transfer the aspartate and glutamate ligands from the periplasm to 
an inner membrane protein (Sun et al., 1998). The ability of this protein to inhibit Aβ 
fibrillisation could be due to binding to Aβ through its hydrophobic patches as its Shigella 
homologus structure is abundant in hydrophobic patches. Alternatively, binding to 
aspartate or glutamate residues in the Aβ sequence may avoid interactions with other 
monomers. Specific binding between an E. coli protein and Aβ peptide might not be very 
likely. However, the E. coli periplasm has a system to control the production of the right 
amounts of curli fibrils. E. coli curli is a natural amyloidogenic protein which the 
bacterium uses for attachment to surfaces. The GLTI protein might have a dual role 
  
198 
 
related to the curli controlling system and it might be designed to prevent fibrillisation of 
amyloidogenic proteins as well as its function as a transporter of amino acids. This may 
be similar to the observation that TTR, cystatin C and other brain proteins regulate 
amyloid β fibrillisation as well as carrying out their natural roles in the human body. 
Future work will require designing a GLTI construct to produce it in sufficient amounts 
to study. The GLTI 15N 1H HSQC is not assigned yet. Production of triple labelled GLTI 
will allow the assignment of its HSQC then titrating Aβ will identify the binding site of 
Aβ on GLTI. Based on this binding region to the Aβ, short peptides can be designed and 
used as a potential small molecule therapeutic. Looking for human homologs and 
investigation of its activity against Aβ aggregation and toxicity is also one of the future 
works which can be performed. 
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